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Summary 
Mass spectrometry based proteomics has become a method of choice for identification 
and quantification of proteins in complex biological systems. It allows for absolute 
quantification – the determination of protein copy numbers and absolute concentrations 
by means of internal standards. This enables kinetic modeling, stoichiometry 
determination and facilitates comparison among different studies. Nonetheless, existing 
absolute quantification methods have limitations. For instance, in peptide-based absolute 
quantification, a single peptide is often spiked in at a late stage of the sample preparation 
workflow, compromising accuracy. Absolute quantification based on full-length 
standards, on the other hand, is time consuming and laborious and therefore low in 
throughput.  
In this thesis, I established a new method for absolute protein quantification, which is 
capable of overcoming existing limitations and applied it to a global proteome study of 
cancer cells, platelets and stoichiometry determination of protein complexes. In the first 
project, I developed the novel absolute quantification strategy termed ‘SILAC-PrEST’, 
which uses SILAC-labeled protein epitope signature tags (PrESTs) as internal standards. 
These PrESTs were generated in the course of the Human Protein Atlas for polyclonal 
antibody production. They are designed to cover a 50-150 amino acids long, unique 
sequence of the protein of interest, and are fused with a purification and solubility tag. 
First, the solubility tag alone is highly purified and its concentration is determined by 
amino acid analysis. Subsequently, each PrEST is quantified against the solubility tag via 
the SILAC ratio (ratio of ‘heavy’ to ‘light’ labeled peptide). Next, the PrESTs are combined 
in a predefined proportion to generate a master mix which is spiked into cell lysate. The 
absolute copy number of the endogenous proteins is then deduced from the measured 
SILAC ratios. This quantification workflow successfully allowed concurrent 
quantification of 43 proteins ranging from 6,000 to 20 million copies in HeLa cells.  
In a second, collaborative project, we combined the SILAC-PrEST method with an 
enrichment step using polyclonal antibodies generated by the Human Protein Atlas. 
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Epitope mapping revealed that the antibodies generated from the PrESTs recognize 
multiple linear epitopes and therefore allowed for enrichment of multiple tryptic peptides 
from the target. We termed this method ‘immuno-SILAC’ and in an application 
demonstrated the successful enrichment of endogenous and PrEST-derived peptides by a 
mixture of up to 50 immobilized antibodies. Immuno-SILAC enables efficient multiplexed 
absolute quantification of proteins from complex mixtures. 
In a further project, I set out to characterize the entire murine platelet proteome using the 
SILAC-PrEST method to determine protein copy numbers. By analyzing proteomes of 
platelets of increasing purity we were able to identify and exclude contaminants 
originating from erythrocytes and plasma. I quantified thirteen platelets proteins directly 
by SILAC-PrEST and used these values as reference points to scale the copy number of 
each protein of the platelet proteome. Altogether we identified and quantified 4,400 
proteins, constituting a close-to-complete reference map of the platelet proteome. 
Remarkably, proteins with estimated copy numbers of less than 10 per platelet were 
measured. 
In the last and collaborative project, we applied the SILAC-PrEST method to determine 
the expression levels and stoichiometry of integrin beta 3 and its coactivators talin-1 and 
kindlin-3.  In platelets, integrin αIIB3 is the major adhesion receptor. It binds to ligands 
upon activation via a process termed ‘inside-out’ signaling, whereby intracellular 
signaling and eventual binding of talin-1 and kindlin-3 to the cytoplasmic tail of the 
integrin, induces its conformational change.  We discovered that the stoichiometry of the 
coactivators relative to integrin 3 was 2:1. Experiments on several mouse strains 
expressing different amounts of kindlin-3, revealed that high levels of kindlin-3 are 
required for activation of this integrin. 
In summary, the projects presented in this thesis establish a novel, more accurate method 
for absolute protein quantification, which was successfully applied to diverse biological 
questions. 
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Introduction 
Proteins are involved in virtually all processes and pathways in cellular systems. The 
entire set of proteins present in a cell is referred to as the proteome, a term first introduced 
in 1996 by Marc Wilkins as the entire ‘protein complement expressed by a genome’ [1]. 
Proteome research gained momentum by the availability of numerous genome maps of 
different organism in the 1990s. These gene maps serve as starting point for proteome 
research by predicting the sequence of the potential proteins in the system under 
investigation. The shift of emphasis from DNA to its protein products thus defined the 
start of the post-genome era for the proteomics community [2]. The human genome, for 
example, is believed to consist of about 20,000 protein coding genes. However, since one 
gene can give rise to multiple different proteins due to alternative splicing, sequence 
polymorphism and post-translational modifications, an enormous complexity is expected 
[3]. Furthermore, the abundance level of these polymorphic species varies highly between 
cell types, tissues and developmental stages, as well as responding to extra- and 
intracellular signals. This immense complexity and diversity can only be tackled by high-
throughput technologies. In the beginning, proteomic studies relied on two-dimensional 
gel electrophoresis, but this technique proved unsuitable for in-depth characterization of 
full proteomes for a number of reasons [4]. In contrast, mass spectrometry (MS)-based 
proteomics has matured in the past 25 years to become a powerful and versatile 
technology that can sensitively and accurately identify and quantify proteins, their 
modifications and interactions [5, 6]. This technology is continuously developing thanks 
to advances in instrumentation, samples preparation strategies and computational 
analysis.  
Mass-spectrometric measurements are not inherently quantitative, and various methods 
have been developed in response to this challenge. Many quantification methods are 
‘relative’ in that they report ratios between two or more conditions. As such, the actual 
abundance remains unknown.  In contrast, ‘absolute’ quantification allows determination 
of actual concentrations e.g. ng/ml of a clinical biomarker in plasma, or the copy number 
Introduction 
 
6 
of a protein in a cell. Therefore, in general only data from absolute quantification can be 
used for determination of kinetics and stoichiometries [7]. Moreover, absolute 
quantification data can easily be compared and exchanged among different studies and 
laboratories. Recently, absolute quantification became wide-spread in proteomics with the 
development of strategies employing isotope-labeled standards [8]. Apart from methods 
quantifying one or a small set of proteins, computational methods have also recently been 
developed that estimate the absolute abundance from the summed MS signals of all 
peptides identifying a protein [9-11]. 
In this thesis, I developed a method for absolute quantification termed ‘SILAC-PrEST’ 
based on a novel kind of stable isotope labeled standards. Below, besides the method 
development itself, applications of the absolute quantification strategy are described. The 
following introduction focuses on the basic workflow of MS-based proteomics, mass 
spectrometric instrumentation, proceeds to existing quantitative methods and concludes 
with a short introduction of the biological context in which this new SILAC-PrEST 
method was applied. 
Mass spectrometry-based proteomics 
MS-based proteomics is performed either ‘bottom-up’, where proteolytic peptide 
mixtures are analyzed [6] or ‘top-down’, where intact proteins are studied [12]. The 
former approach is more established, much more powerful and is therefore more widely 
used. A typical bottom-up MS-based proteomic experiment starts with extracting and 
optionally enriching proteins from tissue or cells. Next, the proteins are subjected to 
proteolytic digestion. Trypsin is commonly used as the protease to convert proteins into 
peptides since it specifically cleaves proteins on the carboxyl-terminal side of arginine and 
lysine residues, producing peptides with a size and charge range well-suited for MS 
analysis. To reduce complexity, samples may be fractionated either at the protein level 
based on the molecular weight using SDS-PAGE or gel filtration, or at the peptide level 
based on the peptide’s physical and chemical properties, generally with strong anion 
exchange or isoelectric focusing. 
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Figure 1: Simplified schematic outline of the sample preparation for a typical MS-based proteomics 
experiment 
Next the peptides are separated by high-performance liquid chromatography (HPLC) and 
introduced ‘online’ into the mass spectrometer via electrospray. Mass spectrometers used 
in proteomics are capable of measuring the mass of biomolecules as well as of isolating 
and fragmenting them. They analyze the peptide mixture in a data-dependent fashion. 
First, the mass and intensity are measured in the so-called ‘full scan’ or ‘MS1’ scan and 
then the most abundant peptides are selected for fragmentation, generating ‘tandem’ or 
‘MS/MS’ spectra. The peptides are identified by matching the fragmentation spectra to 
theoretical spectra generated from a sequence database (Figure 2). For protein assembly 
the identified peptides are computationally mapped to the corresponding protein. 
 
Figure 2: Schematic outline of a shotgun LC-MS/MS experiment divided into , (B) liquid chromatography 
and mass spectrometry, (C) spectra interpretation. Adapted from [13]. 
The aforementioned workflow is referred to as ‘shotgun’ proteomics [14] and is by nature 
a discovery based strategy, representing a powerful method for global characterization of 
proteomes (qualitatively and quantitatively). Using this shotgun proteomics approach, 
two recent studies identified a close to complete proteome of human cancer cell lines [15, 
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16]. One limitation of data dependent shotgun proteomics is the stochastic nature of the 
data acquisition, as the mass spectrometer does not always pick the same peptides for 
fragmentation. In particular, low-abundant peptides may only be stochastically 
sequenced and identified. However, scanning speed and sensitivity of the mass 
spectrometer has increased significantly in the recent years, and computational 
approaches for transferring identifications between samples have been developed to 
compensate for this potential limitation. 
In addition to the shotgun approach, hypothesis-driven strategies are also available. Such 
‘targeted’ methods by their nature monitor a number of predefined proteins. While the 
sample preparation is the same, the acquisition strategy differs. One implementation of 
targeted proteomics is multiple reaction monitoring (MRM), where predetermined 
precursor ions are selected for fragmentation and one corresponding product ion detected 
[17, 18]. One measurement of a mass-to-charge (m/z) pair is referred to as a ‘transition’ 
and several transitions are performed over the chromatographic peak, resulting in a trace 
of signal intensity versus retention time. To accurately quantify a protein, several peptides 
– each with at least two transitions – are generally targeted, resulting in no more than 50 
proteins being concurrently monitored in a typical measurement. A potential challenge is 
the verification of the identity of the m/z pair measured in the MRM assay. This could in 
principle be overcome by measuring a pseudo tandem MS/MS spectrum, however at the 
expense of sensitivity and analysis speed. In practice, it is not trivial to select appropriate 
peptides for a robust, sensitive and specific assay. Various parameters such as MS 
properties, uniqueness, post-translational modifications, and cleavage sites have to be 
taken in consideration before choosing a peptide [18]. Nevertheless, once the identity of 
targeted species is established, the assay can be highly sensitive and accurate, especially if 
performed on high resolution instruments rather than the typically employed triple 
quadrupoles. MRM in principle allows absolute quantification of the targeted peptides if 
combined with heavy isotope-labeled peptide references. MRM can therefore be used to 
screen clinical samples for specific biomarkers in high-throughput. The targeted strategy 
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offers an attractive alternative to antibody based methods such as ELISA, however, in 
comparison to shotgun proteomics this comes at the expense of unbiased knowledge of 
the system.   
Liquid chromatography mass spectrometry 
Historically, mass spectrometry was restricted to the analysis of small molecules, owing to 
the lack of technique to gently ionize and vaporize biomolecules. The development of two 
ionization methods – electrospray ionization (ESI) [19] and matrix-assisted laser 
desorption ionization (MALDI) [20, 21] – allowed bringing biological macromolecules into 
gas-phase without destroying them, making peptides and proteins amenable to MS 
analysis. In electrospray, the peptides mixture is sprayed in a strong electrical field 
between the needle and the MS inlet, forming charged droplets that rapidly desolvate and 
eventually become ‘lifted’ into the gas phase (Figure 3) [19]. 
 
Figure 3: Electrospray ionization in combination with liquid chromatography. The peptides are separated 
on a typically reverse phase column. The peptides are ionized via electrospray and enter the mass 
spectrometer for analysis. Adapted from [22]. 
The development of these ionization methods – acknowledged with the Nobel Prize in 
Chemistry in 2002 – boosted the field of mass spectrometry based proteomics, particularly 
since ESI is highly compatible with preceding liquid separation technologies. Usually 
reverse phase chromatography is used to separate molecules by their hydrophobicity, so 
that only a limited diversity of peptides is introduced to the mass spectrometer at a given 
time. This consequently improves the accessibility of low-abundant peptides in a shotgun 
experiment and increases the depth of the resulting proteome [23].  
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Instrumentation 
Regardless of the type of instrument, each mass spectrometer consists of three major 
components: an ion source, a mass analyzer and a detector. The heart of each mass 
spectrometer is the mass analyzer which separates ions according to their m/z. 
Commonly, time-of-flight (TOF), quadrupoles, Fourier transform ion cyclotron resonance 
(FT-ICR), linear ion trap (IT) and the recently developed Orbitrap analyzer are used in the 
field of proteomics as mass analyzers [24]. The performance of the individual mass 
analyzers can be characterized by mass range, analysis speed, sensitivity, resolution and 
mass accuracy. FT-ICR and Orbitrap analyzers, for example, are characterized by high 
mass resolving power and high mass accuracy while the ion trap – particularly the linear 
ion traps (LTQ) – features fast scan rates and high sensitivity [25].  Each mass analyzer has 
its merits and limitations and according to some, the ideal mass analyzer does not exist 
[26].  
Hybrid mass spectrometers combining conceptually distinct mass analyzers and 
exploiting the benefits of each component increase the performance and versatility of the 
combined instruments [27]. Examples of such hybrid instruments include quadrupole 
TOFs, LTQ Orbitraps and quadrupole Orbitraps. The quadrupole TOF and quadrupole 
Orbitrap analyzer are broadly used and have proven invaluable in proteomics. In this 
thesis hybrid instruments (LTQ-Orbitrap, LTQ-Velos and Q Exactive) from Thermo Fisher 
Scientific have been used and therefore their mass analyzers (ion trap and Orbitrap) as 
well as their set-up are discussed in more detail below.  
 
Linear ion traps 
The ion trap is one of the most popular mass analyzers in MS-based proteomics. Ion traps 
are devices capable of storing, isolating and fragmenting ions and traditionally existed in 
a three dimensional configuration, which has more recently been largely superseded by 
an implementation of the ion trap based on a quadrupole (linear ion trap). They are 
characterized by their high scanning speed and high sensitivity, but yield only 
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moderately resolved spectra and relatively low mass accuracy. Therefore, ion traps are 
often combined with high resolution analyzers such as the Orbitrap or FT-ICR to form 
hybrid instruments. The quadrupole in the linear ion trap has four hyperbolic rods, each 
rod separated into three sections (Figure 4a). In the central section, one of the pairs of rods 
contain a slot for ion ejection and consequent detection by electron multipliers. An 
elaborate RF/AC/DC system is applied to the rods in all dimensions to achieve radial and 
axial trapping as well as isolation, excitation and ejection of ions (Figure 4b) [24, 25]. 
 
Figure 4: The linear ion trap: (a) Schematic view of the two dimensional ion trap (b) Different voltage are 
applied to achieve radial or axial trapping, respectively. Adapted from [25] and [28] 
 
Orbitrap 
In 2000, the Orbitrap analyzer was introduced by Makarov [29], although a first precursor 
was already described by Kingdon in 1923 [30]. The Orbitrap detector consists of an inner 
spindle-shaped electrode surrounded by an outer barrel-like electrode, which is split into 
two halves allowing radial ion injection. In order to efficiently inject ions into the 
Orbitrap, focused ion packages with narrow spatial and temporal distribution are 
required. This is achieved in the ‘C-trap’ upstream of the Orbitrap [31]. In this curved, C-
shaped quadrupole, the ions are collisionally-cooled with nitrogen bath gas. In the 
following ion optics, the ions are accelerated and made to converge in order to be injected 
tangentially into the Orbitrap via a small aperture [32]. In the mass analyzer, the ions are 
trapped in an electrostatic field by orbiting around the inner electrode and simultaneously 
oscillating along the longitudinal axis. 
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Figure 5: The geometry of the Orbitrap analyzer: (a) inner spindle shaped electrode, around which the ions 
move in addition to oscillating along the z-axis (b) the outer barrel-like electrode with a gap (c) ceramic 
ring electrically isolating the two halves from each other. Adapted from [32] 
Initially in the development of the Orbitrap, the rotational frequency was used to deduce 
the m/z of the ions, but this yielded inaccurate results because these rotational frequencies 
also depended on initial properties of the injected ions. Therefore, the frequency of the 
harmonic oscillation along the z-axis is used instead. The electrical current resulting from 
the oscillating ions (the ‘image current‘) is detected across the split of the outer electrodes 
as an electrical transient, and is Fourier-transformed (FT) to produce frequencies for each 
ion, which in turn are converted to accurate m/z values. The Orbitrap mass analyzer is 
capable of generating very high resolution and high mass accuracy measurements [33]. 
 
Tandem mass spectrometry 
In the mass spectrometer, in the first analysis step the m/z value and intensity of an ion are 
determined (referred to as MS, MS1, survey scan or full scan) and in the second analysis 
step they are fragmented and the fragmentation spectrum is recorded (termed ‘tandem 
mass spectrometry’, MS/MS or MS2): Tandem MS involves activation of a selected and 
isolated precursor ion and then dissociation of the peptide backbone yielding various 
product ions [34]. To achieve fragmentation, electric fields are applied and consequently 
the ions collide with a low pressure bath gas. In collision induced dissociation (CID) and 
higher energy collisional dissociation (HCD), the cleavage typically occurs at the C-N 
peptide bond. Depending on where the charge is retained, the amino-terminal or 
carboxyl-terminal fragments can be observed. Following the Roepstorff-Fohlmann-
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Biemann nomenclature, these fragments are referred to as b- or y-type ions, respectively 
(Figure 6) [35]. 
 
Figure 6: Peptide fragmentation: excitation of peptide ions induces cleavage of distinct bonds of the 
peptide backbone, yielding N-terminal and C-terminal ions. The fragments are named according to the 
Roepstorff–Fohlmann–Biemann nomenclature. Adapted from [22, 35]. 
Based on a complete series of fragmented ions, differing in mass by a single amino acid 
residue, the sequence can be determined either by manual interpretation (‘de-novo 
sequencing’) or computationally by comparing the fragmentation pattern to a sequence 
database (further described in the computational proteomics part). 
 
Hybrid instrumentation 
In case of the LTQ-Orbitrap, which was commercially introduced in 2005, the sensitivity 
of the ion trap was united with high resolving power of the Orbitrap analyzer [31, 36]. It 
quickly became a popular instrument for proteomics applications. Nevertheless, the set-
up was constantly improved, and the next generation, termed LTQ-Orbitrap Velos, 
instruments were significantly faster and more sensitive. To achieve this boost in 
sensitivity, the ion optics were modified by replacing the tube lens with a S-lens, allowing 
better ion transmission. Furthermore, the linear ion trap was replaced by a dual-pressure 
ion trap that comprised two identical linear quadrupole cells. These cells are operated at 
different gas pressures, allowing capture and fragmentation to be uncoupled from 
scanning and detection. The first, high pressure ion trap efficiently captures the ions and 
generates fragments ions faster and more efficiently due to reduced activation time. The 
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second, low pressure ion trap allows for enhanced scanning speed while maintaining 
adequate resolution (Figure 7)  [37].  
In the LTQ-Orbitrap Velos, the introduction of highly efficient combination of the C-trap 
with the HCD collision cell enabled two fragmentation strategies. Before this, the full scan 
was measured at high resolution in the Orbitrap, while collision induced dissociation and 
fragmentation spectra acquisition were performed at low resolution in the highly 
sensitive ion trap in parallel. This mode of operation is referred to as ‘high-low’. The new, 
highly efficient HCD fragmentation method allowed routine use of a ‘high-high’ mode, in 
which both the MS determination of peptides (‘precursors’) and of the fragments are 
performed in the Orbitrap analyzer. Therefore, in the new ‘high-high’ mode, both the 
survey spectrum and the fragmentation spectra are obtained at very high resolution and 
consequently with high mass accuracy. In addition, acquisition of the HCD fragment ions 
in the Orbitrap allows observation of low mass fragment ions, which are usually not 
observed in CID performed in ion traps, improving peptide characterization. 
 
 
Figure 7: The hybrid mass spectrometer configuration of the LTQ Velos. Adapted from [37]. 
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In the latest Orbitrap mass spectrometer, the bench top Q Exactive, the ion trap is replaced 
by a quadrupole operating as mass filter, leaving the Orbitrap as the only mass detector. 
In this setup, survey scans and the fragmentation scans are exclusively acquired at high 
resolution in the Orbitrap analyzer (Figure 8) [38]. 
 
 
Figure 8: The Q Exactive set-up. Compared to previous models, the ion trap has been replaced by a 
quadrupole. Adapted from [38]. 
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Computational proteomics 
In a typical shotgun experiment, the complex peptide mixture is separated by liquid 
chromatography and analyzed by the mass spectrometer to generate a map of retention 
time and m/z values (Figure 9a). In brief, the mass spectrometer first acquires a survey 
scan, containing the precursor masses with intensity information. As explained above, 
five to twenty of the most abundant ions are then isolated and subjected to fragmentation. 
This cycle is repeated throughout the whole chromatographic gradient. 
The large amount of data acquired prohibits manual interpretation, and rather requires 
sophisticated software. Various packages are available, most performing the following 
common steps: (i) peak detection (ii) identification of the corresponding MS/MS spectra 
(iii) statistical validation of the identifications (iv) protein assembly and (v) quantification. 
For this thesis the powerful MaxQuant software, including its own search engine 
‘Andromeda’ was used and is therefore described in more detail [39, 40]. 
 
Figure 9: (a) Visualization of all peptides feature detected in a single LC-MS run. (b) Isotope cluster of one 
peptide, which is (c) targeted for fragmentation and successfully identified. 
First, a series of MS scans spanning a peptide’s elution profile is used to construct a three-
dimensional peak, which is used to extract the accurate mass and the intensity (Figure 9b). 
The next and central step of the data analysis is the assignment of the corresponding 
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MS/MS spectrum to a peptide sequence, which is achieved by database searching. In this 
process, the observed spectra, retaining the top 12 peaks per 100 Da interval, are 
compared against theoretical fragment ion spectra. These theoretical spectra are obtained 
by an in silico digestion of all proteins in a reference protein sequence database. A 
successful match between the observed and theoretical spectrum requires the same m/z 
within an individualized mass tolerance not exceeding 20 ppm (Figure 9c). Clearly, the 
choice of database plays an important role since they vary in terms of completeness, 
degree of redundancy and quality of sequence annotation.  
Currently, the standard database used in MS-based proteomics is UniProtKB, which 
consists of the manually-curated Swiss-Prot and the computationally generated TrEMBL 
(Translated EMBL Nucleotide Sequence Data Library) [41]. Inclusion of TrEMBL allows 
one to confirm existence of predicted proteins based on experimental data. Once the 
peptide sequence is established, the probability that the database match is a random event 
is determined and reported as score (-10*log(probability)), which can be interpreted as the 
confidence in the identification. Additionally, to identify false positive hits the ‘target-
decoy’ strategy is employed: the MS/MS spectra are searched against a concatenated 
database of target (intended) but also decoy (reversed) sequences. Peptides identified in 
the decoy database are evidently incorrect and, assuming an equal probability of false 
identification from both databases, the score threshold can be used to control the false 
discovery rate (FDR) to a desired level (typically 1 %) [42]. 
Because peptides rather than proteins are identified in the bottom-up workflow, the 
actual proteins have to be reassembled computationally. However, mapping peptides to 
the corresponding proteins is not trivial, since peptides sequences can be shared between 
homologous proteins, protein families, multiple isoforms and even redundant entries in 
the reference database [43]. To obtain a protein list best describing the original sample, the 
concept of ‘protein groups’ was introduced. 
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Figure 10: Protein grouping. Non unique peptides that might be assigned to two or more protein groups 
are placed into the protein group with most peptides. Adapted from [13]. 
In essence, proteins not distinguishable on the basis of identified peptides are collapsed 
into one group [44]. Peptides are considered ‘unique’ if they only occur in one protein 
group. ‘Razor’ peptides could also be assigned to another protein group, yet they are 
placed in the protein group with most peptides (Figure 10). After protein assembly the 
same basic principle of FDR is applied to receive a high-confidence protein list. Once the 
proteins in the sample are established, a measure of protein quantity is calculated. 
Various methods to achieve relative or absolute quantification are described in the next 
section. 
To gain functional insights and to draw biological conclusions from the data set, further 
computational analysis needs to be performed. Downstream analyses can include 
hierarchical clustering, principal component analysis, tests for differential regulation, time 
series, pathway and ontology enrichment analysis. A myriad of software packages that 
offer suitable statistical tools and algorithms (mainly developed for microarray data) are 
publicly available, for example Bioconductor for R [45]. Here we use the Perseus program, 
which is very comprehensive and part of the MaxQuant software package [46].  
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Quantitative proteomics 
Perturbation of a biological system usually results in quantitative change in protein 
expression levels, more so than qualitative change in the identity of the proteins being 
expressed. Previously, proteomic studies using mass spectrometry only yielded peptide 
or protein identification, i.e. they purely enumerated proteins without offering a 
quantitative estimate of the level of the proteins in a biological system [8, 47]. Mass 
spectrometry itself is not inherently a quantitative technique, since signal intensity of a 
peptide depends on numerous of its physicochemical features e.g. length, charge, 
hydrophobicity and ionization efficiency. Therefore, a wide variety of strategies for 
protein quantification have been developed. 
Protein quantification can either measure relative changes between two experimental 
states, or absolute protein amounts in the sample. In relative quantification, two states are 
compared and fold changes are determined between them. In absolute quantification, 
protein concentrations or copy numbers per cell are assessed (note that absolute 
quantification in two states, also allows relative comparisons between them) [48]. In either 
case, most quantification techniques employ stable isotope labeling to introduce distinct 
mass differences that can be distinguished in the mass spectrometer. These mass 
differences are created by ‘heavy’ and ‘light’ stable isotope versions of the protein or 
peptide, and can be (i) incorporated metabolically, (ii) attached by chemical reactions, or 
(iii) introduced enzymatically during protein digestion. Quantification may also be 
achieved by spiking in stable isotope-labeled proteins or peptides as internal standards. 
As a complement to stable isotope labeling, ‘label-free methods’ that compare the peptide 
intensity or count the number of spectra, have emerged over the past decade and have 
been successfully established in the field (Figure 11). In the section below, the most 
common quantification methods are further described and practical aspects, applicability 
and pitfalls are discussed. 
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Figure 11: Quantitative proteomics workflow. The blue and yellow boxes symbolize the two experimental 
conditions to be compared. The horizontal line indicates the stage at which the samples are combined. The 
fewer the steps that are performed in separate, parallel processes, the higher the accuracy and the 
robustness of the quantification. Adapted from [48]). 
 
Relative quantification using stable isotope-based methods 
To introduce a mass shift, stable (non-radioactive) isotopes of nitrogen (15N) and carbon 
(13C) are widely used, however, oxygen (18O) and hydrogen (2H) have also been employed. 
The advantage of ‘heavy’ isotopes is that their incorporation into an amino acid does not 
change the physicochemical characteristics of the resulting proteins and their constituent 
peptides. This holds true during sample preparation, reverse phase chromatography 
separation and – importantly – ionization in the mass-spectrometer. This means that the 
MS signals derived from a peptide pair (heavy and light version) are separated by a 
defined mass shift, and that the MS intensity ratios reflect the quantitative abundance 
ratio of the peptide pair. However, this does not entirely hold true for deuterium 2H, 
which is more polar and is therefore retained slightly longer on the reverse phase column 
than its 1H counterpart. This leads to retention time shifts (‘deuterium isotope effect’), 
which possibly introduces errors during quantification. Deuterium is thus less often used 
as label. 
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Metabolic Labeling 
Metabolic labeling strategies introduce the isotope labels in vivo during cell growth and 
division. Therefore, different samples can be merged at an early step in the proteomic 
workflow, avoiding errors resulting from variation in parallel sample preparation and 
proteolytic digestion. Typically, cells are grown in media to which isotope-labeled 
compounds (salt or amino acids) are added. The labeled compounds are incorporated into 
the entire proteome of the sample [49]. Metabolic labeling was first performed in 
proteomics using 15N by Chait and coworkers in 1999 to label yeast [50]. Since then it is 
mostly applied in prokaryotes and lower eukaryotes, in particular bacteria and yeast as 
well as plants. The advantage of metabolic labeling with 15N is that every labeled peptide 
acquires a mass offset regardless of its amino acid composition. Thus, an 15N -labeling 
experiment is uniquely unconstrained in the choice of protease used for digestion. 
However, the mass difference between labeled and unlabeled can only be calculated once 
the peptide sequence is known, which increases the complexity of the subsequent data 
analysis. Furthermore, care must be taken that only 15N nitrogen sources are metabolically 
available to the organism.  
A more commonly used metabolic labeling method is Stable Isotope Labeling of Amino 
Acids in Cell Culture (SILAC). This quantification technique introduced in 2002 [51] is 
based on in vivo incorporation of labeled amino acids that are essential for the organism. 
First, the quantification strategy was shown with deuterated leucine. However, owing to 
the above-mentioned retention time shifts of deuterium and the fact that not every tryptic 
peptide contains a leucine in the sequence, other amino acids are more frequently used 
today. In particular, 13C615N4 arginine and 13C615N2 lysine are utilized, which introduce a 
mass shift of 10 and 8 Dalton (Da), respectively. The advantage of labeling lysine and 
arginine is that in combination with trypsin, virtually all proteolytic peptides are 
amenable to quantification, since each tryptic peptide has at least one arginine or lysine 
(except the C-terminal peptide of the protein) [52]. The cell culture media is supplemented 
with the labeled amino acids and dialyzed serum is used to make the heavy amino acids 
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the exclusive source for protein synthesis. After 5 – 8 doublings virtually all proteins in 
the cells have incorporated the heavy amino acids, typically reaching an incorporation 
rate of 98 % or more. One possible pitfall in SILAC is the metabolic conversion of arginine 
to proline, leading to an additional peptide peak containing heavy proline. Although this 
happens to the same degree in light and heavy labeled cells, and therefore does not 
introduce an error, it makes the peptide mixtures more complex and is therefore 
undesirable. The Arg-Pro conversion can be addressed by titrating arginine concentration 
to eliminate excess arginine or by supplementing the media with proline [53]. After 
labeling, cells from the two states to be compared can be mixed and all sample 
preparation steps are then performed together. In the mass spectrometer, ‘heavy’ and 
‘light’ isotope clusters appear for every peptide, constituting a SILAC pair, between which 
a ratio can be calculated (Figure 12). Introducing a third, ‘medium’ label, makes it possible 
to compare up to three conditions (‘light’, ‘medium’ and ‘heavy’) in a single experiment. 
For more complex comparisons, such as time courses, ‘double-triple’ SILAC can be 
employed, in which two experiments share a common conditions that is used as a 
reference point [54, 55]. 
 
Figure 12: SILAC based quantification: Cells are grown in media containing heavy isotope labeled amino 
acids. The two conditions can be mixed at the protein level prior to optional sample fractionation and 
proteolytic digestion. In the mass spectrum a defined mass shift can be observed and peptide abundance 
can be directly compared. Adapted from [48]. 
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The SILAC toolbox has been continuously extended and now also includes labeling of 
microorganisms such as bacteria [56, 57], yeast [58] as well as multicellular organisms 
such as rodents [59], nematodes [60], flies [61] and plants [62]. The SILAC method 
requires metabolic labeling of the studied system, and therefore cannot be used directly to 
analyze human tissue or clinical samples. To overcome this limitation, the super-SILAC 
approach [63] was introduced: A mixture of different SILAC-labeled cell lines are used as 
internal reference standard. The super-SILAC mix is ideally a good representative of the 
heterogeneous tissue and covers most proteins expressed in the complex tissue proteome. 
Differences between the tissue samples are determined on the basis of the ratio to the 
super-SILAC mix. This approach has successfully been applied to analyze human tumors 
from breast cancers [64] to lymphomas [65]. With the introduction of the super-SILAC 
approach, many more samples have become amenable to SILAC quantification. Yet 
another variation of SILAC is pulse-SILAC, in which the labeled amino acid is introduced 
for a given time period and which can be applied to study protein turnover [66]. 
 
Chemical Labeling 
In addition to metabolic labeling, chemical labeling strategies have been established. In 
chemical labeling reactive side chains of amino acids or the peptide and protein termini 
are derivatized with an isotopic labeling agent (Figure 13). Therefore, virtually any 
sample, including clinical samples and body fluids can be quantified via chemical labels.  
 
Figure 13: Chemical labeling. Any reactive amino acid side chain can in principle be used to attach an 
isotope label (i) Sulfhydryl group (cysteine), (ii) Amine-directed (amino terminus and ε-amino group of 
lysine), (iii) Carboxyl-directed (carboxyl terminus, aspartic and glutamic acid). Adapted from [48]. 
In 1999, Aebersold and coworkers introduced Isotope-Coded Affinity Tags (ICAT) [67] 
targeting sulfhydryl group of cysteines. This tag comprises a specific chemical reactive 
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group, an isotopically coded linker containing either zero or eight deuterium atoms and a 
biotin tag for enrichment of the labeled peptides. The advantage of the affinity tag is that 
the complexity of the sample is significantly reduced since only cysteine containing 
peptides, which are biotinylated through the tag are selected for quantification. However, 
because only cysteine-containing peptides contribute to quantification of a given protein, 
quantification accuracy is limited accordingly (and non-cysteine containing proteins are 
not quantified). Similarly, potentially interesting non cysteine-containing peptides 
carrying a post-translational modification (PTM) cannot be quantified. 
Another strategy is to derivatize amino or carboxyl groups, that are formed during 
proteolysis. Tryptic peptides, for example, contain a primary amine at their N-terminus 
and a basic amino acid at their C-terminus, and additionally an ε-amino group in the case 
of lysine. Here, the advantage is that all peptides have derivatizable groups independent 
of the amino acid sequence and of their reactive side chains [68]. Isobaric tags for relative 
and absolute quantification (iTRAQ) and tandem mass tags (TMT), both very popular 
chemical labeling methods, target the amines with a tag that is built of a reporter group, a 
balancer group and an amine-specific reactive group [69, 70]. The total mass of the tag 
remains the same while the isotopic composition between the reporter group and balancer 
group varies in the different labels. The labeled peptides are indistinguishable in the 
survey scan. Upon fragmentation, however, the tag produces different MS/MS reporter 
ions in the low mass region of the tandem spectrum. Quantification values are 
determined from the ratios of these reporter ions. Multiplexing capacity is one of the 
strengths of isobaric labeling since the complexity of the chromatographic separation 
(labeled peptides comigrate) as well as the mass spectra does not increase as with SILAC 
labeling. Initially, iTRAQ and TMT were used in four-plex and six-plex experiments, 
respectively. More recently, multiplexing of up to 18 samples has been demonstrated by 
combining metabolic with isobaric labeling [71]. Although multiplexing saves 
measurement time, it also limits the dynamic range that can be observed in a proteomic 
measurement because less of each sample can be loaded on the LC column.  
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A weakness of isobaric labeling methods is that the peptide quantification is based on 
single MS/MS spectrum. Another caveat of method is that the reporter ions appear in the 
lower mass region (masses less than 150 m/z), therefore not all mass spectrometers are 
suitable for the analysis - e.g. ion traps hardly recover ions below 30 % of the precursor 
m/z. Another issue are ions of similar m/z that coelute and are therefore isolated and 
fragmented together with the selected ion. These ‘contaminating’ ions contribute to the 
reporter ion ratio and therefore interfere with peptide quantification [72]. Decreasing the 
isolation window of the peptide of interest partially address this issue, however, at the 
cost of decreased sensitivity. Two dedicated approaches to deal with interfering ions have 
recently been described: an MS3-based method [73] and gas-phase purification [74]. In the 
former, the most abundant fragment ion from MS2 is further isolated and fragmented to 
read out the reporter ion intensities. In gas-phase purification, the ion charge is reduced to 
increase the m/z difference between the selected and contaminating ion prior to 
fragmentation. Both strategies, however, suffer from reduction of sensitivity and 
acquisition speed.  
Another established labeling technique in the quantitative proteomics field is dimethyl 
labeling, where primary amines of proteolytic peptides are targeted and converted into 
dimethylamines [75, 76]. First a Schiff base is generated with formaldehyde, which is then 
reduced by the addition of cyanoborohydride. Formaldehyde and cyanoborohydride 
containing varying number of heavy isotopes (13C and 2H) lead to mass shifts of 28, 32 and 
36 Da for the ‘light’, ‘intermediate’ and ‘heavy’ label, respectively. The reaction is efficient 
and fast, and can also be performed online in reverse phase chromatography columns 
[77]. In contrast to iTRAQ or TMT, the reagents used for dimethyl labeling are 
inexpensive and therefore up-scaling up to milligrams of proteins is feasible. Because 
deuterium is part of the label, retention time shifts can occur.  
Chemical labeling methods can be performed either on the protein or the peptide level. 
Clearly it is better that the samples are tagged and mixed at an early stage of the 
experiment. Errors introduced during the sample preparation would be eliminated if 
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tagging is performed at the protein level. However, chemical labeling methods targeting 
primary amines, in particular the ε-amine of lysine, cannot be performed prior to 
digestion as they interfere with trypsin and LysC digestion. 
 
Absolute protein quantification using stable isotope-based methods 
Accurate absolute quantification involves adding a known concentration of a stable 
isotope-labeled internal standard to the sample. The internal standard can be a peptide, a 
concatemer of peptides, a protein fragment or a full-length protein. The concept to spiking 
in an isotope-labeled internal standard was first described by Kai and coworkers in 1983, 
where they generated labeled peptides by digesting a protein in H218O water [78].  
An example of the use of labeled peptides is AQUA (absolute quantification), in which 
synthetic peptides are added to the protein digest [79]. Commonly, peptides uniquely 
identifying a protein and likely to be observable in the mass spectrometer with unique 
transitions in MRM (the so-called ‘proteotypic peptides’) are used as standards [80]. To 
facilitate peptides synthesis, lengths below 15 aa are preferred and reactive side chains 
(cysteine, methionine) should be avoided. A major advantage of the AQUA technique is 
that post-translationally modified peptides can be synthesized, which can be useful to 
study signaling pathways [81]. However, one pitfall is that the standard is spiked in at the 
peptide level, and therefore does not corrected for errors introduced during sample 
processing and proteolytic digestion. This can lead to underestimation of the actual 
concentration in the sample. Moreover, incomplete digestion leading to missed cleaved 
peptides represents another source of error. Since AQUA peptides are commercially 
available, the method is broadly applied even though the synthetic, heavy peptides are 
relatively expensive. Owing to economic reasons targeted proteins are often quantified 
with only a single AQUA peptide, compromising accuracy.  
To extend peptide-based absolute quantification methods to samples with very high 
dynamic range such as plasma, Anderson and coworkers in 2004 introduced a method 
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termed Stable Isotope Standards and Capture by Anti-Peptide Antibodies, short SISCAPA 
[82]. As the name implies, antibodies raised against the peptides of interest are used to 
enrich it along with its corresponding spike-in standard. Besides increasing the sensitivity 
by enrichment of low-abundant peptides, the MS analysis time is reduced owing to low 
complexity (because ideally only the peptide of interest needs to be analyzed). Both, 
AQUA and SISCAPA are typically used in combination with multiple reaction 
monitoring (MRM), where specific peptide and fragment ions are monitored (also see 
page 6).  
 
Figure 14: Sample preparation workflows in MS-based absolute quantification of proteins. Various 
methods are available, each introducing the internal standard at a different step in the workflow. Adapted 
from [57, 83] 
For reliable quantification, it is highly desirable to quantify several peptides of the target 
protein in order to eliminate the effect of missed cleavages or possible unknown 
modifications on peptide quantification. The QconCAT (Quantification concatemer) 
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method is based on an artificial protein that is a concatenation of proteotypic peptides [84, 
85]. This enables efficient synthesis of many labeled peptides, which can be used for 
simultaneous quantification of tens of proteins, each with multiple peptides, thus 
increasing the confidence in quantification. The peptides within the concatemer are 
equimolar, restricting quantification to peptides with similar concentrations. To overcome 
this issue, peptides with similar abundance are grouped together into one QconCAT 
constructs.  
The QconCAT constitutes a synthetic gene, which can be recombinantly expressed and 
labeled in Escherichia coli (E. coli). The concatemer is purified with an affinity tag, 
quantified and then digested together with the sample to yield the internal standard 
peptides and endogenous peptides, therefore, potential errors introduced during 
proteolysis are corrected. Nevertheless, proteolysis efficiencies have to be monitored for 
each peptide because the protease digestion does not happen in the natural sequence 
context. Ito and coworkers further advanced the QconCAT methodology by surrounding 
the peptides on both sides with their natural flanking sequence, making cleavage 
efficiency more similar to the endogenous protein [86].  
The gold standard for accurate and reliable quantification is isotope-labeled full-length 
proteins, since they are the complete equivalent of the target protein, having identical 
biochemical characteristics. Full-length protein standards can be added directly to cell 
extracts or body fluids, allowing for extensive sample pre-fractionation or sample 
depletion [83]. Such pre-fractionation can be especially valuable for samples such as 
plasma, where it may allow detection of low-abundant proteins. Three methods based on 
full- length labeled proteins recently established: Protein standard absolute quantification 
(PSAQ) [87], absolute SILAC [57] and FLEXIQuant [88]. The labeled proteins are typically 
produced recombinantly in cell-free systems or in E. coli. The full-length proteins are 
highly purified and precisely quantified, commonly using amino acid analysis. The 
FLEXIQuant method differs in this respect as it uses an in vitro synthesized FLEXIQuant 
standard that is tagged with a FLEX-peptide. Quantification of this standard is achieved 
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by adding a known amount of AQUA peptide (FLEX-peptide) to the extract only 
quantifying the standard, therefore extensive purification is not required. The production 
of full-length protein is laborious and expensive, and therefore only a small number of 
proteins of interest are targeted for quantification using these methods. Moreover, not all 
proteins can be produced recombinantly, e.g. membrane proteins represent a particularly 
difficult class. In summary, an ideal absolute quantification approach would use the 
native sequence context during digestion, use multiple peptides for quantification, allow 
multiplexed quantification of proteins and enable a streamlined and economic strategy for 
standard production. 
 
Label-free quantification methods for relative and absolute quantification 
In label-free quantification, as the name implies, no label is introduced to the sample. 
These strategies are therefore applicable to virtually any sample, including and in 
particular clinical samples [89]. Samples are prepared and analyzed separately and a 
measure of protein abundance is assigned to each protein in each sample. In relative, 
label-free quantification these are compared computationally, therefore allowing for 
comparison of an unlimited number of samples. Because sample processing, LC and MS 
analysis are carried out separately, the variation between samples is typically higher than 
in label-based methods (Figure 11). Consequently, label-free quantification methods 
require a robust and ideally automated sample handling workflow. Label-free 
quantification strategies can be divided into two classes: (i) spectral counting and (ii) 
intensity based methods (Figure 15). 
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Figure 15: Label-free quantification: the first approach, spectral counting, compares the number of 
acquired spectra for each peptide, while the second, intensity based approach compares the 
chromatographic peak of the peptide. Adapted from [89]. 
In spectral counting, the number of fragmentation spectra identifying a protein are 
counted and used as a quantitative measure of the protein abundance. It is based on the 
empirical observation that the number of MS/MS spectra is directly related to the 
abundance of the peptide, therefore both absolute and relative quantification between 
different samples is possible [90, 91]. Spectral counting is a simple, intuitive method 
especially used in combination with low resolution mass spectrometric data. However, 
parameters such as the length of dynamic exclusion (time that a precursor mass is 
excluded from being sequenced again), chromatographic peak width and mass 
spectrometric scan speed can greatly influence the number of spectral counts and need to 
be tightly controlled. Therefore, to detect small changes in protein abundance to an 
acceptable precision, a relatively high number of MS/MS spectra is required [47]. 
Furthermore, protein size affects the number of proteolytic peptides detectable in the 
mass spectrometer and possibly introducing a bias. To account for the protein size, a 
‘spectral abundance factor’ (SAF) was defined [92] and later further refined into a 
‘normalized spectral abundance factor’ (NSAF) to make different runs comparable by 
normalizing with the total experiment SAF [93]. Another approach to normalize spectral 
counting data is termed ‘Absolute Protein Expression’ (APEX), which additionally 
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considers the physicochemical properties of the expected proteolytic peptides. This 
probability of observing a peptide in the mass spectrometer can be predicted using 
machine learning algorithms on large data sets [80]. Finally, to enable absolute protein 
quantification APEX relates total spectral counts to the total material loaded [94]. 
Besides counting spectra, the protein abundance can also be estimated by simple peptide 
counting. The protein abundance index (PAI) is defined as the number of observed 
peptides in the experiment divided by the number of theoretically observable peptides for 
each protein within the mass range of the MS [95]. The exponentially modified PAI 
(emPAI), an advancement of the PAI, is directly proportional to the protein content in a 
sample and can therefore be used to roughly estimate absolute protein quantities. 
The second class of label-free strategies are based on peptide intensities. The integrated 
signal response of peptide ions in the mass spectrometer is compared between states, as it 
is well known that in the MS the peak intensity correlates linearly to the concentration of 
the peptide within a large concentration range (see for example [96, 97]). The method is 
applied to shotgun proteomics data, in which peptides are chromatographically separated 
according to particular physicochemical properties (typically hydrophobicity) and then 
their peptide ion signals are recorded by the mass spectrometer generating the intensity 
profile as a function of the retention time (Figure 15). Therefore the accuracy of this 
method depends on achieving high separation of eluting peaks in the retention time and 
m/z dimensions. To obtain reliable quantification, the data have to further be corrected for 
errors introduced during parallel handling, and as well as for run-to-run variations in 
performance of the chromatography, the mass spectrometer, and the amounts of injected 
samples. Common post-processing steps in advanced computational proteomics are 
feature detection, alignment of retention times, normalization of total MS intensities, and 
matching and transferring identification between measurements to compensate for 
stochastic peak picking. Within the MaxQuant software label-free quantification is 
performed via the MaxLFQ algorithm, an algorithm including advanced normalization 
that is fully compatible with any peptide or protein separation prior to LC-MS analysis 
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[98].  Even though the computational effort is much higher than in simple spectral 
counting, intensity-based label-free approaches provide much better precision than 
spectral counting, in particular for low-abundant proteins since the continuous intensity 
readout is more informative and less stochastic than single spectra counts. 
Various strategies have been developed for absolute quantification of intensity-based 
label-free experiments. The ‘Top3’ approach proposed by Silva et al takes the median of 
the precursor intensities of the three best ionized (most intense) peptides of each protein 
as a measure of absolute protein abundance. One limitation of this method is that it 
requires at least three peptides of every protein to be quantified [99]. Another strategy to 
obtain absolute values, simply uses the sum of all peptides intensities of the protein as a 
measure for concentration. The summed intensities are divided by the total MS signal of 
all proteins, and the intensity values scaled either by the estimated total protein amount, 
or by using reference point derived from internal standards or natural standards such as 
histone protein content. One of these methods of scaling by estimated total protein 
amount is called intensity-based absolute quantification (iBAQ). In addition to 
normalizing the data by the observable peptides, it uses peptide intensities from, for 
example, commercially available protein standards (such as the Universal Protein 
Standard, UPS) to scale the data [11]. The newly developed ‘proteomic ruler’ concept, 
determines the total MS intensity of histones and makes use of its fixed relationship to the 
total DNA amount in the cell to deduce the cell number and thereby total protein content 
per cell [100]. The proteomics ruler method has the advantage that no spike-in is required 
for scaling, but the approach requires knowledge of parameters like the amount of DNA 
per cell. 
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Antibody-based proteomics 
So far only mass spectrometry-based proteomics has been described. However, protein 
analysis in a global manner can also be performed by antibody based methods. Here, I 
describe the Swedish Human Protein Atlas (HPA) project (directed by Mathias Uhlén) 
because my thesis work is partly based on a collaboration with this venture. The HPA 
aims to systematically explore the human proteome using antibody-based proteomics. 
Within the project they generate two or more independent antibodies for each gene 
product and use these to image the abundance and distribution of all proteins in cells and 
tissues. The first version of the publicly available HPA website and database was released 
in 2005 and included 700 antibodies. After several revisions the database has accumulated 
21 984 antibodies targeting 16 621 genes [101, 102]. The high-throughput antigen 
production, antibody generation and characterization are achieved in an elaborate 
workflow. In brief, the antigens, referred to as Protein Epitope Signature Tag (PrESTs), are 
automatically designed with following characteristics: (i) to have high specificity, and 
therefore they consist of 50 to 150 aa of an unique region representing the target protein 
(ii) to avoid ‘troublesome’ regions such as transmembrane regions and signal peptides. To 
achieve high-throughput production in E. coli, the PrESTs are fused to the Albumin 
Binding Protein (ABP), a solubility tag derived from the streptococcal protein G, which 
facilitates expression. Next, rabbits are immunized with the PrESTs and the antibodies are 
affinity purified from the polyclonal antisera using the target PrEST as ligand (Figure 16).  
 
Figure 16: Workflow of antibody production: the antigens are selected computationally, cloned into an 
expression vector, and this is followed by recombinant protein expression and purification. Rabbits are 
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immunized with the antigens and eventually the antibody is purified from the antisera using the antigen 
as ligand. 
The antibodies are validated by protein arrays and western blots. This allows exclusion of 
highly cross-reacting antibodies and ascertains that bands of appropriate molecular 
weights are recognized. Once quality controlled, the antibodies are used for protein 
profiling in a multitude of normal and cancerous tissues assembled in tissue microarrays, 
as well as in cell lines. The comprehensive HPA online database is divided into a tissue 
atlas, subcellular atlas and cell line atlas and also includes a large amount of high-
resolution imaging data. Additionally the HPA performed deep sequencing of the 
mRNAs (RNA-seq) for some of the cell lines to obtain transcript expression levels. 
 
Figure 17: Multi-functional characterization: first the antibody is tested for specificity in a western blot as 
well as on a protein array, then the protein expression patterns are studies via immunofluorescence and 
immunohistochemistry analysis 
The tissue atlas contains information of protein expression profiles based on 
immunohistochemistry of 46 normal tissues and 20 cancerous tissues from patients, and 
each image is annotated by pathologists. The subcellular atlas provides spatial 
information of protein expression from high-resolution, multicolor images of 
immunofluorescently stained cells. Besides U2OS cells, two additional cell lines based on 
the RNA sequencing data are selected for automated confocal microscopy analysis. The 
cell line atlas contains protein expression data based on immunohistochemistry for 46 
distinct cell lines and 10 leukemia cell lines and PBMCs from patients (Figure 17). To 
summarize, the human protein atlas features millions of high-resolution images showing 
protein expression profiles in tissues and cell lines and spatial distribution of proteins. A 
large number of the antibodies have been made available commercially.  
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Platelets 
The main biological application area of the SILAC-PrEST technology in my thesis were in 
platelet cells, which will be introduced in some detail now. Platelets are, besides 
erythrocytes and leukocytes, the smallest cells in the blood reaching a diameter of no 
more than 0.5 µm in mice or 1-2 µm in humans and one of their main functions is keeping 
the integrity of blood vessels. They are produced in the bone marrow by budding from 
their precursor cell: a giant, polyploidy cell called the megakaryocyte. Each 
megakaryocyte can give rise to thousands of platelets [103]. These cells circulate in the 
blood for 3-4 days in mice or 7-10 days in humans until they are degraded in the 
reticuloendothelial system of the spleen or liver. Platelets are devoid of a nucleus and 
DNA, however they share many features with conventional cells. For instance, they 
contain a cytoskeleton, ribosomes, mitochondria and secretory granules (dense, lysosomal 
and α-granules) (Figure 18). These granules are secreted upon platelet activation. While 
dense granules predominantly contain small molecules such as serotonin and ADP, α-
granules enclose proteins such as the von Willebrand factor and fibrinogen. Additionally, 
platelets have an open canalicular system (OCS) that plays a major role in activation by 
changing the morphological shape from their resting discoid form into their active 
dendritic structure [104]. 
 
Figure 18: Ultrastructure of platelets: (1) microtubuli (2) actin (3) myosin (4) dense granules (5) α-granules 
(6) lysosome (7) glycogen (8) mitochondria (9) plasma membrane (10) membrane invagination (11) open 
canalicular system (12) dense tubular system. Adapted from [105]. 
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Hemostasis 
Hemostasis is the process of building a thrombus to stop bleeding. Temporally it is 
divided into three phase: (1) primary hemostasis is the phase of adhesion and aggregation 
of platelets, and the consequent formation of a thrombus sealing the lesion; (2) secondary 
hemostasis is the activation of the blood coagulation cascade leading to formation of a 
fibrin network that stabilizes the thrombus; and (3) fibrinolysis, where fibrin formation is 
inhibited and the clot is broken down after the vasculature has been repaired. Since 
platelets are mainly involved in primary hemostasis, the following section only explains 
this part of hemostasis. 
In normal blood circulation within an intact vasculature, most platelets never adhere or 
aggregate during their entire life time. However, upon vascular injury subendothelial 
matrix, which includes proteins such as collagen, von Willebrand factor (VWF), 
fibronectin and laminin, is exposed. These adhesive proteins of the matrix serve as ligands 
for platelets in order to adhere and aggregate. In vessels with high shear rates such as 
small arteries and arterioles, the initial contact between platelets and damage vasculature 
occurs via VWF and the platelet surface receptor GPIbα. This interaction is not sufficient 
for stable adhesion, but fast on/off-rates enabling ‘rolling’ of the platelet on the vessel 
surface. This rolling then allows binding of the immunoglobulin superfamily receptor 
GPVI to collagen, which initiates activation. Molecularly, activation is characterized by 
intracellular signaling to shift integrins to a high-affinity state (‘inside-out signaling’) as 
well as by the release of ADP and thromboxane A2 (TXA2). In parallel to platelet 
recruitment, the extracellular matrix (ECM) releases tissue factor (thromboplastin) 
triggering thrombin formation. Together with ADP and TXA2, thrombin stimulates G-
protein coupled receptors (GPCR), which induce further signaling events and eventually 
lead to full platelet activation that include shape change and granula secretion [106]. 
Activated platelets recruit additional platelets by feedback amplification loops thereby 
inducing aggregation and formation of a hemostatic plug. The aggregation is primarily 
mediated by αIIb3 integrin, which bridges platelets to each other.  
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Clinical relevance 
Normally, platelets smoothly circulate through the arteries and veins surveying the 
integrity of the vasculature or in case of vascular injuries they participate in physiological 
hemostasis. Unfortunately, however, they are also involved in pathological thrombus 
formation for example at sites of atherosclerotic plaque rupture, which can lead to 
vascular occlusion. Thrombotic occlusion of the coronary or cerebral artery can lead to 
reduced blood supply to the heart or the brain resulting in acute myocardial infarction or 
acute ischemic stroke, respectively. In the developed world these disease collectively are 
the most common cause of death. Therefore antiplatelet therapies have been developed to 
prevent pathological platelet activation by blocking critical platelets proteins involved in 
activation and aggregation. Prominent examples are aspirin (inhibition of TXA2 
production), Clopidogrel and Ticlopidine (both ADP receptor antagonist) as well as 
Abciximab (αIIb3 integrin antagonist) [107]. 
To develop novel antiplatelet therapies that on the one hand prevent thrombosis, but on 
the other hand avoid the risk of bleeding complications, requires deeper understanding of 
the molecular mechanism by which platelets become activated. Moreover, besides their 
main function in maintaining the integrity of the circulatory system by hemostasis, 
platelets are involved in many processes ranging from combating microbial infection, 
triggering inflammation and promoting angiogenesis and many others [108], which are 
far from completely understood. Therefore determination of the platelet proteome in a 
quantitative way should be very useful to biology and medicine and could reveal new 
molecular players as well as providing starting points for diverse functional studies.   
Proteomics studies of platelets 
Traditionally, proteomic studies of the platelet proteome have been performed by two-
dimensional gel electrophoresis and together gel-based approaches have identified a few 
hundred proteins [109]. Concurrently, transcriptomics studies have been performed to 
predict the proteome [110], however because platelets lack a nucleus and no transcription 
occurs, the information that is gained by mRNA analysis is not easy to interpret. An initial 
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proteomics study of human platelets using modern MS instrumentation has already been 
performed and identified a few thousand proteins [111]. Yet a comprehensive quantitative 
platelet proteome map was not available for any mammalian species and remedying this 
situation was one of the goals of this thesis. 
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Results 
Development of the SILAC-PrEST method  
In this project I set out to develop an absolute quantification technique, which addresses 
the limitations of the present absolute quantification methods. To achieve this we joined 
forces with the Human Protein Atlas (HPA), which has produced a large resource of 
antigens, which have uniquely features making them a close-to ideal protein standard 
(Figure 19). First, antigens covering more than 75% of the human protein-coding genes 
have already been created by the HPA. Second, the 50 to 150 protein specific amino acids 
are selected to be unique regions of the target proteins with no or low homology to any 
other protein. They yield on average five MS-detectable tryptic peptides enabling robust 
and reliable quantification in principle. Third, each PrEST contains a common 120 aa 
albumin binding protein (ABP) solubility sequence enabling high-throughput 
quantification of the PrESTs. Importantly the PrEST standards do not need to be purified 
extensively since only the PrESTs and not the contaminations are quantified via the ABP. 
An inherent advantage of the ABP-PrEST fusion is that expression and purification of 
insoluble proteins are facilitated thereby enabling high-throughput production.  
 
Figure 19: Protein epitope signature tag (PrEST) - protein fragment consisting of an affinity tag, solubility 
tag as well as protein specific region 
As a baseline study we applied our quantification strategy to quantify more than 40 
different proteins in HeLa cells. This was done with light standards in heavy labeled cell 
lines as well as heavy standards in non-labeled cells. Using this streamlined method we 
showed that accurate quantification of any of the targeted proteins was feasible – without 
many of the limitations of existing methods. 
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The study was published in Molecular and Cellular Proteomics in 2012: 
‘A Protein Epitope Signature Tag (PrEST) library allows SILAC-based absolute quantification and 
multiplexed determination of protein copy numbers in cell lines’ 
Marlis Zeiler*, Werner L. Straube*, Emma Lundberg, Mathias Uhlén and Matthias Mann 
Mol Cell Proteomics. 2012 Mar;11(3) 
A Protein Epitope Signature Tag (PrEST)
Library Allows SILAC-based Absolute
Quantification and Multiplexed Determination
of Protein Copy Numbers in Cell Lines*□S
Marlis Zeiler‡**, Werner L. Straube‡**, Emma Lundberg§, Mathias Uhlen§¶,
and Matthias Mann‡
Mass spectrometry-based proteomics increasingly relies
on relative or absolute quantification. In relative quantifi-
cation, stable isotope based methods often allow mixing
at early stages of sample preparation, whereas for abso-
lute quantification this has generally required recombi-
nant expression of full length, labeled protein standards.
Here we make use of a very large library of Protein
Epitope Signature Tags (PrESTs) that has been developed
in the course of the Human Protein Atlas Project. These
PrESTs are expressed recombinantly in E. coli and they
consist of a short and unique region of the protein of
interest as well as purification and solubility tags. We first
quantify a highly purified, stable isotope labeling of amino
acids in cell culture (SILAC)-labeled version of the solu-
bility tag and use it determine the precise amount of each
PrEST by its SILAC ratios. The PrESTs are then spiked into
cell lysates and the SILAC ratios of PrEST peptides to
peptides from endogenous target proteins yield their cel-
lular quantities. The procedure can readily be multiplexed,
as we demonstrate by simultaneously determining the
copy number of 40 proteins in HeLa cells. Among the
proteins analyzed, the cytoskeletal protein vimentin was
found to be most abundant with 20 million copies per cell,
while the transcription factor and oncogene FOS only had
6000 copies. Direct quantification of the absolute amount
of single proteins is possible via a SILAC experiment in
which labeled cell lysate is mixed both with the heavy
labeled solubility tag and with the corresponding PrEST.
The SILAC-PrEST combination allows accurate and
streamlined quantification of the absolute or relative
amount of proteins of interest in a wide variety of
applications. Molecular & Cellular Proteomics 11:
10.1074/mcp.O111.009613, 1–13, 2012.
MS-based proteomics has become a method of choice to
study proteins in a global manner (1–3). Mass spectrometry is
not inherently quantitative but many methods have been de-
veloped to overcome this limitation. Most of them are based
on stable isotopes and introduce a mass shifted version of the
peptides of interest, which are then quantified by their “heavy”
to “light” ratio. Stable isotope labeling is either accomplished
by chemical addition of labeled reagents, enzymatic isotope
labeling, or metabolic labeling (4–6). Generally, these ap-
proaches are used to obtain relative quantitative information
on proteome expression levels in a light and a heavy labeled
sample. For example, stable isotope labeling by amino acids
in cell culture (SILAC)1 (7, 8) is performed by metabolic incor-
poration of light or heavy labeled amino acids into the pro-
teome. Labeled proteomes can also be used as internal
standards for determining protein levels of a cell or tissue
proteome of interest, such as in the spike-in SILAC approach
(9).
Absolute quantification is technically more challenging than
relative quantification and can only be performed accurately
for a single or a small number of proteins at a time (10). Typical
applications of absolute quantifications are the determination
of cellular copy numbers of proteins (important for systems
biology) or the concentration of biomarkers in body fluids
(important for medical applications). Furthermore, any precise
method of absolute quantification, when performed in more
than one sample, also yields the relative amounts of the
protein between these samples.
Several methods for absolute quantification have emerged
over the last years including absolute quantification (AQUA)
(11), quantification concatamer (QConCAT) (12, 13), protein
standard absolute quantification (PSAQ) (14), absolute SILAC
(15), and FlexiQuant (16). They all quantify the endogenous
protein of interest by the heavy to light ratios to a defined
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amount of the labeled counterpart spiked into the sample and
are chiefly distinguished by either spiking in heavy labeled
peptides or heavy labeled full length proteins. The AQUA
strategy is convenient and streamlined: proteotypic peptides
(17) are chemically synthesized with heavy isotopes and
spiked in after sample preparation. AQUA peptides are com-
mercially available but currently relatively expensive, espe-
cially when many peptides or proteins need to be quantified.
More fundamentally, the AQUA strategy suffers from quanti-
fication uncertainties that are introduced because of spiking in
of the peptide standard after sample preparation and enzy-
matic proteolysis, which is a late stage in the workflow. Fur-
thermore, any losses of the peptides—for example during
storage—would directly influence quantification results. The
QconCAT approach is based on artificial proteins that are
concatamers of proteotypic peptides. This artificial protein is
recombinantly expressed in Escherichia coli and spiked into
the sample before proteolysis. QconCAT in principle allows
efficient production of labeled peptides but does not auto-
matically correct for protein fractionation effects or digestion
efficiency in the native proteins versus the concatamers. The
PSAQ, absolute SILAC and FlexiQuant approaches sidestep
these limitations by metabolically labeling full length proteins
by heavy versions of the amino acids arginine and lysine.
PSAQ and FlexiQuant in vitro synthesize full-length proteins in
wheat germ extracts or in bacterial cell extract, respectively,
whereas absolute SILAC was described with recombinant
protein expression in E. coli. The protein standard is added at
an early stage, such as directly to cell lysate. Consequently,
sample fractionation can be performed in parallel and the
SILAC protein is digested together with the proteome under
investigation. However, these advantages come at the cost of
having to produce full length proteins, which limits throughput
and generally restricts these methods to soluble proteins.
In this study we advance the absolute SILAC approach by
making use of a highly scalable and already established sys-
tem for protein standard production. We employ short Protein
Epitope Signature Tags (PrESTs), which are produced in a
high-throughput manner by the Human Protein Atlas project
and subsequently used as antigens for antibody production
(18–20). The ultimate goal of the Human Protein Atlas is to
produce at least two specific antibodies to all human proteins
and to use this resource to study the tissue distribution and
the subcellular distribution of the human proteome (21–24).
PrESTs incorporate a sequence of about 100 amino acids of
the target protein chosen for minimal homology to other pro-
teins. Other criteria include avoidance of signal peptide se-
quences and sequences from transmembrane spanning re-
gions. These PrEST sequences are fused to a 6xHis tag for
purification and to a solubility tag derived from the albumin
binding domain of the streptococcal protein G (25). We rea-
soned that these attributes, combined with the fact that more
than 30,000 PrESTs, representing 18,300 human genes have
already been produced, would make the PrEST library an
excellent resource for streamlined, absolute SILAC based
quantification of human proteins.
EXPERIMENTAL PROCEDURES
Protein Epitope Signature Tags—The short protein fragments were
produced in high-throughput by the Human Protein Atlas where they
are used as antigens for antibody production (26, 27). In brief, suitable
Protein Epitope Signature Tags (PrESTs) representing unique regions
of each target protein were designed using the human genome se-
quence as template (EnsEMBL). Unique PrESTs with a size between
50 to 150 amino acids and low homology to other human proteins
were selected, excluding epitope- and domain-sized similarities to
other proteins, signal peptides, and transmembrane regions (26). The
cloning, protein expression, and purification were performed as pre-
viously described (27, 28). Part of the quality control is that all PrESTs
are evaluated and purity verified using SDS-PAGE and the molecular
weight is determined by mass spectrometry before further use. This
also excludes major “laddering” of the PrESTs. For optimal storage
PrESTs were lyophilized and dissolved in 8 M urea and stored at
20 °C until further use. To ascertain that the PrESTs had an endog-
enous counterpart in HeLa cells, we selected 50 proteins spread over
the abundance range of a HeLa proteome that we had measured at a
depth of about 4000 proteins. Proteins were picked without regards
to specific protein classes, cellular localizations, or functions. Of
these 50 proteins, 43 were readily available from the Protein Atlas
pipeline in recombinantly expressed form. For multiplexing experi-
ments these 43 PrESTs were mixed together—each at the appropri-
ate concentration. This “master mix” that was then spiked into cell
lysates.
Cell Culture—For SILAC labeling, HeLa cells were cultured in Dul-
becco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA) contain-
ing 10% dialyzed fetal bovine serum (Invitrogen) and penicillin/strep-
tomycin (Invitrogen). Heavy arginine (high purity Arg10, Cambridge
Isotope Laboratories, Andover, MA) and heavy lysine (high purity
Lys8, Cambridge Isotope Laboratory) were added to a final concen-
tration of 33 g/ml or 76 g/ml, respectively. After six passages cells
were fully labeled as assessed by mass spectrometry. Cells were
counted using a Countess cell counter (Invitrogen) and aliquots of 106
cells were snap frozen and stored at 80 °C.
Protein Expression and Purification of ABP (Albumin Binding Pro-
tein)—The expression vector pAff8c (Human Protein Atlas) was mod-
ified via SLIC cloning (29) inserting a OneStrep affinity tag to the C
terminus of the Albumin Binding Protein (ABP). To express heavy
labeled ABP in E. coli, an expression strain auxotrophic for arginine and
lysine was used (40). Cultures were grown in PA5052 minimal autoin-
duction media as previously described in (30) but with the addition of 18
normal (light) amino acids and heavy arginine and lysine. Cultures were
grown overnight and harvested at an OD600 of about 5.7. E. coli cells
were lysed in 100 mM Tris, 150 mM NaCl and Protease Inhibitor (Roche)
using a Bioruptor (Diagenode, Denville, NY). Cell debris was removed by
centrifugation and the supernatant was cleared by filtration through a
22-m filter. The soluble ABP was purified by affinity chromatography
on a StrepTap Hitrap column (GE Healthcare) coupled to an A¨KTA
system. The protein was loaded in binding buffer (100 mM Tris, 150 mM
NaCl, 1 mM dithiothreitol). After washing with 10 column volumes it was
eluted with elution buffer (100mM Tris, 150mMNaCl, 1 mM dithiothreitol,
2.5 mM desthiobiotin) (31). The purity of the protein was evaluated by
mass spectrometry via an in-solution digest followed by liquid
chromatography tandem MS (LC MS/MS). Abundances of ABP and
contaminants were estimated by adding the signal for their most
intense peptides. ABP was dialyzed in phosphate-buffered saline
(PBS), aliquoted, snap-frozen and stored at 80 °C. The concen-
tration of purified ABP was measured by amino acid analysis (Ge-
naxxon BioScience GmbH).
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The heavy labeled PrESTs were produced as described above
except that the PrEST was expressed and labeled using the aux-
otrophic E. coli strain in media containing Arg10 and Lys8.
Sample Preparation—HeLa cells were lysed in 100 mM Tris, 4%
SDS, 100 mM dithiotreitol, incubated for 5 min at 95 °C and disrupted
using a Bioruptor. The lysate was cleared by centrifugation through
SpinX filters (22 m, Corning, Corning, NY). The PrESTs were added
at appropriate concentrations (see main text) to labeled HeLa cells
and the samples were further processed by the FASP method (32). In
brief, proteins were captured on a 30-kDa filter and SDS was ex-
changed with an urea containing buffer. Proteins were alkylated with
iodoacetamide and trypsinized (Promega, Charbonnie`res, France).
Further peptide separation was performed using pipette-based six
fraction SAX as described (33).
The PrESTs and ABP were mixed and solubilized in denaturation
buffer (6 M urea, 2 M thiourea in 10 mM HEPES, pH 8), reduced with
dithiotreitol and subsequently alkylated with iodoacetamide. The pro-
tein mixture was digested with LysC (Wako) for 3 h, diluted with
ammonium bicarbonate and further digested with trypsin overnight.
The digestion was stopped by acidifying with trifluoroacetic acid and
desalted on C18-Empore disc StageTips (34).
Liquid Chromatography and Mass Spectrometry—Analysis of the
PrESTs spiked into HeLa cells was performed on an LTQ-Orbitrap Velos
mass spectrometer (Thermo Fisher Scientific) coupled to an Easy nano-
HPLC via a nanoelectrospray ion source (Proxeon Biosystems, now
Thermo Fisher Scientific). The peptides were separated on a 20 cm
fused silica emitter packed in-house with reversed phase material Re-
proSil-Pur 120 C18-AQ 1.8 m resin (Dr. Maisch GmbH) and eluted with
a 205-min gradient from 5–35% buffer B (80% acetonitrile, 0.5% acetic
acid). The mass spectrometer was operated in a data dependent fash-
ion to automatically measure MS and consecutive MS/MS. LTQ-Or-
bitrap full scan MS spectra (from 100 or 300 to 1650m/z) were acquired
with a resolution of 60,000 atm/z 400. The ten most abundant ions were
sequentially isolated and fragmented using higher energy collisional
dissociation (HCD) followed by analysis in the Orbitrap (35).
The ratios of the light PrEST versus heavy ABP peptides were
analyzed online on the Exactive instrument with HCD option (Thermo
Fisher Scientific) using the same nano-HPLC setup as described
above. The peptides were eluted with a linear gradient with 5–30%
buffer B over 40 min. The Exactive mass spectrometer identified
peptides with all ion fragmentation (AIF) by performing alternating
MS scans (300–1600 m/z) of the precursor ions and all ion fragmen-
tation scans (100–1600 m/z) using stepped HCD fragmentation (36).
Both scans were acquired at a resolution of 100,000 at m/z 200.
The heavy PrESTs versus light ABP peptides were analyzed using
the TriVersa Nanomate (Advion Biosciences), a chip implementation
of nanoelectrospray coupled to a LTQ Orbitrap XL. The samples were
eluted in 50% methanol, 0.5% formic acid. A voltage of 1.6 kV and a
nitrogen gas pressure of 0.35 psi was applied to spray the peptides
into the mass spectrometer. Each sample is sprayed to a single
nozzle on the electrospray ionization chip eliminating carryover. A
standard data dependent top10 collision-induced dissociation frag-
mentation method was applied for 2 min acquiring 40 full scans for
quantification (37).
Data Analysis—Acquired data were analyzed with MaxQuant (38)
(version 1.2.0.11) using the human IPI database (version 3.68; 87,083
entries). Common contaminants and the sequence of the ABP solu-
bility tag were added to this database. For peptide identification we
used Andromeda, a probabilistic search engine incorporated in to the
MaxQuant framework (39). Carbamidomethylation of cysteine was
included in the search as a fixed modification and methionine oxida-
tion as well as N-terminal acetylation were included as variable mod-
ifications. We allowed two miscleavages and required a minimum of
six amino acids per identified peptide. The initial mass tolerance for
precursor ions or fragment ions was set to 6 ppm and fragment
masses were allowed to deviate by up to 0.5 Th. For statistical
evaluation of the data obtained, the posterior error probability and
false discovery rate (FDR) were used. The false discovery rate was
determined by searching a reverse database and was set to 0.01 for
peptide identification. Additional peptides were identified by the
“match between run” option in MaxQuant, which matches precursor
masses in a 2-min retention time window (after realignment of the
runs) based on the accurate mass.
The AIF data was processed as described above except that up to 50
peaks were analyzed per 100 m/z with a tolerance of 15 ppm. The
precursor ion mass was matched with the possible fragment ion can-
didates on the basis of the cosine correlation value of at least 0.6 (36).
Enzyme-linked Immunosorbent Assay—Absolute amount measure-
ments of proto-oncogene c-Fos and Stratifin (14–3-3 ) was carried
FIG. 1. Schematic workflow for accurate determination of PrEST
concentrations. Heavy or light ABP is recombinantly expressed in an
auxotrophic E. coli strain and purified using the C-terminal OneStrep
tag. The heavy labeled ABP, whose concentration is measured sepa-
rately by amino acid analysis, and the PrEST are mixed together and an
in-solution digest is performed. Peptides are measured with a short LC
MS/MS run on a benchtop mass spectrometer and the PrEST concen-
tration is accurately determined by the SILAC ratio of the ABP peptides
originating from the PrEST and the ABP.
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out by ELISA. The kits were purchased from USCNK Life Science and
performed according to the manufacturer’s instructions. The HeLa
cells were lysed in PBS, RIPA 1 (50 mM Tris pH 7.5, 150 mM NaCl, 1%
Nonidet P-40) or RIPA 2 (50 mM Tris pH 7.5, 150 mM NaCl, 1%
Nonidet P-40; 0.1% SDS) with protease inhibitors. The cells were
disrupted by 3 freeze-thaw cycles and sonication using the Biorupter.
For the ELISA the samples were diluted 1:10. Fluorescence activity
was measured by a microplate reader (Tecan) and converted to actual
concentration by a standard curve.
RESULTS
Unlike relative quantification, absolute quantification is a
two-step process that requires measurement of firstly the
absolute amount of the standard and secondly the relative
amount of the standard compared with the analyte of interest.
Determination and subsequent control of the level of standard
is by no means trivial and can easily be the step that limits the
overall accuracy of the approach. Below, we first describe a
generic method to determine the absolute amount of each
PrEST with high accuracy. Then we construct a “master mix”
of different PrESTs and evaluate the ability of the SILAC -
PrEST method to accurately quantify cellular proteins. We
then apply the master mix to determine the copy numbers of
40 proteins in HeLa cells, a human cervical carcinoma cell
line. Finally, we describe an alternative workflow for the quan-
tification of single proteins of interest, in which the two steps
are combined into one LC MS/MS analysis.
Accurate Measurement of PrEST Concentrations—Each
PrEST is already fused to the ABP, a solubilization tag of 120
amino acids. In silico digest of ABP results in 40 tryptic
peptides with a length between 6 and 30 amino acids
(supplemental Table S1). We recombinantly expressed a
heavy SILAC labeled version of the ABP protein tag. When
necessary, we used a dual affinity approach based on an
N-terminal His-tag and a C-terminal OneStrep tag to generate
highly purified protein fragment and to ensure that only full
length ABP was obtained. The absolute concentration of ABP
protein fragment was determined by amino acid analysis,
which is the most accurate method for protein quantification,
but which is only applicable to highly purified proteins in
relatively large amounts. Heavy SILAC incorporation into ABP
was 99% and its purity was about 97% as judged by mass
spectrometry (see Experimental Procedures). Because these
two factors operate in a compensating direction and because
of the small size of the effect, the measured concentration of
ABP was not adjusted for them.
LC MS/MS of ABP indeed revealed many readily detectable
tryptic peptides (see below). Each of the 43 PrESTs from the
Protein Atlas Project was separately mixed with a known
amount of labeled ABP as schematically outlined in Fig. 1 to
allow for a SILAC LC-MS/MS experiment. As this experiment
requires a separate LC MS/MS run for each PrEST it was likely
to be rate-limiting for the overall project. We therefore decided
to perform this analysis on an economical and robust bench-
top Orbitrap instrument rather than on a Velos instrument. The
Exactive instrument cannot isolate peptide precursors, there-
fore we identified the peptides by AIF (36) in 1-h runs.
Typically, at least eight labeled ABP peptides could be
quantified against the corresponding ABP peptides from the
PrESTs, leading to a median coefficient of variation (CV) of 7%
for PrEST quantification (Fig. 2A).
To overcome the step of measuring the PrESTs concentra-
tion, which limits overall throughput, the heavy PrESTs were
measured by static nanoelectrospray on an automated chip-
based system (TriVersa Nanomate). This enabled higher
throughput measurements of these simple mixtures of ABP
peptides using low sample amounts. The peptide ratio
showed a median coefficient of variation 5.5%, an improve-
ment over the Exactive based measurement of 7%.
Importantly, a particular PrEST quantification can be re-
peated at this stage until a desired accuracy is achieved.
Here, this was not done, because the accuracy of PrEST
FIG. 2. Accuracy of ABP quantification. A, Density plot of the overall distribution of the 43 coefficients of variation (CVs) of the ABP peptides
measured on a benchtop Exactive mass spectrometer. B, Representative example proteins showing the H/L peptide ratios of the ABP peptides
deriving from the ABP standard and the ABP peptides in the PrESTs and their coefficients of variation (CVs).
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FIG. 3. Peptide ratios along the PrESTs sequences. The PrEST master mix was spiked into a lysate of HeLa cells and measured against
the endogenous protein. The peptide ratios were extracted to quantify the proteins. The variation of the peptide ratios along the sequence is
depicted. Overlapping peptides are because of missed cleavages. The gray bars correspond to the predicted limit tryptic peptides for the
PrEST region.
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quantification was estimated to be higher than that of the
other steps in the workflow. A few typical examples of results
from the PrEST quantification are shown in Fig. 2B. The
median of the SILAC ABP ratios is used for robustness. This
largely eliminates the contribution of outliers such as the ABP
peptide (ISEATDGLSDFLKSQTPAEDTVK) in the PrESTs for
proteins PPIB and UQCRC1, which had signals very close to
noise levels. Note that the quantification accuracy does not
depend on the cellular abundance or any other attributes of
the target protein, because the same amounts of PrEST is
used in each PrEST quantification experiment. Importantly,
quantification accuracy in our workflow also does not depend
on the purity of the PrEST because our method specifically
measures the concentration of PrEST and not of total protein.
PrEST Master Mix and Endogenous Protein Quantification—
Having quantified the PrEST amounts we proceeded to mea-
suring protein expression levels in HeLa cells. For conven-
ience we first used unlabeled PrESTs and quantified against
heavy SILAC labeled HeLa cells. Because digested total cell
lysates consist of hundreds of thousands of tryptic peptides,
the addition of a single or even a large number of PrESTs does
not change the overall complexity of the mixture. On the basis
of the quantitative amounts established above, we here mixed
43 PrESTs together. In initial experiments we used equimolar
mixtures of PrESTs, which were spiked into HeLa lysate in
different amounts. The measured SILAC ratios established
appropriate levels of each PrEST in the master mix, such that
the SILAC ratios were within the most accurately quantifiable
range, i.e. relatively close to one to one.
The master mix with appropriate levels of all the 43 PrESTs
was spiked into the lysate of SILAC labeled cells. The mixture
was digested according to the FASP protocol followed by
SAX fractionation and resulting in six fractions that were sep-
arately measured with 4-h gradients on an LTQ Orbitrap Velos
mass spectrometer. We were able to quantify 40 of the 43
proteins targeted by our PrEST master mix. Proteins were
generally quantified with several PrEST derived peptides (av-
erage 3.98 and median 3), leading to an overall median CV of
12% (supplemental Table S2). As an example, the adhesion
protein IQGAP1 was quantified with six peptides, which each
gave nearly identical quantification results (CV 9.9%). Five of
the six quantified tryptic peptides of ATP5B (mitochondrial
ATP synthase subunit beta), had very close SILAC ratios,
however, one peptide had a ratio that differed by 43% from
the median. This peptide is clearly an outlier and its deviating
value contributes substantially to the CV value, raising it from
8.7% to 23%. Note however, that we base protein quantifica-
tion on the median of the peptide values; therefore the outlier
peptide hardly contributes to the measured protein expression
value and the CV value therefore underestimates the accuracy
actually obtained in this experiment. For the same reason mod-
ifications of the endogenous proteins in the region covered by
the PrEST could cause outlier peptide ratios, which would con-
tribute little to the measured protein ratio (Fig. 3).
To independently assess the precision of this step of ab-
solute protein quantification, we compared the ratios deter-
mined from “limit tryptic peptides” (those without internal
arginine or lysine) to those determined from the longer ver-
FIG. 4. Reproducibility of the absolute quantification procedure. Three independent quantification experiments for representative
examples, in which the master mix preparation as well as the PrEST quantification were performed independently. The bars reflect the median
of the peptide ratios for each protein.
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sions of the peptide containing one or two missed tryptic
cleavage sites. These peptides are very problematic for pep-
tide standard based methods such as AQUA, but in our
measurements very similar ratios were measured for such
peptides. This shows that digestion proceeded identical for
PrEST and endogenous protein (Table I). Thus, far from intro-
ducing uncertainty, in the SILAC-PrEST approach these pep-
tides can provide additional quantification information.
To assess the degree of variability associated with both
steps of the absolute quantification procedure, we repeated
the entire workflow two more times, including PrEST quanti-
fication and master mix generation as well as measurement of
cellular abundance of the target proteins. This analysis
showed that the standard errors of the mean associated with
all steps together are on average 20%. This value is excellent
and to our knowledge the most accurate determination of
cellular expression levels reported so far. Even more impor-
tantly, the errors of each of the steps in the workflow for each
of the proteins are immediately apparent from the individual
CVs. Thus all protein expression level measurements can be
classified and accepted or discarded according to the confi-
dence of measurements. Fig. 4 displays typical examples of
protein expression determination from the triplicate measure-
ments. Comparing the peptide ratio spreads to the variability
of the mean protein values revealed that the preparation of the
master mix contributed the largest variability whereas errors
because of SILAC ratio determination were somewhat lower.
Automated preparation of the master mix could therefore lead
to further improvements in the future.
Protein Copy Number Determination in HeLa Cells—Next
we used the absolute values for protein amounts in our HeLa
cell lysate to calculate the corresponding copy numbers in
cells. HeLa cells numbers were determined automatically in
a cell counter (see Experimental Procedures). Given the
known amount of each PrEST and their SILAC ratios with
respect to the endogenous proteins we determined the cel-
lular copy numbers of 40 different proteins. Very high accu-
racy of absolute quantification to within a standard error of
25% was achieved for 35 of 40 proteins (Table II).
Cellular copy numbers are only known for very few proteins
and it is therefore interesting to relate these copy numbers to
the known functions of the proteins (supplemental Table S3).
The cytoskeletal protein vimentin forms intermediate filaments
and was the most abundant protein with 20 million copies per
cell. At the other extreme, the transcription factor and onco-
gene FOS is present in about 6000 copies in our HeLa cell
FIG. 5. Protein copy numbers determined per HeLa cell. The dot plot shows the protein copy numbers per cell measured in three
independent experiments. The error bars correspond to the CVs. Proteins with copy numbers ranging from 6000 to 20,000,000 per cell were
quantified (see also Table II).
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sample. As expected, proteins involved in cell signaling are
generally expressed at lower values—as an example even the
scaffolding factor mitogen-activated protein kinase scaffold
protein 1 (MAP2K1IP1) is present at only 140,000 copies.
However, ubiquitous signaling factors with a general chaper-
one-like role—such as 14-3-3 isoforms—are very highly ex-
pressed (14-3-3 sigma; 1.8 million copies). Two members of
the mitochondrial ribosome have about 200,000 copies in this
cell line (S23 and S28), whereas a third (L50) has about
400,000 (Note that not all ribosomal protein subunits have
equal stoichiometry). The mitochondrial genome only en-
codes 13 genes therefore it is perhaps surprising that proteins
involved in their translation are needed in such high copy
numbers. A member of the respiratory chain, ATP5B, has
about 4.5 million copies per HeLa cells—about fivefold higher
than PSMC3, a regulatory component of the proteasome. The
T-complex is a member of a chaperone system and as ex-
pected it has a very high copy number (about 4.5 million).
Fatty acid synthase, a classical enzyme, is expressed at 3.5
million copies, whereas another enzyme acyl coenzyme A
thioester hydrolase (ACOT7) is expressed about sevenfold
lower (500,000 copies). Such expression numbers could be
interesting for modeling metabolic pathways. These are an-
ecdotal examples but they illustrate that knowledge of the
absolute expression levels of cellular proteins can contribute
to the understanding of their roles in the cell.
Absolute Quantification Using Heavy PrESTs—Above we
used already expressed and purified PrESTs and quantified
TABLE I
Comparison of limit tryptic peptides and peptides with missed tryptic cleavage sites. Peptides with one or two miscleavages as well as their
ratios are depicted. The ratios of the two versions vary on average by 12%, which is in the normal range of variation of peptides derived from
one protein
Gene name Sequence
Missed
cleavages
Ratio H/L
mastermix
(1)
CV (%)
Ratio H/L
mastermix
(2)
CV (%)
Ratio H/L
mastermix
(3)
CV (%)
ATP5B IPVGPETLGR 0 0.85299 8.13 0.84263 16.92 1.1617 8.76
ATP5B VLDSGAPIK 0 0.76219 0.67515 0.99543
ATP5B VLDSGAPIKIPVGPETLGR 1 0.89528 0.95159 1.1652
CCT2 ILIANTGMDTDK 0 0.47498 39.26 0.37474 48.58 1.0965 –
CCT2 ILIANTGMDTDKIK 1 0.26858 0.1831 –
CCT2 VAEIEHAEK 0 0.4707 6.37 0.45578 8.24 1.1598 10.43
CCT2 VAEIEHAEKEK 1 0.51512 0.51219 1.3444
ECHS1 KLFYSTFATDDR 1 – 6.52 0.13372 23.26 – 0.01
ECHS1 LFYSTFATDDR 0 0.16792 0.15756 1.1803
ECHS1 LFYSTFATDDRK 1 0.18416 0.20966 1.1801
FASN QQEQQVPILEK 0 0.73946 4.04 0.69517 2.02 0.8985 1.63
FASN RQQEQQVPILEK 1 0.69837 0.67562 0.87805
FEN1 LDPNKYPVPENWLHK 1 0.73377 1.04 0.68 2.58 1.2048 3.81
FEN1 YPVPENWLHK 0 0.72303 0.70528 1.1416
HSPA4 EDQYDHLDAADMTK 0 0.2685 14.36 0.20351 5.45 0.79843 3.91
HSPA4 NKEDQYDHLDAADMTK 1 0.21899 0.21981 0.84382
PPIB DKPLKDVIIADCGK 2 0.47962 12.85 0.41764 14.10 1.0739 14.23
PPIB DVIIADCGK 0 0.5755 0.51014 1.3142
PRDX6 ELAILLGMLDPAEK 0 0.77082 14.35 0.61275 4.80 1.2449 1.05
PRDX6 ELAILLGMLDPAEKDEK 1 0.62879 0.65579 1.2636
PRDX6 VVFVFGPDK 0 0.6815 12.56 0.74577 2.37 1.1822 15.71
PRDX6 VVFVFGPDKK 1 0.81434 0.72122 0.94586
SFN YLAEVATGDDK 0 0.41281 1.53 0.38665 5.75 0.98489 15.17
SFN YLAEVATGDDKK 1 0.404 0.41942 0.79403
TPR LESALTELEQLR 0 0.1666 3.45 0.15943 8.07 1.1901 8.15
TPR LESALTELEQLRK 1 0.17493 0.17872 1.3357
VCP DHFEEAMR 0 0.20879 1.21 0.20611 10.27 1.4096 2.44
VCP RDHFEEAMR 1 0.20524 0.17819 1.459
VCP KYEMFAQTLQQSR 1 0.12676 33.99 NaN – 0.47634 72.12
VCP YEMFAQTLQQSR 0 0.20698 0.24338 1.4679
VIM QVDQLTNDK 0 0.79102 4.92 0.72609 2.57 1.3024 3.52
VIM RQVDQLTNDK 1 0.84806 0.70013 1.2391
VIM EKLQEEMLQR 1 NaN – 0.77968 7.15 NaN –
VIM LQEEMLQR 0 0.87912 0.8627 1.8464
VIM ILLAELEQLK 0 0.7214 0.83 0.71178 – 1.3289 49.04
VIM ILLAELEQLKGQGK 1 0.7299 NaN 2.7399
VIM DNLAEDIMR 0 0.813 23.04 0.79552 1.43 1.6492 29.83
VIM VEVERDNLAEDIMR 1 0.58525 0.77955 1.0746
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against heavy ABP protein and heavy SILAC-labeled cell ly-
sate. Although convenient to determine copy numbers in cell
lines, in other applications it would be more appropriate to
express heavy labeled PrESTs, which can then be mixed into
any proteome of choice—including tissue and clinical body
fluid samples. To apply our absolute quantification approach
to nonlabeled samples we expressed 28 of the PrESTs in
heavy SILAC labeled E. coli, purified them and prepared a
heavy master mix. To streamline quantification of PrEST lev-
els, we developed an automated set up employing static
nanoelectrospray (Advion NanoMate; see EXPERIMENTAL
PROCEDURES). As expected, spiking the heavy master mix
into normal, non-SILAC labeled cells allowed equally straight-
forward quantification of the targeted proteins, with good
correlation to the previous experiment (Fig. 6).
Absolute Quantification in Single Experiments—We also
wished to develop a variation on the SILAC-PrEST strategy to
quantify single protein target. In this case, the two experimen-
tal steps involved in absolute protein quantification can be
collapsed into one as outlined schematically in Fig. 7A. A
TABLE II
Protein copy numbers per HeLa cell
Protein names Gene name Median RSD (%)a Mastermix 1 Mastermix 2 Mastermix 3
14-3-3 protein sigma SFN 1,870,568 19.81 2,364,005 1,870,568 1,604,145
26S protease regulatory subunit 6A PSMC3 1,062,048 11.37 1,062,048 950,200 1,192,875
28S ribosomal protein S23, mitochondrial MRPS23 223,198 17.26 223,198 203,672 282,020
28S ribosomal protein S35, mitochondrial MRPS28 422,825 24.80 473,409 284,783 422,825
39S ribosomal protein L50, mitochondrial MRPL50 194,935 18.14 177,937 250,001 194,935
AFG3-like protein 2 AFG3L2 369,737 41.68 369,737 412,509 165,983
ATP synthase subunit beta, mitochondrial ATP5B 4,511,967 14.68 5,672,473 4,376,424 4,511,967
ATPase family AAA domain-containing protein 2 ATAD2 63,835 23.40 63,835 61,373 91,846
Carbonyl reductase NADPH 3 CBR3 79,823 94.26 79,823 61,399 322,454
Charged multivesicular body protein 6 CHMP6 83,028 67.19 122,476 43,581 -
Coiled-coil domain-containing protein 55 CCDC55 –b – – – –
COP9 signalosome complex subunit 5 COPS5 323,791 22.62 323,791 284,218 435,937
Cytochrome b5 reductase 4 CYB5R4 10,180 30.80 16,205 10,180 9,515
Cytochrome b-c1 complex subunit 1, mitochondrial UQCRC1 1,022,450 19.50 1,022,450 713,318 1,025,854
Cytosolic acyl coenzyme A thioester hydrolase ACOT7 512,746 4.79 512,746 472,208 514,556
Endoplasmic reticulum lipid raft-associated
protein 2
ERLIN2 149,867 19.53 206,262 148,785 149,867
Enoyl-CoA hydratase, mitochondrial ECHS1 2,105,336 28.10 2,965,394 1,723,133 2,105,336
Eukaryotic translation initiation factor 3 subunit 6 EIF3E 1,067,627 34.63 1,067,627 599,306 1,253,469
FACT complex subunit SSRP1 SSRP1 1,095,695 8.52 1,095,695 1,022,209 1,209,724
Fatty acid synthase FASN 3,536,145 17.98 4,043,129 2,804,853 3,536,145
Flap endonuclease 1 FEN1 2,019,699 20.42 2,372,346 2,019,699 1,563,785
Heat shock 70 kDa protein 4 HSPA4 1,646,549 19.22 2,146,713 1,499,858 1,646,549
Hepatocellular carcinoma-associated antigen 59 C9orf78 265,003 25.76 289,516 171,397 265,003
Lysophosphatidylcholine acyltransferase 1 AYTL2 – – – – –
Mitogen-activated protein kinase scaffold protein 1 MAP2K1IP1 141,520 68.85 182,796 27,116 141,520
Mixed lineage kinase domain-like protein MLKL 114,801 17.14 128,711 – 100,891
Nucleoprotein TPR TPR 357,637 17.53 397,408 278,736 357,637
Peptidyl-prolyl cis-trans isomerase B PPIB 10,502,199 29.14 15,610,836 9,112,850 10,502,199
Peroxiredoxin 6 PRDX6 8,781,079 3.07 8,881,373 8,377,838 8,781,079
Poly ADP-ribose polymerase 4 PARP4 63,971 7.07 60,775 67,168 –
Prefoldin subunit 1 PFDN1 476,849 36.22 476,849 523,643 243,332
Pre-mRNA-splicing regulator WTAP WTAP 49,143 51.10 31,385 – 66,902
Probable ATP-dependent RNA helicase DDX20 DDX20 213,466 19.17 242,403 184,529 –
Proto-oncogene c-Fos FOS 6,643 32.41 9,956 6,643 5,359
Purine nucleoside phosphorylase NP 1,555,814 23.04 2,101,680 1,357,920 1,555,814
Ras GTPase-activating-like protein IQGAP1 IQGAP1 1,296,511 20.65 1,796,903 1,260,937 1,296,511
SRA stem-loop-interacting RNA-binding protein,
mitochondrial
C14orf156 1,397,500 32.95 1,665,787 828,707 1,397,500
T-complex protein 1 subunit beta CCT2 4,479,130 48.47 7,447,762 2,757,533 4,479,130
THO complex subunit 1 THOC1 204,962 13.16 239,173 184,576 204,962
Transitional endoplasmic reticulum ATPase VCP 2,719,254 10.44 2,719,254 2,358,278 2,904,468
Uncharacterized protein C1orf65 C1orf65 – – – – –
Vimentin VIM 22,886,339 15.22 22,974,646 17,376,010 22,886,339
Zinc finger protein 828 C13orf8 72,135 19.47 74,281 51,084 72,135
a Standard error of the mean (S.E.) for the three replicates in percent.
b No valid data obtained.
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precisely known amount of the ABP solubility tag is mixed into
cell lysate together with the labeled PrEST. LC-MS/MS anal-
ysis of the sample then provides SILAC ratios of light ABP
solubility tag to labeled PrEST ABP peptides. These ratios
accurately quantify the amount of PrEST that was used. The
same LC MS data also contain the ratios of labeled PrEST
peptides to the unlabeled endogenous protein counterpart.
Together, these ratios quantify the absolute amount of endog-
enous protein in a single experiment (Fig. 7B). Note that
triple-SILAC labeling is not required in this approach because
the ratios are determined against different regions of the
PrEST construct, namely the common ABP solubility tag re-
gion (for quantifying the PrEST) and the protein specific PrEST
region (for quantifying the endogenous protein).
This single-plex method for quantification was performed
for three different HeLa proteins in which the SILAC-labeled
cell lysate and SILAC-labeled ABP was quantified against
unlabeled PrESTs. As shown in Fig. 7C, consistent values
were obtained in these measurements based on triplicate
experiments. The absolute levels generally agreed well with
the copy numbers determined independently in the multi-
plexed PrEST-SILAC experiment described above (maximum
difference between the means of 40%), validating both ap-
proaches.
Enzyme-linked Immunosorbent Assay—ELISA is a standard
method in biochemical research to determine absolute
amounts, or at least to reproducibly determine protein levels.
We therefore compared the SILAC-PrEST method to this
established technology. When performing the ELISA assay for
Stratifin (14-3–3 ) under typical conditions—filtered cell ly-
sate and PBS as recommended by the manufacturer—the
ELISA recorded less than 20% of the amount quantified by
MS. (Note that there is no interference by 14-3-3 isoforms
because these peptides are different.) The recommendation
of the manufacturer to dissolve in PBS could not solubilize the
pellet. The solubility was increased by adding the nonionic
detergent Nonidet P-40, which was able to dissolve most of
the sample pellet. Adding a low concentration of sodium
dodecyl sulfate (SDS), an anionic detergent, further improve-
ment significantly increased measured protein amount (Fig.
8A). Still the absolute amounts were underestimated twofold
compared with mass spectrometry analysis, presumably be-
cause the FASP protocol enables complete solubilization by
the use of 4% SDS.
We also investigated the levels of the transcription factor
and proto-oncogene FOS by ELISA, the lowest abundance
protein quantified in our mix. Here solubilization did not ap-
pear to be an issue and we received excellent agreement
between quantitative values determined by MS and by ELISA
using different buffer conditions (Fig. 8B).
DISCUSSION AND OUTLOOK
Here we have developed methods to determine the abso-
lute levels of proteins in cells by taking advantage of the
absolute SILAC concept as well as the availability of a large
library of PrEST protein fragments. PrESTs already contain an
ABP solubility tag, which facilitates recombinant expression
of PrESTs against a wide variety of cellular targets. We found
that this solubility tag is an excellent “quantification tag” be-
cause it generates a large number of readily quantifiable pep-
tides upon tryptic digestion. After producing a highly purified
and accurately quantified “gold standard” of the ABP tag
alone, it can be used to quantify all PrESTs in turn. Impor-
tantly, the purity of the PrEST is not a concern because
quantification is only performed against the PrEST compo-
nent and not against possible E. coli or other contaminants.
PrESTs have already been produced against 80% of the
human proteome and an “industrialized pipeline” for their pro-
duction is in place. Although almost all PrESTs so far have been
produced for human target proteins, they could in principle be
made for any other species in exactly the same way. Further-
more, in many cases more than one PrEST has been made for
the same protein to allow for the generation of paired antibodies
and pair-wise validation of antibody staining patterns (23). Like-
FIG. 6. Absolute Quantification using heavy PrESTs. A, Comparison of copy numbers obtained by quantifying light PrESTs against SILAC
labeled heavy cell lysate (black symbols) versus quantifying heavy PrESTs against unlabeled cell lysate (red symbols). B, Values shown in A
but plotted as a scatter graph.
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wise, different PrESTs could be produced in cases where the
current ones are not optimal for MS-based quantification.
For preparation of a SILAC-PrEST mixture we estimated the
appropriate amount of PrESTs in a two-step procedure. In the
future it may be simpler to estimate the amount of protein
roughly from the peptide signals from in-depth proteome
experiments. PrESTs spiked in at corresponding amounts will
likely be in the easily quantifiable range in most cases. The
overall accuracy of the SILAC-PrEST approach can be mon-
itored for each step in the procedure and it currently appears
to be limited by manual pipetting accuracy. It is likely that
precision of all steps in the procedure can be improved sig-
nificantly in the future.
Here we have demonstrated applications of SILAC-PrESTs
for copy number determination in cell lines. However, the
principle should be applicable in the same way to absolutely
quantify proteins from any source and we plan to investigate
this shortly.
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FIG. 7. Direct quantification of a single protein in HeLa cell lysate. A, Principle of the ‘single-plex’ strategy for the direct quantification of a
single protein. In the same experiment, SILAC peptide ratios mapping to the ABP quantification tag determine the amount of PrEST whereas SILAC
ratios mapping to the protein specific region of the PrEST construct determine the level of the endogenous proteins. The experiment can be
performed with SILAC heavy labeled cells, unlabeled PrEST construct and heavy labeled ABP tag (left side) or vice versa (right side). B, Single-plex
determination of absolute protein amount. In the workflow depicted here, an unlabeled PrEST construct as well as a heavy labeled ABP tag are both
spiked into HeLa cell lysate before digestion. C, Comparison of copy numbers obtained from the “master mix” experiment with those from the
single-plex experiments for three different proteins. Error bars are standard deviations of the mean from triplicate measurements.
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Results 
 
55 
Development of the immuno-SILAC method  
Having PrESTs and corresponding antibodies in hand it was attractive to combine both to 
develop a very sensitive and fast quantification method for a number of proteins of 
interest by using the antibodies for enrichment of the peptides from complex samples. In 
particular, clinical samples such as plasma are highly complex and can have a very large 
concentration difference between abundant proteins and clinical relevant marker proteins. 
In some respects the method conceptually resembles other affinity enrichment methods 
such as SISCAPA [82, 112], however it also has major differences and advantages. Since 
polyclonal antibodies, raised against protein fragments (PrESTs) are used, multiple 
peptides can be enriched for the same PrEST target. In fact epitope mapping detected on 
average three epitopes per antibody. However, we also discovered that sometimes the 
epitopes contain a cleavage site making the corresponding peptides inaccessible for 
enrichment. The study clearly highlights one of the main advantages of using PrESTs 
compared to methods like SISCAPA: Because the standard is spiked in prior to digestion, 
differences in proteolytic efficiency between standard and sample and in particular 
missed cleavages do not affect quantification detrimentally. By multiplexing different 
antibodies for the enrichment step, many proteins can be quantified in parallel in a short 
time – demonstrated here with relatively short 15 min gradients. In summary, this study 
successfully established the immuno-SILAC concept in HeLa cells and compared it to the 
SILAC-PrEST method. 
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Immunoproteomics Using Polyclonal
Antibodies and Stable Isotope–labeled
Affinity-purified Recombinant Proteins*□S
Fredrik Edfors‡§, Tove Bostro¨m§¶, Bjo¨rn Forsstro¨m‡, Marlis Zeiler,
Henrik Johansson**, Emma Lundberg‡, Sophia Hober¶, Janne Lehtio¨**,
Matthias Mann, and Mathias Uhlen‡¶‡‡
The combination of immuno-based methods and mass
spectrometry detection has great potential in the field of
quantitative proteomics. Here, we describe a new method
(immuno-SILAC) for the absolute quantification of pro-
teins in complex samples based on polyclonal antibodies
and stable isotope–labeled recombinant protein frag-
ments to allow affinity enrichment prior to mass spec-
trometry analysis and accurate quantification. We took
advantage of the antibody resources publicly available
from the Human Protein Atlas project covering more than
80% of all human protein-coding genes. Epitope mapping
revealed that a majority of the polyclonal antibodies rec-
ognized multiple linear epitopes, and based on these re-
sults, a semi-automated method was developed for pep-
tide enrichment using polyclonal antibodies immobilized
on protein A–coated magnetic beads. A protocol based
on the simultaneous multiplex capture of more than 40
protein targets showed that approximately half of the
antibodies enriched at least one functional peptide de-
tected in the subsequent mass spectrometry analysis.
The approach was further developed to also generate
quantitative data via the addition of heavy isotope–labeled
recombinant protein fragment standards prior to trypsin
digestion. Here, we show that we were able to use small
amounts of antibodies (50 ng per target) in this manner for
efficient multiplex analysis of quantitative levels of pro-
teins in a human HeLa cell lysate. The results suggest that
polyclonal antibodies generated via immunization of re-
combinant protein fragments could be used for the en-
richment of target peptides to allow for rapid mass
spectrometry analysis taking advantage of a substantial
reduction in sample complexity. The possibility of build-
ing up a proteome-wide resource for immuno-SILAC
assays based on publicly available antibody resources is
discussed. Molecular & Cellular Proteomics 13:
10.1074/mcp.M113.034140, 1611–1624, 2014.
Mass spectrometry–based proteomics is fast developing in
the direction of clinical applications. Therefore, reliable quan-
tification methods for absolute protein concentration determi-
nation are indispensible tools for future applications. So far,
enzyme-linked immunosorbent assays and similar antibody-
based methods excel in the sensitive detection of low levels of
proteins in complex matrices, whereas mass spectrometry
enables unbiased approaches and can provide unsurpassed
specificity. The fact that most proteomes have a very high
dynamic range between high and low abundant proteins, in
particular for clinical samples, such as plasma and serum,
often makes it necessary to use protein depletion of the most
abundant proteins (1, 2) and/or elaborate fractionations (3–5)
before running the mass spectrometry analysis. This has
prompted several investigators to introduce a protein or pep-
tide capture step using specific antibodies to allow for immu-
noaffinity enrichment prior to the MS analysis. In this way, a
“sandwich” assay is obtained, but instead of having a readout
in the analysis step based on a second antibody, the analysis
step is performed using MS. In such an approach, either the
intact protein is captured using an anti-protein antibody (6) or
a peptide derived from the protein is captured using an anti-
peptide antibody that has been raised to the target peptide of
interest (7–11). This is the principle behind stable isotope stand-
ards and capture by anti-peptide antibodies (SISCAPA),1 devel-
oped by Anderson and co-workers (12–15). In immunoaffinity
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proteomics, it is preferable for the affinity of the anti-peptide
capture antibody to be high, but the requirement for high se-
lectivity is lower, because the mass spectrometer can readily
distinguish and quantify the analyte peptide of interest despite
the binding of other peptides in the digested sample.
A disadvantage with the immunoaffinity proteomics strat-
egy is the limited availability of suitable antibodies that rec-
ognize peptides from the corresponding protein targets. The
affinity enrichment of peptides usually requires the generation of
custom antibodies for each target peptide, and this very time-
consuming process makes high-throughput efforts very difficult
to pursue. Most efforts so far have been aimed toward gener-
ating monoclonal antibodies against specific peptides selected
as appropriate for mass spectrometric detection, which is a
laborious and costly exercise. It would therefore be of great
interest to explore whether antibodies generated toward native
proteins or protein fragments could be used for the capture of
peptides and in this way take advantage of the huge resource of
already existing reagents for immunoproteomics.
Here, we investigated whether the publicly available re-
sources on polyclonal antibodies could be used for immuno-
enrichment followed by quantitative proteomics. According to
the Antibodypedia portal, there exist more than a million pub-
licly available antibodies toward human protein targets, and
more than 70% of these antibodies are polyclonal antibodies.
These antibodies are of course interesting starting points as a
resource for immunoproteomics, although this application
was not intended at the time when the antibodies were gen-
erated. More specifically, we have investigated the use of
polyclonal antibodies from the Human Protein Atlas project,
covering more than 80% of all human protein-coding genes.
These antibodies have been raised against human recombi-
nant proteins called protein epitope signature tags (PrESTs),
and we have therefore investigated the direct use of this
resource for quantitative proteomics.
An attractive strategy for quantitative proteomics using im-
muno-enrichment is to use stable isotope approaches, includ-
ing methods based on adding stable isotope–labeled pep-
tides (16, 17), proteins (18, 19), or protein fragments (20).
These methods are built on the detection of peptides gener-
ated by protease cleavage of the proteins in the sample, and
the quantification is achieved by reading out the ratio between
the endogenous peptide and the heavy-labeled spiked-in
peptide. Because the endogenous protein and the labeled
internal standard behave identically throughout the sample
preparation including the immuno-enrichment, the relative ra-
tio provides quantitative information, as the peptides can be
distinguished by the mass spectrometer because of the shift
in mass. We recently described (20) a method for protein
quantification making use of the large library of PrESTs that
has been developed in the course of the Human Protein Atlas
(21) project. Heavy isotope–labeled PrESTs were quantified
against an ultrapurified and accurately quantified protein
standard using the albumin binding protein (ABP) tag. There-
after, known amounts of heavy PrESTs were spiked into cell
lysates, and the SILAC ratios were used to determine the
cellular quantities of the endogenous proteins. That approach
sidesteps the quantification-, storage-, and digestion-related
causes of quantification error that are inherent to peptide-
based methods. The PrEST-SILAC principle was used to si-
multaneously determine the copy numbers of 40 proteins in
HeLa cells demonstrating quantitative measurements over a
wide range of protein abundances, from the highly abundant
cytoskeletal protein Vimentin, with 20 million copies, down to
the low abundant transcription factor FOS, with only 6000
copies per cell.
Here, we combined the use of polyclonal antibodies for
immunocapture with quantitative proteomics using heavy
isotope–labeled proteins. A semi-automated immuno-SILAC
method was developed for multiplex analysis of protein tar-
gets, taking advantage of the linear epitopes of the antibod-
ies. A special effort was made to decrease the amounts of
antibodies used in the assay. Based on the results, a new
strategy for rapid mass spectrometry readout for target-spe-
cific proteomics is outlined in which antibodies are used for
the multiplex immunocapture of peptides generated via tryp-
sin digestion of cell extracts spiked with isotope-labeled re-
combinant protein fragments corresponding to the protein
targets.
EXPERIMENTAL PROCEDURES
Generation of Antibodies—Antigens were designed using the soft-
ware PRESTIGE (22). Gene fragments were amplified from a pool of
RNA isolated from human tissues, cloned into a vector, and ex-
pressed in Escherichia coli. To generate polyclonal antibodies, puri-
fied and validated recombinant protein fragments were used for the
immunization of New Zealand White rabbits, and the polyclonal rabbit
sera were purified using their corresponding antigens as affinity li-
gands (23).
Epitope Mapping Using High-density Peptide Array—High-density
peptide arrays were designed to contain 12-mer peptides with an
overlap of 11 amino acid residues, in total covering all the antigen
sequences. Parallel in situ peptide synthesis on microscope slides
and removal of side chain protecting groups were performed by
Roche NimbleGen Inc. (Madison, WI). Each slide containing 12 iden-
tical subarrays was covered with a PX12-mixer mask (Roche Nimble-
Gen Inc.) according to the manufacturer’s instructions. The polyclonal
antibodies were combined into pools of 20 antibodies and diluted in
binding buffer (10 mM Tris, 0.45% NaCl, pH 7.4, alkali soluble casein
0.5%) to a final concentration of 0.5 g/ml for each antibody. The
samples were added to the peptide arrays and incubated overnight at
room temperature in a NimbleGen Hybridization Station (Roche
NimbleGen Inc.). After primary incubation, the mixer masks were
removed and the slides were washed in coplin jars twice with TBSTT
(20 mM Tris, 0.9% NaCl, pH 7.4, 0.1% Tween 20, 0.4% Triton X-100)
and twice with TBS, with each wash lasting 10 min. Secondary
DyLight649 conjugated anti-rabbit antibodies (Jackson Immuno-
Research, West Grove, PA) were diluted to 0.15 g/ml in binding
buffer in LockMailer jars, and the slides were incubated for three
hours on a shaking table. The slides were washed again twice with
TBSTT and twice with TBS as described above, quickly rinsed three
times in filtered de-ionized water, and dried using a microarray slide
centrifuge. The slides were scanned at 2 m resolution using a
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NimbleGen MS200 scanner (Roche NimbleGen Inc.), and the median
fluorescence intensities of the peptide features in the scanned images
were analyzed using the NimbleScan software (Roche NimbleGen
Inc.).
Preparation of PrEST Digest—PrESTs were mixed into three pools
of 41, 42, and 44 targets, respectively. Samples containing 10 g of
each PrEST were first reduced with DTT and thereafter digested using
the filter-aided sample preparation method (24). Briefly, the sample
was added to a 30-kDa cutoff spin filter (Millipore, Bedford, MA), and
the buffer was exchanged to denaturation buffer. The sample was
alkylated with iodoacetamide and the buffer was changed to 50 mM
NH4HCO3 before trypsin (Sigma-Aldrich, St. Louis, MO) was added,
and the sample was incubated at 37 °C overnight.
Affinity Enrichment of Peptides Using Polyclonal Antibodies—Im-
munoaffinity enrichment of peptides from the trypsin-digested PrEST
mixture was carried out with a subset of 127 polyclonal rabbit anti-
bodies. A total of 250 ng of each antibody was pooled into 41-, 42-,
and 44-plex pools, and the final volume was adjusted to 300 l with
PBS and Chaps detergent to yield a final concentration of 0.03%
(w/v). In parallel, 5.3 mg of Protein A Dynabeads (Invitrogen, #10001D)
was placed on a handheld magnet (Dynal, Oslo, Norway), and the
storage buffer was removed before the beads were washed twice
with wash buffer (1 PBS, 0.03% (w/v) CHAPS). Each subset of
pooled antibodies was immobilized together with 150 g of Protein
A–coated beads per microgram of antibody and incubated for 30 min
on a rotor mixer for 1 h at room temperature. A total of 200 ng of each
trypsin-digested PrEST was diluted to 50 l with PBS-supplemented
CHAPS to a yield a final concentration of 1 PBS, 0.03% (w/v)
CHAPS. All samples were prepared in duplicate and transferred to
one 96-well standard microplate (ABgene, Hamburg, Germany) that
was inserted into a Magnatrix 1200 (Magnetic Biosolutions AB, Stock-
holm, Sweden) automated bead processing system. Afterward, im-
mobilized antibody–bead mixtures corresponding to 50 ng of anti-
body per target were transferred in triplicate to separate wells in a
96-well PCR plate (Thermo Scientific), and the plate was inserted into
the Magnatrix 1200 system. The beads were washed twice with wash
buffer and mixed with the peptide mixture from the trypsin-digested
PrEST mixture using robotics. The 96-well standard microplate was
manually covered with an opaque adhesive foil, and peptides were
enriched for 16 h overnight at room temperature on a microtiter plate
shaker at 1350 rpm. The following day, the plate was inserted into the
Magnatrix 1200, and the beads were washed twice with wash buffer
and then twice with 50 mM NH4HCO3. The enriched peptides were
eluted with 10 l of 0.1% formic acid (pH 2.5) for 2 min. All samples
were heat treated at 96 °C for 5 min in order to denature antibodies
that were eluted along with peptides from the solid bead support.
Each sample was manually supplemented with 1 l of 33% acetoni-
trile prior to storage at 20 °C until LC-MS analysis.
Production of Antigen Standards for Absolute Quantification—The
expression vector pAff8c containing a fragment coding for the quan-
tification standard HisABPOneStrep was transformed into E. coli
Rosetta DE3 cells (Novagen, Merck, Darmstadt, Germany), and
HisABPOneStrep was expressed according to the standard protocol
used within the Human Protein Atlas project (25). After purification
using immobilized metal ion affinity chromatography and buffer ex-
change to 1 PBS (10 mM NaP, 150 mM NaCl, pH 7.3) on a PD-10
desalting column (GE Healthcare, Uppsala, Sweden), a second puri-
fication step was performed using a StrepTrap™ HP column (GE
Healthcare) on an A¨KTAexplorer system (GE Healthcare) according to
the suggested protocol. The concentration of the purified protein was
determined using amino acid analysis. Expression vectors containing
PrEST fragments were transformed into an E. coli strain auxotrophic
for lysine and arginine (26) for the production of heavy isotope–
labeled PrESTs. A total of 41 targets were chosen for this purpose.
Included PrESTs contained at least five theoretical tryptic peptides
that had previously been detected in discovery proteomics experi-
ments (data not presented here). These PrESTs were non-overlapping
with the set used for the affinity enrichment screening. Cultivations of
10 ml were performed in 100-ml shake flasks using minimal autoin-
duction media as previously described (20, 27). Heavy isotope–
labeled (13C and 15N) arginine and lysine (Cambridge Isotope Labo-
ratories, Tewksbury, MA) and light versions of the remaining 18 amino
acids (Sigma-Aldrich) were added to the medium to a final concen-
tration of 200 g/ml. After cultivation, the cells were lysed and the
PrESTs were purified according to the standard Human Protein Atlas
protocol (25).
Quantification of PrESTs—HisABPOneStrep and heavy isotope–
labeled PrESTs were mixed in 50 mM NH4HCO3. The sample was
reduced with DTT, alkylated with iodoacetamide, and digested with
trypsin (Sigma-Aldrich) overnight. The samples were diluted in 5%
acetonitrile, 0.1% formic acid, injected onto a 150 mm  0.5 mm
Zorbax 80SB-C18 column (Agilent, Santa Clara, CA), and separated
using a 20-min gradient of 10%–40% acetonitrile with a flow rate of
20 l/min on an Agilent 1200 capillary-LC system. The peptides were
analyzed using an Agilent 6520 electrospray ionization quadrupole
TOF mass spectrometer in a data-dependent manner; three precursor
ions per cycle were chosen and fragmented via collision-induced
dissociation. The isolation width was set at 4 m/z. Full-scan MS
spectra were acquired between 300 and 2000 m/z, and product ion
scans between 100 and 2000m/z. Data analysis was performed using
the software APP (unpublished), combining several MS analysis mod-
ules into one data analysis tool. The search engine X!Tandem (28)
(version 2011.12.01.1) was used with the human UniProt database
(70,555 entries, downloaded May 28, 2013) with the addition of the
HisABPOneStrep sequence. Carbamidomethylation of cysteines was
added as a fixed modification, and methionine oxidation was allowed
as a variable modification. The minimum peptide length was five
amino acids, and a maximum of two missed cleavages was allowed.
Data from X!Tandem were further processed with PeptideProphet (29)
and ProteinProphet (30), and SILAC ratios were determined with
XPRESS software (31) (all from TPP v4.6 occupy rev 3). Three tech-
nical replicates were performed for each PrEST, and the median value
was used when determining the protein concentration.
Preparation of HeLa Cell Lysates and Trypsin Digestion—HeLa
cells (32) were cultivated in Dulbecco’s modified Eagle’s medium
(Sigma-Aldrich) containing 10% fetal bovine serum (Sigma-Aldrich)
and antibiotic and antimycotic solution (Sigma-Aldrich). Cells were
released from the culture dish with a trypsin-EDTA solution (Sigma-
Aldrich) and frozen at 80 °C in aliquots of 10 million cells per tube.
Tubes were thawed on ice, and the cells were lysed with 1 ml of lysis
buffer (0.1 M Tris-HCl, 4% SDS, 10 mM DTT, pH 7.6). Samples were
incubated at 95 °C for 3 min and sonicated for 1 min. Aliquots of 100
l corresponding to 1 million HeLa cells were used for tryptic diges-
tion. For the first experiment, 1 pmol of each heavy isotope–labeled
PrEST was spiked into the HeLa sample. Triplicate samples were then
prepared in which the PrEST amounts had been adjusted to a ratio
close to 1:1 relative to the corresponding endogenous protein. The
correct amount of each PrEST was mixed and reduced with DTT
before the PrEST mix was spiked into the HeLa lysate. The sample
was diluted with denaturing buffer (8 M urea, 0.1 M Tris-HCl, pH 8.5)
and centrifuged through a 0.65-m spin filter (Millipore) to get rid of
cell debris. Digestion was performed using the filter-aided sample
preparation method (24) as described above.
Peptide Fractionation for PrEST-SILAC—Before MS analysis, 30
g of the peptide mixture was divided into six fractions by means of
strong anion exchange chromatography. This was done in a pipette-
tip format as previously described (33). In brief, pipette tips were
packed with strong anion exchange material (3M Bioanalytical Tech-
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nologies, St. Paul, MN), and the peptide sample was loaded. Peptides
were eluted according to isoelectric point with buffers of decreasing
pH. After fractionation, eluted peptides were desalted using C18
StageTips.
Absolute Quantification of HeLa Cell Lysate—Immunoaffinity en-
richment of peptides from trypsin-digested HeLa lysate, into which
heavy PrESTs had been spiked prior to digestion, was carried out in
the same way as described above for 41 polyclonal rabbit antibodies
for which heavy-labeled PrESTs were available. Here, a total of 15 g
of trypsin-digested HeLa lysate with spiked-in heavy PrESTs was
diluted to 50 l with PBS-supplemented CHAPS to a yield a final
concentration of 1 PBS, 0.03% (w/v) CHAPS. A total of 500 ng of
each corresponding antibody was pooled (41-plex), and the final
volume was adjusted to 500 l with PBS and CHAPS detergent to
yield a final concentration of 0.03% (w/v). All antibodies were immo-
bilized onto 3.15 mg Protein A–coated magnetic beads. All samples
were prepared in triplicate and processed in the same way as de-
scribed above.
Liquid Chromatography and Mass Spectrometry—For PrEST-
SILAC samples, 2 g of peptides per fraction were analyzed, and for
immuno-SILAC, only 50% of the sample was used. Peptides were
first trapped on a Zorbax 300SB-C18 column (Agilent) and separated
on an NTCC-360/100–5-153 (Nikkyo Technos Co., Ltd., Tokyo, Ja-
pan) column using a gradient of 6%–40% acetonitrile over 180 min
(PrEST-SILAC) or 15 min (immuno-SILAC) with a flow rate of 0.4
l/min on an Agilent 1200 nano-LC system. MS analysis was per-
formed on a Q Exactive instrument (Thermo Fisher Scientific, San
Jose, CA) operated in a data-dependent manner, with five precursors
selected for fragmentation by higher energy collisional dissociation in
each full MS scan. MS spectra were recorded between 300 and 1700
m/z at 70,000 resolution, and MS fragment ion spectra were recorded
at 17,500 resolution.
Analysis of PrEST-SILAC and Immuno-SILAC MS Data—Data from
Q Exactive MS runs were analyzed using MaxQuant software (34)
(version 1.3.0.5) with the built-in search engine Andromeda (35). A
human UniProt database (70,555 entries, downloaded May 28, 2013)
was used in the search. The minimum peptide length was six amino
acids, and two missed cleavages were allowed. Carbamidomethyla-
tion of cysteines was set as a fixed modification, and methionine
oxidation and N-terminal acetylation were chosen as variable modi-
fications. The initial MS mass tolerance for recalibration was 20 ppm,
the initial mass deviation for the precursor ions was 4.5 ppm, and a
maximum error of 20 ppm was allowed for MS/MS spectra. The false
discovery rate was set at 0.01, and the match between runs option
was used with a 2-min retention-time window. Identified peptides
were grouped with their corresponding PrEST, and copy numbers
were calculated for each peptide. The median peptide value was used
as the copy number for the corresponding protein as well as the
median value among the technical replicates.
RESULTS
Principle of the Targeted Immunoproteomics Method—The
principle of immuno-SILAC is shown in Fig. 1. The method
relies on the use of stable isotope–labeled recombinant pro-
tein fragment standards (PrESTs) produced in bacteria (Fig.
1A). In immuno-SILAC, a cell lysate is mixed with known
amounts of accurately quantified heavy-labeled protein frag-
ment standards, generated with heavy isotope–labeled ver-
sions (15N and 13C) of the amino acids arginine and lysine. The
protein mixture is enzymatically digested, and the generated
peptides are subsequently captured by antibodies immobi-
lized onto Protein A–coated magnetic beads as illustrated in
Fig. 1C. Following enrichment from the complex peptide mix-
ture, target peptides are eluted with formic acid from the solid
phase bead support. If the peptides are eluted in an MS-
compatible buffer, only acetonitrile has to be added before
LC-MS/MS analysis. The low complexity of the resulting sam-
ple enables very short analysis times. Here, a single 15-min
HPLC gradient was sufficient for separation of a multiplexed
sample in which up to 44 different antibodies were used for
peptide enrichment. The ratios of light peptides originating
from the endogenous digested proteins and peptides from the
spiked-in heavy isotopic standards are compared, giving an
absolute quantitative measurement of the studied proteins.
A schematic overview comparing the workflows for the
related SISCAPA and immuno-SILAC methods is shown in
Fig. 1B. In SISCAPA, known amounts of heavy-labeled syn-
thetic peptides are spiked in after trypsin digestion, whereas
in immuno-SILAC the protein fragments are added prior to
trypsin digestion. The addition of protein fragments as stan-
dards before enzyme digestion has the advantage of com-
pensating for miscleavages or otherwise incomplete diges-
tion, as the heavy protein standards undergo the same
processing as the endogenous proteins (36). In this way,
possible losses during sample preparation do not introduce
quantification errors.
Analysis of Linear Epitopes of Polyclonal Antibodies Using
High-density Peptide Arrays—In order to analyze the number
of linear epitopes for polyclonal antibodies generated in a
standardized manner using protein fragments (PrESTs), a
high-density array with 175,000 overlapping synthetic 12-mer
peptides with a single-amino-acid lateral shift was designed
covering 941 protein fragment sequences. The target pro-
teins, a majority of all human kinases and a number of inter-
esting biomarkers for cancer, were selected by the 7th Euro-
pean Union framework project Affinomics (37) for the ultimate
goal of generating corresponding affinity reagents. Parallel in
situ peptide synthesis of the arrays was achieved via repeated
cycles of selective activation using a UV-light source and a
micromirror device followed by the incorporation of amino
acids with a photolabile protective group. Each of the synthe-
sized peptide arrays was incubated with a pool containing 20
of the selected polyclonal antibodies, and a fluorophore-con-
jugated secondary anti-rabbit antibody was used to detect
antibody–peptide interactions. The small shift of only a single
amino acid between the overlapping peptides allowed very
detailed mapping of the linear epitopes recognized by the
antibodies. Previous results for polyclonal antibodies epitope-
mapped together with two separate pools of 29 unrelated
antibodies showed very similar binding profiles, indicating
limited cross-reactivity of the unrelated antibodies to the an-
tigen sequence peptides (data not shown). Two examples of
epitope mapping are shown in Figs. 2A and 2B, where the
bars represent the median fluorescence intensity of each
of the overlapping peptides. The anti-AGAP2 antibody
HPA023474 showed two distinct linear epitopes (Fig. 2A),
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whereas the antibody HPA027341, targeting the protein fu-
marate hydratase, recognized four linear epitopes (Fig. 2B).
The epitope mapping of the 941 antibodies showed that the
number of linear epitopes varied for the different antibodies
(Fig. 2C), but on average 2.9 linear epitopes were detected.
The fact that most of the analyzed polyclonal antibodies rec-
ognized multiple linear epitopes suggests the possibility of
using these polyclonal antibodies as capturing agents for the
enrichment of peptides from trypsin-digested complex sam-
ples. It is noteworthy that 40% of the identified epitopes
contained a trypsin cleavage site (data not shown), suggest-
ing that they might not be functional for immuno-enrichment
of the corresponding peptides.
Immunocapture of Peptides for Mass Spectrometry Analy-
sis—In order to investigate the performance of the epitope-
mapped antibodies for immuno-enrichment of target protein
FIG. 1. The principle of the immuno-SILAC method. A, absolute protein quantification using PrESTs as the internal standard. Peptides
originating from the albumin binding protein (ABP) tag (yellow) are used to quantify each PrEST against an ultrapurified ABP protein standard.
The PrEST can thereafter be used as an internal standard in unknown samples to quantify the corresponding endogenous protein (red) in
LC-MS. B, schematic representation of the immuno-SILAC workflow. Highly purified and accurately quantified isotopic heavy-labeled PrESTs
are spiked into cell lysates prior to trypsin digestion, thereby minimizing the risk of differences arising between samples and standards during
sample preparation. Antibodies coupled to magnetic solid phase support enrich target peptides from the digested sample, and the
endogenous protein concentration is calculated from the ratio of heavy to light peptides detected via MS. C, comparison between the SISCAPA
technology (7) using heavy-labeled peptides (blue) and immuno-SILAC using heavy-labeled protein fragments (green) for absolute protein
quantification.
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peptides from complex digested samples, we chose a ran-
dom subset of 150 antibodies. For 127 of these, the corre-
sponding recombinant PrESTs were available. The protein
fragments had previously been expressed in E. coli and puri-
fied as described before (25). The 127 PrESTs were pooled
together in equimolar amounts and used for trypsin cleavage
using a standardized protocol (24). The peptide mixtures were
transferred to a robotic work station for magnetic bead han-
dling (38), and immuno-enrichment of target peptides was
performed using a multiplex mixture of 40 to 45 of the corre-
sponding polyclonal antibodies captured on Protein A–
coated magnetic beads, using only 50 ng of each antibody.
After overnight affinity capture, the beads were thoroughly
washed and the enriched peptides were eluted with formic
acid suitable for the subsequent mass spectrometry analysis.
The MS analysis revealed that 57 out of the 127 target pro-
teins were successfully identified by at least one tryptic
peptide (supplemental Table S1). A representative subset of
identified peptides and the corresponding mapped linear
epitopes for the antibody used can be seen in Fig. 3. As
shown by the examples, predicted epitopes as determined by
epitope mapping using overlapping 12-mer peptides often
correlated with the sequences of enriched peptides in im-
muno-SILAC. However, in some cases (e.g. FLT1 and CAMK4
(Fig. 3)), some peptides were not predicted from the high-
density array mapping. It is tempting to speculate that in many
of these cases, the epitopes seen by the antibody were not
covered within the 12-mer peptides displayed on the high-
density array, implying that these epitopes needed longer
peptides to form than available on the peptide arrays. It is also
apparent from the examples that many of the linear epitopes
predicted by the epitope mapping were not observed after the
MS analysis. Many of these epitopes contain lysines or argin-
ines, and the corresponding peptides are thus not expected
to be captured, as the epitope is cleaved by trypsin. It is also
likely that many other peptides were not detected in the MS
analysis because of technical issues (39). In summary, the
results presented here, based on 127 antibodies, suggest that
approximately half of the polyclonal antibodies enriched at
least one peptide that could subsequently be detected via
mass spectrometry.
Comparative Analysis of PrEST-SILAC and Immuno-SILAC—
In order to investigate the success rate of finding functional
immunoproteomics pairs using corresponding recombinant
PrESTs as internal standards, we analyzed a new set of 41
protein targets known to be present in HeLa cells based on
RNA sequencing data (40). The targets were chosen based on
sequences of the corresponding PrESTs, with a minimum of
FIG. 2. Epitope mapping of polyclonal antibodies on planar peptide arrays. Linear epitopes of 941 polyclonal antibodies were analyzed
using synthetic 12-mer peptides with an overlap of 11 amino acids, covering the antigen sequences. Two examples of the epitope mappings
are shown in A (HPRA023474) and B (HPA027341), where each bar on the x-axis corresponds to one of the overlapping peptides and the height
shows the median fluorescence intensity. C, distribution of the number of polyclonal antibodies recognizing 0 to 10 linear epitopes.
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five tryptic peptides required. A HeLa cell lysate was analyzed
using both the PrEST-SILAC method described earlier (20)
and the immuno-SILAC protocol in parallel. Isotope-labeled
protein fragments corresponding to 41 human protein targets
were spiked into a cell lysate sample as schematically shown
in Fig. 1C, and the mixture of heavy standards and light
peptides was captured using the immobilized multiplex anti-
bodies (n  41). Of the 41 antibodies used in the multiplex
analysis, 22 managed to capture peptide(s) corresponding to
the correct target protein. Two targets were successfully
quantified using two different antibodies, resulting in 20 quan-
tified proteins. The targets are shown in Table I, and the cell
FIG. 3. Comparison of mapped epitopes and peptides identified in immuno-SILAC screening of polyclonal antibodies against
trypsin-digested PrESTs. The upper part of each panel shows the binding intensities in median fluorescence intensity to overlapping 12-mer
peptides in the epitope mapping, where epitopes are shown as clusters of bound peptides. The blue horizontal bars in the lower part show the
locations of peptides identified in immuno-SILAC screening on their corresponding antigen, and gray vertical lines indicate trypsin cleavage sites.
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lysate was an extract from the HeLa cell cultivation. The
concentrations of the endogenous proteins were calculated
based on the ratio between the light peptides from the sample
and the corresponding heavy peptide from the protein stan-
dard. In parallel, the same protein targets were analyzed using
the PrEST-SILAC protocol. For immuno-SILAC, 15 g of a
digested HeLa sample was used in the peptide enrichment
and prior to MS analysis; a 15-min HPLC gradient was needed
for sufficient peptide separation. For PrEST-SILAC, 30 g of
peptides was divided into six fractions, and then each fraction
was further separated on an HPLC column using a 3-h gra-
dient. The difference in sample complexity between the two
methods is illustrated in Fig. 4, where example chromato-
grams from one immuno-SILAC run and one of the six frac-
tions from a corresponding PrEST-SILAC run are shown. An
example MS spectrum (at the retention time indicated by the
arrow) showing a peptide from SERPINB6 is shown for both
methods. The peptide intensities are similar in the two spec-
tra, but the absence of interfering peaks in the immuno-SILAC
spectra indicates a better separation of peptides along the
HPLC gradient. To further demonstrate the difference in sam-
ple complexity between the two methods, intensities for pep-
tides corresponding to the target proteins were compared
with the total intensity of all identified endogenous peptides
TABLE I
Quantified protein copy number per HeLa cell for immuno-SILAC and PrEST-SILAC. Copy numbers are shown for each replicate, along with
the median copy number, relative standard deviation (RSD), and number of peptides used for quantification
Gene
name
Copy number
replicate 1
Copy number
replicate 2
Copy number
replicate 3
Median copy
number
RSD (%)
Number of
peptides
Immuno-SILAC
ACOT7 1 283 838 998 876 498 230 998 876 42.9 2
ANXA1 6 664 952 9 833 375 6 362 332 6 664 952 25.2 4
ANXA3 2 219 240 2 298 319 4 650 459 2 298 319 45.2 1
BLVRB 2 148 052 - 3 002 937 2 575 495 23.5 1
CANT1 - 70 703 42 667 56 685 35.0 1
CAPG 3 078 134 2 579 694 - 2 828 914 12.5 1
CLPP 1 208 794 1 087 915 777 082 1 087 915 21.7 1
DAP3 1 498 865 1 016 070 900 236 1 016 070 27.9 6
DECR1 - - 588 225 588 225 - 1
DIMT1 - - 235 127 235 127 - 1
ERLIN1 529 872 923 508 1 013 719 923 508 31.3 2
P4HA1 277 258 307 834 431 686 307 834 24.1 1
PDIA5 94 844 166 129 186 790 166 129 32.3 3
PRPF4 306 890 316 067 342 904 316 067 5.8 1
PTPN1 763 589 1 035 203 686 727 763 589 22.1 2
SERPINB6 885 677 2 539 203 1 477 373 1 477 373 51.3 2
SIL1 - 117 997 - 117 997 - 1
SLC25A24 2 317 150 2 099 723 1 239 592 2 099 723 30.2 1
STUB1 573 646 474 906 490 305 490 305 10.4 1
UGDH 193 277 501 192 605 305 501 192 49.5 1
PrEST-SILAC
ACOT7 771 360 1 170 086 955 768 955 768 20.7 4
ANXA1 12 516 639 10 077 946 11 725 516 11 725 516 10.9 14
ANXA3 1 899 959 2 428 880 4 058 745 2 428 880 40.2 12
BLVRB 779 755 836 484 624 563 779 755 14.7 4
CANT1 - 67 847 - 67 847 - 2
CAPG 2 238 047 2 535 800 2 762 024 2 535 800 10.5 4
CLPP 1 017 569 705 756 639 815 705 756 25.6 3
DAP3 329 798 - 638 890 484 344 45.1 2
DECR1 - - - - - -
DIMT1 337 769 408 358 342 916 342 916 10.8 6
ERLIN1 559 997 963 844 803 794 803 794 26.2 5
P4HA1 1 114 521 627 467 733 443 733 443 31.0 11
PDIA5 134 089 253 862 152 319 152 319 25.5 4
PRPF4 411 509 274 967 566 398 411 509 34.9 6
PTPN1 520 007 542 602 597 039 542 602 7.2 5
SERPINB6 576 320 974 111 1 269 089 974 111 37.0 9
SIL1 96 363 155 829 111 533 111 533 25.5 1
SLC25A24 1 077 749 1 015 007 925 753 1 015 007 7.6 4
STUB1 719 533 604 201 692 742 692 742 9.0 4
UGDH 1 000 743 888 750 746 425 888 750 14.5 5
Number of peptides: the total number of different peptides used for the quantification.
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(common contaminants excluded). The proportion of target
peptides in immuno-SILAC was 83%, as compared with 0.5%
for PrEST-SILAC (data not shown).
In Fig. 5, a comparison of identified peptides from targets
quantified via both immuno-SILAC (blue) and PrEST-SILAC
(yellow) is shown for 6 of the 20 proteins together with the
epitopes mapped on peptide arrays (green). In general,
PrEST-SILAC identified, as expected, more unique peptides
than immuno-SILAC, as no specific peptides were enriched.
However, the peptide enrichment step reduces the complex-
ity of the input material, consequently decreasing the analysis
time drastically. For SLC25A24, four peptides were found
using PrEST-SILAC, and one peptide was found when using
the corresponding antibody for peptide enrichment, as this
peptide contained the consensus epitope determined on the
peptide array. The same peptide was also identified in PrEST-
SILAC, indicating that it was present at sufficient levels for MS
analysis even without peptide enrichment. This was the case
for most of the analyzed proteins, as the target proteins were
all moderate to highly abundant proteins in HeLa cells. Inter-
estingly, some peptides were identified only in immuno-SILAC
(see PRPF4 and STUB1). In the case of PRPF4, two epitope
regions were detected during mapping, but the most C-ter-
minal epitope contains a trypsin cleavage site (indicated by
dotted vertical lines) and, as expected, the antibody failed to
bind any of the two resulting tryptic peptides. The N-terminal
epitope region probably consists of two overlapping epitopes,
of which at least one is still intact after digestion and can be
enriched. For SERPINB6, two different peptides can be
identified.
Quantitative Analysis of 20 Targets in HeLa Cell Lysates
Using Immuno-SILAC and PrEST-SILAC—A quantitative
analysis of 20 protein targets in a human HeLa cell lysate was
performed. The same targets were analyzed using three tech-
nical replicates for both immuno-SILAC and PrEST-SILAC
methods. Given the amount of HeLa cells used in the assay,
absolute quantification of endogenous proteins as copy num-
bers per HeLa cell was determined from the ratio of heavy to
light peptides. Heavy standard amounts were spiked into the
lysate close to the level of endogenous protein in order to
generate SILAC ratios close to 1:1 and hence more reliable
quantitative data. Relative standard deviations ranged be-
tween 10% and 40% for most targets, with somewhat lower
numbers for PrEST-SILAC (Table I).
FIG. 4. Comparison of HPLC chromatograms and MS spectra from one immuno-SILAC and one PrEST-SILAC sample. The upper
panels show HPLC chromatograms for one immuno-SILAC sample (left) and one PrEST-SILAC fraction (right). The peptide SGGGGDIHQG-
FQSLLTEVNK from SERPINB6 was identified in both experiments as a triple-charged ion ofm/z 682.01 (light version). The middle panels show
extracted full MS spectra at the respective retention times, and the lower panels show the same MS spectra at m/z between 675 and 695.
FIG. 5. Comparison of epitope mapping, immuno-SILAC, and
PrEST-SILAC peptides. Horizontal bars show the locations of linear
epitopes (green) and peptides identified in immuno-SILAC (blue) and
PrEST-SILAC (yellow) on their corresponding antigen; dashed vertical
lines indicate trypsin cleavage sites. Above each plot, the raw epitope
mapping binding intensities to overlapping 12-mer peptides are
shown as vertical bars.
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FIG. 6. Comparison of peptide ratios along the PrEST sequences for PrEST-SILAC (yellow) and immuno-SILAC (blue). Identified
peptides from the two methods are plotted along the PrEST-sequence (x-axis) showing ratios (y-axis) between heavy and light peptides used
for quantification of endogenous protein in HeLa cell lysate. The dotted line represents the median ratio for PrEST-SILAC. Overlapping peptide
sequences come from missed cleavages. Two different heavy PrESTs were used for annexin 1 (ANXA1) and PDIA5.
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Ratios obtained from the MS analysis for all peptides used
for quantification in immuno-SILAC in comparison with
PrEST-SILAC are shown in Fig. 6. A good correlation between
the PrEST-SILAC and the immuno-SILAC can be observed for
all 20 targets. Note that miscleaved peptides also can be used
for quantitative analysis. Here, miscleaved peptides refer to
peptides that still contained one or more potential cleavage
sites after trypsin digestion. These miscleaved peptides be-
come an issue in methods relying on spiked-in peptide stan-
dards for protein quantification (41), such as AQUA (17), in
which peptides are spiked in after the enzymatic digestion.
However, it is noteworthy that information from these mis-
cleaved peptides can be used in the quantitative analysis in
immuno-SILAC; here we took advantage of heavy-labeled
protein fragments enzymatically digested along with the pro-
tein target. The observed ratios suggest that the enzymatic
digestion was equal for both protein fragment standards and
endogenous proteins, and these peptides add extra and val-
uable information rather than introducing ambiguity to the
subsequent quantitative analysis.
The absolute quantifications for all 20 targets as determined
via immuno-SILAC are shown in Fig. 7A. Among the 20 iden-
tified proteins, copy numbers ranged from 6.6 million copies
per cell for annexin 1 down to 57,000 copies per cell deter-
mined for calcium activated nucleotidase, which represents
moderately to highly abundant proteins. The absolute quan-
titative data given by immuno-SILAC was compared with that
obtained via the previously described PrEST-SILAC method
(20). Cell copy numbers determined via each respective ab-
solute quantitative method (Table I) were plotted against each
other as illustrated in Fig. 7B. In total, 17 and 18 proteins were
quantified in at least two out of three replicates using the
immuno-SILAC and PrEST-SILAC methods, respectively. Out
of these, 59% of the targets (10 out of 17 proteins) were
detected with only a single peptide using immuno-SILAC,
whereas only 6% of the targets (1 out of 18) were detected
with only one peptide using PrEST-SILAC. It should be noted
that the data used for quantification with the two methods
differed, as in general PrEST-SILAC identified more peptides
per protein than immuno-SILAC. However, even though many
proteins were quantified with only one proteotypic peptide in
immuno-SILAC, good correlation could be observed between
the two methods. To investigate whether the determined pro-
tein cell copy numbers showed any correlation to mRNA
levels of the corresponding genes, we determined the tran-
script levels of all genes in the HeLa cell culture using deep
sequencing of mRNA molecules using RNA sequencing (42).
Fig. 7C shows a comparison between protein cell copy num-
bers as determined from the immuno-SILAC experiments and
the absolute transcript levels for the 20 targets analyzed here.
Even though a completely linear relationship between protein
and RNA levels cannot be assumed and it is especially diffi-
cult to compare protein and RNA using data from only a single
cell line, the analysis still showed a trend between RNA and
protein levels. It is clear from Fig. 7C that the RNA levels to
some extent indicated protein levels.
DISCUSSION
Here, we show that polyclonal antibodies raised against
recombinant protein fragments can be used for immunopro-
teomics analysis. The immuno-SILAC method takes advan-
tage of the fact that the majority of the epitopes of the gen-
erated antibodies are directed to relatively short linear
epitopes and are therefore useful for immunocapture of pep-
tides generated after trypsin cleavage. In addition, the method
takes advantage of the fact that protein fragments used for
generating the antibodies can be efficiently expressed in bac-
teria (E. coli) using cultivation in minimal media with isotope-
labeled arginines and lysines followed by a standardized pro-
tocol for affinity purification using an affinity tag. Thus, it is
FIG. 7. Immuno-MS results from antibodies toward 20 different target proteins in HeLa cell lysates. A, immuno-SILAC quantification
of 20 target proteins as copy number per cell. The analysis was performed in triplicate, and median values were plotted with error bars showing
the standard deviation. B, comparison of copy numbers per cell obtained using immuno-SILAC (y-axis) and PrEST-SILAC (x-axis). C,
comparison of protein copy number (y-axis) and transcript abundance from RNA sequencing (x-axis).
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easy to generate protein standards, and these can be quan-
tified in an exact manner using the PrEST-SILAC method
previously described by us (20).
The method resembles other immunoproteomics methods,
such as SISCAPA (7) and the use of AQUA peptides (17), but
this new method has several important differences. First, the
use of protein fragments often generates multiple peptides,
and it is in many cases possible to obtain quantitative data
from several independent peptides using the same antibody
and protein standard. In addition, the fact that the protein
fragments are added prior to the trypsin cleavage ensures that
uncleaved endogenous peptides will not affect the quantifi-
cation as long as the digestion efficiency of the protein stan-
dard is the same as that of the endogenous protein target.
Furthermore, miscleaved peptides can be used as additional
standards, and the problem of miscleaved peptides is there-
fore transformed into an opportunity to generate more data
that can be used in the analysis. Finally, the generation of the
protein standards does not involve peptide synthesis, and the
quantification of the protein standards can be easily per-
formed using the quantification tag included as a fusion on
every protein fragment (20).
The publicly available antibodies from the Human Protein
Atlas project constitute a huge antibody resource for the
immuno-SILAC method described here. These polyclonal an-
tibodies are generated in a standardized manner involving
immunizations of animals using recombinant protein frag-
ments selected for their low sequence identity to other human
proteins. In addition, more than a million antibodies toward
human targets are listed in the antibody portal Antibodypedia
(43), and70% of these antibodies are polyclonal antibodies.
However, the fact that the method described here relies on
polyclonal antibodies makes it important to decrease the con-
sumption of antibody reagent in each assay. Although it is
possible to renew polyclonal antibodies through re-immuni-
zation of the same antigen in more animals, batch-to-batch
variations exist, and one can never be sure of an unlimited
resource of renewable antibodies, as is the case with mono-
clonal antibodies. We have investigated various protocols to
lower the consumption of the antibody reagent used in each
assay. The protocol described here requires only 50 ng of
antibody for each target, and these antibodies do not need to
be chemically immobilized to a solid support and can be
simply mixed with Protein A–coated magnetic beads in a
multiplex manner. Although the amount of antibodies varies
greatly for publicly available polyclonal antibodies, the mean
concentration of the18,000 polyclonal antibodies generated
within the framework of the Human Protein Atlas program is
140 g/ml (unpublished); thus an aliquot of 100 l can be
used for more than 250 individual assays, and the whole
batch with10 ml of affinity-purified antibodies would last for
25,000 assays. Furthermore, it is likely that the need for anti-
bodies can be reduced even further through the use of smaller
magnetic beads and altered capture procedures, such as the
use of microfluidics. Thus, the publicly available polyclonal
antibodies covering more than 90% of the human protein-
coding genes listed in Antibodypedia are an attractive re-
source for efforts to develop new immunoproteomics assays.
Here, we have screened polyclonal antibodies raised
against human protein fragments to investigate their function-
ality for immunoproteomics. In total, the immuno-enrichment
experiments generated 79 new immunoproteomics pairs,
each with an antibody suitable for immuno-SILAC. Here, ap-
proximately half of the analyzed antibodies (57/127) yielded
functional antibodies for peptide immuno-enrichment in the
initial screening, and the subsequent quantitative HeLa anal-
ysis had a similar success rate (22/41). It is noteworthy that
the high-density microarray assay identified approximately
three linear epitopes per polyclonal antibody on average,
but the results presented here suggest that only a fraction of
these epitopes are suitable for immuno-SILAC.
The rapid turn-around times coupled with the ease of
automating all the unit operations of sample preparation
makes the immuno-SILAC method ideal for both research
applications and future clinical diagnostic assays. In total, the
PrEST-SILAC method described here required an MS analysis
time of around 24 h for the six fractions of the sample. To
compare, the MS analysis time for the 40-plex immuno-SILAC
experiments took 40 min. It is noteworthy that more than
80% of the total intensities from the mass spectrometry anal-
ysis corresponded to the target peptides for the immuno-
SILAC experiment, suggesting that the analysis time can be
reduced even further. The method allows for multiplex analy-
sis, and we have used it for the simultaneous analysis of 20
protein targets using both PrEST-SILAC and immuno-SILAC.
As a large number of antibodies are publicly available, it might
not be unrealistic to increase the multiplexing to several hun-
dreds of protein targets. Particularly for samples with a huge
dynamic range between abundant proteins and proteins to be
diagnosed, such as plasma and serum analysis, the immuno-
capture step prior to the mass spectrometry analysis is an
attractive way forward. In summary, we have shown that small
amounts of polyclonal antibodies can be used for efficient
multiplex analysis of quantitative levels of proteins, opening
up the possibility of building up a proteome-wide resource for
immuno-SILAC reagents based on already available public
antibody resources.
Acknowledgments—We acknowledge the entire staff of the Human
Protein Atlas program and the Science for Life Laboratory for valuable
contributions.
* Funding was provided by the Knut and Alice Wallenberg Founda-
tion, the ProNova center through a grant from VINNOVA, and
PROSPECTS and Affinomics 7th Framework grants from the Euro-
pean Directorate.
□S This article contains supplemental material.
‡‡ To whom correspondence should be addressed.
§ These authors contributed to this work equally.
Immunoproteomics Using Polyclonal Antibodies
1622 Molecular & Cellular Proteomics 13.6
REFERENCES
1. Bjorhall, K., Miliotis, T., and Davidsson, P. (2005) Comparison of different
depletion strategies for improved resolution in proteomic analysis of
human serum samples. Proteomics 5, 307–317
2. Steel, L. F., Trotter, M. G., Nakajima, P. B., Mattu, T. S., Gonye, G., and
Block, T. (2003) Efficient and specific removal of albumin from human
serum samples. Mol. Cell. Proteomics 2, 262–270
3. Jin, W. H., Dai, J., Li, S. J., Xia, Q. C., Zou, H. F., and Zeng, R. (2005) Human
plasma proteome analysis by multidimensional chromatography prefrac-
tionation and linear ion trap mass spectrometry identification. J. Pro-
teome Res. 4, 613–619
4. Pieper, R., Gatlin, C. L., Makusky, A. J., Russo, P. S., Schatz, C. R., Miller,
S. S., Su, Q., McGrath, A. M., Estock, M. A., Parmar, P. P., Zhao, M.,
Huang, S. T., Zhou, J., Wang, F., Esquer-Blasco, R., Anderson, N. L.,
Taylor, J., and Steiner, S. (2003) The human serum proteome: display of
nearly 3700 chromatographically separated protein spots on two-dimen-
sional electrophoresis gels and identification of 325 distinct proteins.
Proteomics 3, 1345–1364
5. Pernemalm, M., Lewensohn, R., and Lehtio, J. (2009) Affinity prefraction-
ation for MS-based plasma proteomics. Proteomics 9, 1420–1427
6. Berna, M., Ott, L., Engle, S., Watson, D., Solter, P., and Ackermann, B.
(2008) Quantification of NTproBNP in rat serum using immunoprecipita-
tion and LC/MS/MS: a biomarker of drug-induced cardiac hypertrophy.
Anal. Chem. 80, 561–566
7. Anderson, N. L., Anderson, N. G., Haines, L. R., Hardie, D. B., Olafson,
R. W., and Pearson, T. W. (2004) Mass spectrometric quantitation of
peptides and proteins using Stable Isotope Standards and Capture by
Anti-Peptide Antibodies (SISCAPA). J. Proteome Res. 3, 235–244
8. Whiteaker, J. R., Zhao, L., Abbatiello, S. E., Burgess, M., Kuhn, E., Lin, C.,
Pope, M. E., Razavi, M., Anderson, N. L., Pearson, T. W., Carr, S. A., and
Paulovich, A. G. (2011) Evaluation of large scale quantitative proteomic
assay development using peptide affinity-based mass spectrometry.
Mol. Cell. Proteomics 10, M110.005645
9. Neubert, H., Gale, J., and Muirhead, D. (2010) Online high-flow peptide
immunoaffinity enrichment and nanoflow LC-MS/MS: assay develop-
ment for total salivary pepsin/pepsinogen. Clin. Chem. 56, 1413–1423
10. Hoofnagle, A. N., Becker, J. O., Wener, M. H., and Heinecke, J. W. (2008)
Quantification of thyroglobulin, a low-abundance serum protein, by im-
munoaffinity peptide enrichment and tandem mass spectrometry. Clin.
Chem. 54, 1796–1804
11. Ahn, Y. H., Lee, J. Y., Lee, J. Y., Kim, Y. S., Ko, J. H., and Yoo, J. S. (2009)
Quantitative analysis of an aberrant glycoform of TIMP1 from colon
cancer serum by L-PHA-enrichment and SISCAPA with MRM mass
spectrometry. J. Proteome Res. 8, 4216–4224
12. Razavi, M., Frick, L. E., LaMarr, W. A., Pope, M. E., Miller, C. A., Anderson,
N. L., and Pearson, T. W. (2012) High-throughput SISCAPA quantitation
of peptides from human plasma digests by ultrafast, liquid chromatog-
raphy-free mass spectrometry. J. Proteome Res. 11, 5642–5649
13. Anderson, N. L., Jackson, A., Smith, D., Hardie, D., Borchers, C., and
Pearson, T. W. (2009) SISCAPA peptide enrichment on magnetic beads
using an in-line bead trap device. Mol. Cell. Proteomics 8, 995–1005
14. Whiteaker, J. R., Zhao, L., Zhang, H. Y., Feng, L. C., Piening, B. D.,
Anderson, L., and Paulovich, A. G. (2007) Antibody-based enrichment of
peptides on magnetic beads for mass-spectrometry-based quantifica-
tion of serum biomarkers. Anal. Biochem. 362, 44–54
15. Whiteaker, J. R., Zhao, L., Anderson, L., and Paulovich, A. G. (2010) An
automated and multiplexed method for high throughput peptide immu-
noaffinity enrichment and multiple reaction monitoring mass spectrom-
etry-based quantification of protein biomarkers. Mol. Cell. Proteomics 9,
184–196
16. Barr, J. R., Maggio, V. L., Patterson, D. G., Jr., Cooper, G. R., Henderson,
L. O., Turner, W. E., Smith, S. J., Hannon, W. H., Needham, L. L., and
Sampson, E. J. (1996) Isotope dilution–mass spectrometric quantifica-
tion of specific proteins: model application with apolipoprotein A-I. Clin.
Chem. 42, 1676–1682
17. Gerber, S. A., Rush, J., Stemman, O., Kirschner, M. W., and Gygi, S. P.
(2003) Absolute quantification of proteins and phosphoproteins from cell
lysates by tandem MS. Proc. Natl. Acad. Sci. U.S.A. 100, 6940–6945
18. Brun, V., Dupuis, A., Adrait, A., Marcellin, M., Thomas, D., Court, M.,
Vandenesch, F., and Garin, J. (2007) Isotope-labeled protein standards:
toward absolute quantitative proteomics. Mol. Cell. Proteomics 6,
2139–2149
19. Singh, S., Springer, M., Steen, J., Kirschner, M. W., and Steen, H. (2009)
FLEXIQuant: a novel tool for the absolute quantification of proteins, and
the simultaneous identification and quantification of potentially modified
peptides. J. Proteome Res. 8, 2201–2210
20. Zeiler, M., Straube, W. L., Lundberg, E., Uhlen, M., and Mann, M. (2012) A
Protein Epitope Signature Tag (PrEST) library allows SILAC-based ab-
solute quantification and multiplexed determination of protein copy num-
bers in cell lines. Mol. Cell. Proteomics 11, O111.009613
21. Uhlen, M., Oksvold, P., Fagerberg, L., Lundberg, E., Jonasson, K., Fors-
berg, M., Zwahlen, M., Kampf, C., Wester, K., Hober, S., Wernerus, H.,
Bjorling, L., and Ponten, F. (2010) Towards a knowledge-based Human
Protein Atlas. Nat. Biotechnol. 28, 1248–1250
22. Berglund, L., Bjorling, E., Jonasson, K., Rockberg, J., Fagerberg, L., Al-
Khalili Szigyarto, C., Sivertsson, A., and Uhlen, M. (2008) A whole-
genome bioinformatics approach to selection of antigens for systematic
antibody generation. Proteomics 8, 2832–2839
23. Agaton, C., Falk, R., Hoiden Guthenberg, I., Gostring, L., Uhlen, M., and
Hober, S. (2004) Selective enrichment of monospecific polyclonal anti-
bodies for antibody-based proteomics efforts. J. Chromatogr. A 1043,
33–40
24. Wisniewski, J. R., Zougman, A., Nagaraj, N., and Mann, M. (2009) Universal
sample preparation method for proteome analysis. Nat. Methods 6,
359–362
25. Tegel, H., Steen, J., Konrad, A., Nikdin, H., Pettersson, K., Stenvall, M.,
Tourle, S., Wrethagen, U., Xu, L., Yderland, L., Uhlen, M., Hober, S., and
Ottosson, J. (2009) High-throughput protein production—lessons from
scaling up from 10 to 288 recombinant proteins per week. Biotechnol. J.
4, 51–57
26. Matic, I., Jaffray, E. G., Oxenham, S. K., Groves, M. J., Barratt, C. L., Tauro,
S., Stanley-Wall, N. R., and Hay, R. T. (2011) Absolute SILAC-compatible
expression strain allows Sumo-2 copy number determination in clinical
samples. J. Proteome Res. 10, 4869–4875
27. Studier, F. W. (2005) Protein production by auto-induction in high density
shaking cultures. Protein Expr. Purif. 41, 207–234
28. Craig, R., and Beavis, R. C. (2004) TANDEM: matching proteins with tan-
dem mass spectra. Bioinformatics 20, 1466–1467
29. Keller, A., Nesvizhskii, A. I., Kolker, E., and Aebersold, R. (2002) Empirical
statistical model to estimate the accuracy of peptide identifications made
by MS/MS and database search. Anal. Chem. 74, 5383–5392
30. Nesvizhskii, A. I., Keller, A., Kolker, E., and Aebersold, R. (2003) A statistical
model for identifying proteins by tandem mass spectrometry. Anal.
Chem. 75, 4646–4658
31. Han, D. K., Eng, J., Zhou, H., and Aebersold, R. (2001) Quantitative profiling
of differentiation-induced microsomal proteins using isotope-coded af-
finity tags and mass spectrometry. Nat. Biotechnol. 19, 946–951
32. Scherer, W. F., Syverton, J. T., and Gey, G. O. (1953) Studies on the
propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a
stable strain of human malignant epithelial cells (strain HeLa) derived
from an epidermoid carcinoma of the cervix. J. Exp. Med. 97, 695–710
33. Wisniewski, J. R., Zougman, A., and Mann, M. (2009) Combination of FASP
and StageTip-based fractionation allows in-depth analysis of the hip-
pocampal membrane proteome. J. Proteome Res. 8, 5674–5678
34. Cox, J., and Mann, M. (2008) MaxQuant enables high peptide identification
rates, individualized p.p.b.-range mass accuracies and proteome-wide
protein quantification. Nat. Biotechnol. 26, 1367–1372
35. Cox, J., Neuhauser, N., Michalski, A., Scheltema, R. A., Olsen, J. V., and
Mann, M. (2011) Andromeda: a peptide search engine integrated into the
MaxQuant environment. J. Proteome Res. 10, 1794–1805
36. Kuhn, E., Whiteaker, J. R., Mani, D. R., Jackson, A. M., Zhao, L., Pope,
M. E., Smith, D., Rivera, K. D., Anderson, N. L., Skates, S. J., Pearson,
T. W., Paulovich, A. G., and Carr, S. A. (2012) Interlaboratory evaluation
of automated, multiplexed peptide immunoaffinity enrichment coupled to
multiple reaction monitoring mass spectrometry for quantifying proteins
in plasma. Mol. Cell. Proteomics 11, M111.013854
37. Stoevesandt, O., and Taussig, M. J. (2012) European and international
collaboration in affinity proteomics. Nat. Biotechnol. 29, 511–514
38. Uhlen, M., Hultman, T., Wahlberg, J., Lundeberg, J., Bergh, S., Pettersson,
B., Holmberg, A., Stahl, S., and Moks, T. (1992) Semi-automated solid-
phase DNA sequencing. Trends Biotechnol. 10, 52–55
39. Mirzaei, H., and Regnier, F. (2006) Enhancing electrospray ionization effi-
Immunoproteomics Using Polyclonal Antibodies
Molecular & Cellular Proteomics 13.6 1623
ciency of peptides by derivatization. Anal. Chem. 78, 4175–4183
40. Nagaraj, N., Wisniewski, J. R., Geiger, T., Cox, J., Kircher, M., Kelso, J.,
Paabo, S., and Mann, M. (2011) Deep proteome and transcriptome
mapping of a human cancer cell line. Mol. Syst. Biol. 7, 548
41. Glatter, T., Ludwig, C., Ahrne, E., Aebersold, R., Heck, A. J., and Schmidt, A.
(2012) Large-scale quantitative assessment of different in-solution protein
digestion protocols reveals superior cleavage efficiency of tandem Lys-C/
trypsin proteolysis over trypsin digestion. J. Proteome Res. 11, 5145–5156
42. Danielsson, F., Wiking, M., Mahdessian, D., Skogs, M., Ait Blal, H., Hjel-
mare, M., Stadler, C., Uhlen, M., and Lundberg, E. (2013) RNA deep
sequencing as a tool for selection of cell lines for systematic subcellular
localization of all human proteins. J. Proteome Res. 12, 299–307
43. Bjorling, E., and Uhlen, M. (2008) Antibodypedia, a portal for sharing
antibody and antigen validation data. Mol. Cell. Proteomics 7,
2028–2037
44. Malm et al. (2014), unpublished
Immunoproteomics Using Polyclonal Antibodies
1624 Molecular & Cellular Proteomics 13.6
Results 
 
71 
Copy number analysis of the murine platelet proteome  
Platelets are small cells circulating in the vasculature mediating hemostasis. In case of 
injuries of the vessels they seal the lesion by building a clot. Their physiological function 
to maintain hemostasis is crucial since abnormalities might lead to excessive bleeding 
during and after injury. Deep understanding of platelet activation and aggregation is only 
possible if all proteins involved are known. We decided to measure the murine proteome 
since mice represent a valuable model to study disease, in particular in knock-out mice. 
Using MS-based proteomics in combination with SILAC-PrESTs we identified nearly all 
platelet proteins and their estimated their copy numbers, paving the way for further 
functional studies.  
Since this study was performed in mice, we established the PrEST production 
independently of the Human Protein Atlas project, which is specific to the human system. 
This also gave us the liberty to design the PrEST sequences to be optimal for mass 
spectrometric analysis, specifically by selecting unique regions having many tryptic 
peptides. 
 
The study is currently in revision at Molecular and Cellular Proteomics: 
‘Copy number analysis of the murine platelet proteome spanning the complete abundance range’ 
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Knowledge of the identity and quantity of expressed proteins of a cell type is a 
prerequisite for a complete understanding of its molecular functions. Mass 
spectrometry (MS)-based proteomics has allowed the identification of the entire 
protein complement of yeast and the close-to-complete set of proteins expressed in 
mammalian cell lines. Using recent technological advances we here characterize the 
proteome of murine platelets, key actors in mediating hemostasis and thrombosis. We 
accurately measured the absolute protein concentrations of thirteen platelet proteins by 
SILAC-Protein Epitope Signature Tags (PrESTs) and used them as reference points to 
estimate the copy number of all proteins of the platelet proteome. To distinguish 
contaminants such as plasma or erythrocyte proteins from true platelet proteins, we 
monitored protein abundance profiles across multiple purification steps. In total, we 
absolutely quantified 4,400 platelet proteins, with estimated copy numbers ranging 
from less than ten to about a million per cell. Stoichiometries derived from our data 
correspond well with previous studies. Our study provides a close-to-complete 
reference map of platelet proteins, which will be useful to the community, for instance 
for interpreting mouse models of human platelets diseases. 
Platelets are cells derived from the cytoplasm of megakaryocytes, which are found in 
bone marrow and constantly produce and release platelets into the blood circulation. In 
the blood they circulate and survey the integrity of the vasculature. Upon injury of the 
endothelium  platelets prevent hemorrhages and uncontrolled blood loss by sealing the 
vascular lesions. The ability to form aggregates is important for their hemostatic function, 
however, pathological platelet activation, for example during rupture of an atherosclerotic 
plaque, may reduce blood supply to the heart or brain during vascular occlusion and 
thereby induce cardiac infarction or stroke. It is therefore important to understand the 
molecular processes that control platelet activation and aggregation and to develop new 
therapeutic strategies to block critical platelet proteins involved in these processes [1]. A 
deeper, quantitative understanding of the platelet proteome will facilitate the 
identification of new drug targets and therefore the development of novel anti-platelet 
therapies. 
With a diameter of only 0.5 -1 µm in mouse and 2-5 µm in human, platelets are the 
smallest blood cell type and have a very short life span of 3-4 days (human 7-10 days). 
Platelets lack a nucleus and therefore there is no transcription that could replenish their 
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residual megakaryocyte-derived mRNA. As a consequence mRNA levels are very low. 
Nevertheless, platelets translate mRNA into protein upon activation, however, whether 
this is important for platelet function is not clear [2]. The low mRNA levels make 
transcriptomics challenging because even a minimal contamination of the platelet sample 
by nucleated cells could make a substantial contribution to the measured transcriptome. 
In addition, functional interpretation of the measured transcript levels is complicated by 
the fact that they may reflect the parental megakaryocyte transcriptome rather than 
platelet specific processes [3]. Despite these difficulties, several studies have measured 
mouse and human platelet transcriptomes leading to the identification of approximately 
6,500 and 9,500  transcripts, respectively [4]. In contrast to transcriptomics, proteomics 
approaches are intrinsically better suited to understand the cellular functions of platelets, 
because proteins are the biochemical functional units. Furthermore, they are the drug 
targets in antithrombotic or antiplatelet therapy [1]. Historically, studies of the platelet 
proteome have been performed by two-dimensional gel electrophoresis and typically 
have quantified up to several dozens of proteins [5]. This approach has now been 
superseded by mass spectrometry (MS)-based proteomics with much higher resolution 
and mass accuracy. The high peptide sequencing speed of modern instrumentation, 
combined with other technological advances enables the mapping of close-to-complete 
proteomes with high confidence, despite the broad dynamic range of protein quantities 
expressed [6, 7]. Recently, Burkhart et al. employed modern mass spectrometric 
instrumentation to confidently identify the to date deepest proteome of about 4,000 
human platelet proteins [8]. Based on the tendency of the shotgun proteomics workflow 
to identify peptides from more abundant proteins more frequently (spectral counting), the 
authors were able to derive a quantitative measure of the majority of the identified 
proteome. These values were then scaled to copies per cell through a literature review of 
absolute copy number measurements from diverse sources, such as quantitative Western 
blotting.  
Results 
 
76 
We have recently developed a method for absolute protein quantification, in which we 
produced isotope labeled recombinant protein fragments (PrESTs) in E. coli and combined 
them with stable isotope labeling in cell culture (SILAC) [9, 10]. In this SILAC-PrEST 
method, protein fragments are expressed as fusion proteins with the Albumin Binding 
Protein (ABP) as a solubility tag. Upon purification their absolute concentrations are 
determined in relation to a common sample of ultra-pure ABP, whose concentration has 
previously been measured by amino acid analysis. The heavy PrESTs with known 
concentration are then spiked into cell lysates and the SILAC ratios of several peptides 
enabled calculation of the cellular concentrations and copy numbers of their endogenous 
protein counterparts. Using this approach, we previous were able to quantify HeLa cell 
proteins with copy numbers ranging from thousands to several millions per cell [10].  
In this study we set out to analyze the murine platelet proteome by the high resolution, 
quantitative methods developed in our laboratory [11, 12]. Using a quadrupole Orbitrap 
mass spectrometer [13], we obtained label-free quantification values for more than 4,400 
proteins. These values were converted to copy numbers per platelet using PrESTs of 13 
proteins for calibration. Furthermore, to distinguish true platelet proteins from 
contaminants experimentally, we followed their decreasing intensity profile through 
successive stages of purification. Our accurate and quantitative picture of a mammalian 
platelet proteome shows that it is much larger than might have been expected from its 
specialized functions.  
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EXPERIMENTAL PROCEDURES 
Platelet preparation - Mice (strain C57BL/6) were bled under anesthesia from the retro-
orbital plexus and approximately 1ml blood was collected using heparin (20 U/ml in TBS) 
as the anticoagulation reagent. Blood was then centrifuged at 100 g for 7 min to obtain the 
platelet rich plasma (PRP), which we termed ‘crude fraction’. The PRP was centrifuged at 
700 g to concentrate the platelets in the top layer (termed ‘purified fraction’). This 
procedure was repeated once to obtain the ‘highly purified fraction’. Eventually the 
platelet pellet was resuspended in 1 ml of Tyrode’s buffer containing PGl2 and apyrase, 
followed by a centrifugation step (Fig. 1a) (termed ‘ultra-purified fraction’). For protein 
correlation profiling since higher sample amounts are required we mixed blood from 
different mice and then performed the extensive purification described above. For each 
sample 30 x 106 platelets each were resuspended in lysis buffer (2 % SDS, 100 mM Tris 
pH 7.5, 100 mM DTT), boiled at 95 °C and further processed using the FASP method [11]. 
In brief, SDS was exchanged to urea on a 30 kDa filter. Peptides were eluted after 
digestion with trypsin and subjected to a StageTip-based [14] Strong Anion exchange 
(SAX) fractionation [12]. Platelet counts were determined using a Hemavet950 analyzer 
(Drew Scientific). 
Absolute Quantification - For absolute protein quantification using the SILAC-PrEST 
method [10], the synthetic genes of the protein standards were fused to Albumin Binding 
Protein (ABP). The murine PrESTs were designed to be optimal for mass spectrometric 
analysis, specifically we selected unique regions having many tryptic peptides also 
allowing us to distinguish isoforms. SILAC standards were produced using an 
auxotrophic E. coli strain [15] in the presence of heavy arginine (13C615N4) and heavy lysine 
(13C615N2). The recombinant His-tag containing proteins were purified via Ni-NTA 
columns and quantified with aliquots of a light ABP preparation, on which amino acid 
analysis had been performed. Next, the thirteen protein standards were mixed and spiked 
into the lysed platelets at approximately endogenous concentration. The sample was 
further processed using the FASP method [11]. 
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Mass spectrometry - The samples were eluted from the stage tip, resuspended in buffer 
A* (2 % acetonitrile (ACN), 0.1 % trifluoroacetic acid (TFA)) and loaded onto a fresh 50 cm 
C18 column packed with Reprosil-Pur 1.9 µm resin (Dr. Maisch GmbH). The samples were 
separated on a UPLC system using a 180 min gradient ranging from 5 to 30 % buffer B 
(80 % ACN, 0.1 % TFA) at a constant flow rate of 250 nl/min and injected via a 
nanoelectrospray ion source into the mass spectrometer. We used a quadrupole Orbitrap 
mass spectrometer (Q Exactive [13], Thermo Fisher Scientific) in a data dependent fashion, 
acquiring a full scan (300 – 1750 m/z, 70,000 resolution at m/z 200, target value 3e6 ions, 
maximum fill time 20 ms) and up to ten subsequent MS/MS scans (17,500 resolution, 
target value 1e5 ions, maximum fill time 120 ms) using higher energy collision 
fragmentation (HCD) for peptide identification [13]. Xcalibur software (Thermo Fisher 
Scientific) was used to acquire data. 
Data Analysis - The raw data was analyzed using MaxQuant version 1.4.1.4 [16] with the 
integrated search engine Andromeda [17]. For peptide identification, the fragmentation 
spectra were searched against the UniProt mouse database (downloaded in May 2013) 
containing 50,829 entries to which 247 common contaminants were added. A ‘software 
lock mass’ was used to recalibrate and improve the mass accuracy of the precursor masses 
[18]. During the main search the maximum allowed initial mass deviation of the precursor 
ions was set to 4.5 ppm, while the maximum mass deviation of the fragmentation ions 
was set to 20 ppm. Cysteine carbamidomethylation was set as ‘fixed modification’ and N-
terminal acetylation and methionine oxidation as ‘variable modification’. The ‘Enzyme’ 
parameter was set as Trypsin, for which N-terminal cleavage to proline and two miss-
cleavages were allowed. A minimum of 7 amino acids were required for valid peptide 
identification. In addition to the standard peptide search, the ‘second peptide’ 
identification and the ‘match between run’ options were enabled in Andromeda. For 
statistical evaluation of the data, a posterior error probability and a false discovery rate 
cut off (determined by target-decoy searching) of 0.01 were used for peptides and 
proteins. For SILAC quantification the MaxQuant standard settings were applied 
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requiring at least two ratio counts between SILAC peptides pairs. Bioinformatics analysis 
was performed with the Perseus tool (version 1.4.1.4) available with the MaxQuant 
environment. For clustering and subsequent identification of contaminating proteins from 
other cell types and plasma we used label-free intensities [19]. In this case we replaced 
missing values using data imputation which is based on the assumption that missing 
values are caused by the detection limit of MS measurement [20]. First, we determined the 
Gaussian distribution of the logarithmized data and next we used a normal distribution 
with adjusted mean and standard deviation in order to simulate signals of low abundant 
proteins. We chose parameters (width = 0.3, downshift = 1.8) where the distribution of the 
imputed values was placed at the lower end of the distribution of measured values. The 
mass spectrometry proteomics data have been deposited to the ProteomeXchange 
Consortium (http://www.proteomexchange.org) via the PRIDE partner repository [21] 
with the dataset identifier PXD000747. 
 
RESULTS AND DISCUSSION 
Removal of contaminant proteins via protein correlation profiling - Platelets are highly 
abundant in blood and can be prepared in high yields by differential centrifugation, but 
proteins from lysed erythrocytes and plasma are inevitably present in platelet fractions. 
To distinguish true platelet proteins from such contaminants, we adapted the protein 
correlation profiling approach (PCP) [22, 23]. Originally, PCP was developed to define 
organelle proteomes by quantifying the distribution of various organelle marker proteins 
across different subcellular fractions, and subsequent matching of proteins with profiles 
similar to the marker. Here, we instead followed protein abundance profiles across 
purification fractions to identify the contamination profile. Mouse platelets were 
separated from erythrocytes and plasma via multiple centrifugation and washing steps 
(Fig. 1a). Aliquots were taken at each step (crude, purified, highly purified, ultra-purified 
fractions, see EXPERIMENTAL PROCEDURES) to perform protein correlation profiling. 
All samples were measured on a Q Exactive mass spectrometer after FASP sample 
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preparation and SAX fractionation [12]. To ensure meaningful profiles, we required at 
least three quantification values either from the three different mice and the highly pure 
platelet preparation or from the three unpurified fractions. After this stringent filtering, 
4,585 protein groups remained.  
 
Figure 1: Platelet preparation and protein correlation profiling (A) The platelet preparation workflow: 
platelets were purified by the depicted centrifugation and washing steps. For the Protein Correlation 
Profiling several mice were pooled and at each purification step a sample was taken. For the ‘mouse’ 
samples only at the ultra-purified fraction a sample was collected (* = ultra-purified) (B) Unsupervised 
hierarchical clustering of protein abundance profiles of the different stages of purity (C) Prototypical 
abundance profile of contaminating proteins (upper panel) and actual profiles of contaminating proteins at 
every abundance level. 
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To identify proteins that have similar abundance profiles across different purification 
steps, we first performed unsupervised hierarchical clustering (Fig. 1b) of the label-free 
intensities (Fig. 1c). From the hierarchical clustering, we observed two major branches of 
the dendrogram grouped based on the different levels of purity— all the ‘ultra-purified’ 
mouse replicates grouped together, separate from the cruder samples (Fig. 1b). 
Intriguingly, groups of proteins at each abundance level had similar profiles over the 
different samples (six clusters in total in six abundance ranges). By cluster analysis and by 
comparing protein profiles to known plasma proteins, we identified 191 contaminant 
proteins. Since there was a gradual decline of protein intensities of the contaminations 
between the highly purified and ultra-purified, we additionally perform a Welch’s t-test 
and detected 191 significant outliers at an FDR of 0.05 (Fig. 2a). Interestingly, these 
outliers covered 90 % of the 191 proteins identified via cluster analysis (18 unique proteins 
each); together amounting to 209 contaminants, of which 55 % (115) are ‘secreted’ 
according to the Uniprot keyword annotation (Fig. 2b). These include apolipoproteins, 
serine protease inhibitors, antibodies and complement factors, confirming that plasma 
was the main source of contaminant proteins. However, contaminants also included 
known erythrocytes markers such as erythrocytic spectrin, erythrocyte membrane protein 
band 4.2 and carbonic anhydrase 1 and 2, indicating that erythrocytes were another 
source of contamination besides plasma (Supplementary Table 1). 
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Figure 2:  Identification of the contaminations via Welch’s t-test. (A) Volcano plot of one-sided Welch’s t-
test, statistically significant (FDR of 0.05) hits are marked in red. (B) Venn diagram depicting the overlap 
between hierarchical clustering and Welch’s t-test. 
 
However, we note that protein correlation profiling does not solve the problem of 
contaminating proteins completely. Due to the platelet’s canalicular system and ‘sponge-
like’ surface as well as their uptake of plasma through vesicles [24], some of these proteins 
remain bound to or are even taken up by platelets making them difficult to identify as 
contaminants.  
The platelet proteome with accurate absolute protein quantification - To determine a 
reference map of the platelet proteome we performed a second quantitative analysis. In 
these experiments we performed the same purification strategy but exclusively measured 
quantitative data on the ‘ultra-purified’ platelets from three different mice. The different 
mice provided the range of variation. The final mean copy number values were 
determined as a combination of these values and the ultra-purified fraction of the 
combined blood sample to obtain the best possible accuracy. To evaluate and visualize the 
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quality of our measurements, we plotted label-free protein abundance values of different 
replicates against each other (Figure 3). This resulted in a Pearson correlation coefficient 
of R=0.98, indicating excellent performance of our workflow and of MaxQuant’s label-free 
algorithm as well as consistency between the inbred mice. Plotting protein abundances of 
the ultra-purified versus the crude fractions highlighted contaminants previously 
identified through protein correlation profiling and Welch’s t-test as outliers from the 
trend line (depicted in red in Figure 3). Once we eliminated the contaminant proteins, a 
final platelet proteome of 4,376 protein groups was obtained (Supplementary Table 2). 
 
Figure 3: Reproducibility of the proteomic measurements. Scatter plot of the proteins comparing replicates 
showing reproducibility as indicated by the Pearson correlation coefficients. Contaminant proteins are 
offset in the semi-purified samples because they are progressively de-enriched. 
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Next, we wished to determine the copy numbers of each platelet protein. To this end, we 
first selected thirteen platelet proteins (Table 1), which cover a wide abundance range of 
the platelet proteome. Absolute protein quantification was achieved using the recently 
developed SILAC-PrEST quantification method [10]. Briefly, from each of the thirteen 
proteins we selected approximately 150 amino acids of unique sequence, containing 
multiple tryptic peptides. We recombinantly expressed these PrESTs with a purification 
and a solubility tag and quantified these standards in a SILAC experiment (see 
EXPERIMENTAL PROCEDURES). Next, we mixed the PrESTs with known concentration 
in appropriate ratios to obtain a master mix [10]. This heavy mix was combined with the 
platelet lysate allowing multiplexed concentration determination of the corresponding 
endogenous proteins via their SILAC ratios (Fig. 4b). To quantify all other platelet 
proteins their intensities were then normalized and scaled by the number of theoretically 
observable peptides through the intensity-based absolute quantification (iBAQ) algorithm 
incorporated in the MaxQuant software, using the PrESTs as the iBAQ standards [25]. The 
copy numbers reported are the mean of three different ultra-purified mice and the ultra-
purified fraction from the protein correlation profiling. The coefficient of variation (in %) 
for each protein copy number was calculated from the four measurements and is reported 
in Supplementary table 2. The overall median coefficient of variation of the all copy 
numbers between the different mouse replicates is 20.6 %. 
To assess the accuracy of iBAQ-derived protein copy numbers we plotted them against 
the values measured via SILAC-PrEST. The estimates from iBAQ quantification agreed 
well with the measured values using the PrESTs, with estimated copy numbers generally 
located within an average 1.8-fold range, depending on protein abundance (Figure 4d). 
The data from the two different methods concurred well with a high correlation 
coefficient of 0.94, indicating the reliability of the copy numbers determined by 
interpolation. 
 
Results 
 
85 
Table 1: Selected platelet proteins for reference points 
Gene Name Protein Name Copy Number Coefficient of 
Variation (%) 
Akt1 RAC-alpha serine/threonine-protein kinase 500 35.6 
Akt2 RAC-beta serine/threonine-protein kinase 700 40.9 
Akt3 RAC-gamma serine/threonine-protein 
kinase 
1,600 109.0 
Fermt3 Fermitin family homolog 3 286,700 3.5 
Fyn Tyrosine-protein kinase Fyn 3,400 26.6 
Gp6 Platelet glycoprotein VI 19,700 33.9 
Itgb3 Integrin beta-3 7,300 7.9 
Itgb2 Integrin beta-2 136,300 4.8 
P2rx1 P2X purinoceptor 1 5,500 24.7 
Prkca Protein kinase C 24,900 16.6 
Prkg1 cGMP-dependent protein kinase 1 2,100 29.5 
Selp P-selectin 42,200 31.3 
Tln1 Talin-1 267,000 4.1 
 
 
Figure 4: Absolute protein quantification (A) Quantification of the PrEST. Highly purified ABP are 
quantified by amino acid analysis. The concentration of the SILAC-labeled PrESTs is determined using 
the common ABP derived tryptic peptides. (B) In a separate experiment, previously quantified PrESTs are 
multiplexed and spiked into the platelets lysate. The sample is processed via filter-aided sample 
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preparation (FASP) and the concentration of the endogenous proteins is read out using the SILAC ratio 
determined in the mass spectrometer. (C) Thirteen different PrESTs were used to quantify proteins of 
interest over the whole abundance range. (D) Comparison of protein copy numbers of thirteen selected 
proteins obtained using SILAC-PrEST to those calculated using iBAQ method. 
 
Adhesion and signaling receptors – Having protein copy numbers by hand we set out to 
examine important adhesion and signaling receptors. The primary function of platelets is 
to control hemostasis by scanning the blood system for vascular lesions. Most platelets 
never adhere or aggregate during their entire lifetime and are degraded in the 
reticuloendothelial system of the spleen or liver. In the case of a vessel lesion, however, 
different platelets receptors mediate adhesion, aggregation and signaling [26]. Figure 5 
depicts the major adhesion and signaling receptors of platelets.  
The GPIb-IX-V complex consists of four proteins (GPIbα:GPIbβ:GPIX:GPV) and 
represents the second most important platelet receptor after αIIb3 integrin. Its absence or 
deficiency in human leads to Bernard- Soulier syndrome, the second most common 
bleeding disorder [27]. It is responsible for initial platelet recruitment and platelet 
activation and is the major receptor for von Willebrand Factor (VWF), a protein binding to 
subendothelial collagen whose absence is the most common cause for coagulation 
deficiency. The GPIb-IX-V complex associates in a certain stoichiometry, which was 
thought to be 2:2:2:1 (GPIbα:GPIbβ:GPIX:GPV). However, Li and co-workers [28] recently 
reported that GPIb is bound via two disulfide bridges, which would lead to two GPIbβ 
molecules for one GPIbα protein. Indeed, the stoichiometry of 1.3:4.4:1.8:1 found in our 
study agrees with this conclusion. Given this stoichiometry, we find 36,000  ±5000 GPIb-
IX-V complexes to be present in each platelet on average. 
Integrins represent the major class of adhesion and signaling receptors and are expressed 
in almost all cells. They consist of α and  subunits and only correctly folded and 
associated heterodimers are transported to the plasma membrane. Upon activation 
integrins shift towards an active conformation with high affinity for their ligands [29]. 
Platelets express six different integrins, αIIbβ3, αv3, α21, α51, α61 and αL2, each 
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binding to different ligands. Mutations in the αIIb or β3 genes cause Glanzmann 
thrombostenia, the most common bleeding diathesis in patients. As expected from its 
prominent cellular and disease roles, the αIIb3 integrin was measured as the most 
abundant adhesion receptor with 110,000 ±7,900 to 130,000 ±10,100 copies per platelet 
estimated from our dataset. The α21 integrin is the second most important integrin, 
which mediates adhesion to collagen. We find it expressed at 18,000 ±1,300 copies per 
platelet. The laminin receptor α61 integrin is involved in binding to laminins of the 
basement membrane, which is not thought to be of equal importance to the binding of 
platelets to collagen. Therefore it was surprising to find that the laminin receptor was 
expressed at similar levels (20,000 ±1,500 copies). This indicates that it may have a so far 
underestimated role in platelet adhesion to subendothelial lesions, which expose laminins 
of the basement membrane. The expression levels of the other integrins are listed in Table 
2. Our dataset reflects the 1:1 stoichiometry of the various integrin complexes within the 
expected accuracy, further supporting the validity of our copy number estimates. 
 
Table 2: Integrin Stoichiometry 
Integrin 
subunit 
Protein 
Copy 
Number 
Collagen 
receptor 
Fibrinogen 
receptor 
Vitronectin 
receptor 
Fibronectin 
receptor 
Laminin 
receptor 
unknown 
role 
Itga2b 106,600  106,600     
Itgß3 131,700  ~131,000* ~600    
Itga5 1,900    1,900   
Itga2 17,600 17,600      
Itgß1 30,900 ~13,530   ~1,460 ~15,910  
Itga6 20,700     20,700  
Itgav 500   500    
ItgaL 5,800      5,800 
Itgß2 11,000      11,000 
*Integrins are heterodimers. Copy numbers of each of these (Collagen receptor, Fibrinogen 
receptor etc.) were estimated from the measured copy numbers of their alpha subunits. The 
proportion of beta subunits in each integrin receptor was allocated to this ratio (indicated by ~ 
symbols). 
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Glycoprotein VI (GPVI) represents an Ig superfamily member and is the other major 
collagen receptor. We directly quantified it by a SILAC-PrEST leading to a copy number 
of 19,000 ± 6,700 per platelet. Interestingly, both collagen receptors are expressed at 
similar levels. GPVI forms a complex with the common FcRg chain (75,000 ±15,400 
copies), which is critical for the signaling process. Although GPVI may also have a role in 
platelet adhesion to collagen, its major role is platelet activation via phospholipase Cγ2 
(11,000 ±1,300 copies), which induces Ca2+ release and the activation of α21 integrins. 
Collagen-bound GPVI and α21-derived signals are both required for full platelet and 
αIIbβ3 integrin activation [30]. The knowledge of copy numbers of the different collagen 
receptors might help to understand their roles in collagen adhesion and subsequent 
signaling. 
Beside these adhesion receptors, platelets contain a number of other receptor types. As 
many of them are thought to be expressed at very low levels, it is remarkable that they 
were identified and quantified in our measurements without any special enrichment step 
(Fig. 5). G-protein-coupled receptors belong to the seven transmembrane receptors and 
represent the major agonist receptor family in platelets. Protease-activated receptors Par4 
(5,200 ±1,500) and Par3 (3,900 ±1,400), which reside on mouse platelets (in contrast to 
human platelets, where PAR-1 and PAR-4 are expressed), are activated by thrombin, one 
of the most potent platelet agonist. ADP is another important platelet agonist, which is 
secreted from platelet dense granules and acts as an autocrine agonist. It is bound by the 
two purinergic receptors, P2Y1 (1,000 ±100) and P2Y12 (2,700 ±500). Many FDA-approved 
antiplatelet drugs such as Ticopidine, Clopidogrel, Prasugrel target P2Y12 and cause 
significant inhibition of ADP-mediated platelet activation [1]. Other GPCRs important in 
transmitting signals from thromboxane, prostacyclin (PGI2), and epinephrine are 
thromboxane A2 receptor (1,900 ±800), prostanoid IP receptor (2,200 ±800), and alpha-2A 
adrenergic receptor (140 ±60), respectively. The serotonin receptor 5HT2A is also known 
to be expressed on platelets; however, because we only quantified it in two of three 
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replicates (with average copy number 175 ±20), it did not pass our stringent threshold for 
copy number assignment. 
 
Figure 5: Selection of platelet specific proteins and pathways. Overview of major adhesion and signaling 
receptors of platelets as well as downstream signaling pathways. Copy numbers derived in this study are 
depicted in grey (Copy numbers with an asterisk were measured with SILAC-PrEST quantification). 
 
One central step in platelet activation triggered by the above mentioned adhesion and 
signaling receptors is an increase in intracellular calcium levels. This is mediated by 
phospholipase C hydrolyzing PIP2 to IP3, which in turn induces the release of Ca2+ from 
the dense tubular system (DTS). Depletion of Ca2+ from the DTS activates Stim1 (33,000 
±1,900), causing it to relocate to the plasma membrane to open the ion channel Orai1 
(1,700 ±300) resulting in Ca2+ influx from plasma. Another important Ca2+ channel is the 
P2X purinoceptor, which is activated independently by ATP. We measured 5,500 ±1,400 
copies of this receptor via direct PrEST quantification. Increased calcium levels are for 
instance crucial for αIIb3 integrin activation, leading to platelet adhesion and 
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aggregation. Knowledge of the copy numbers of these proteins may be informative for 
pharmacological approaches to target calcium signaling.  
 
Determination and quantification of isoforms - Many protein families include different 
isoforms, which may have distinct functions. Quantification of isoforms by shotgun 
proteomics is complicated by the fact that peptides may be shared between these 
isoforms. Here, we restricted our analysis to cases in which the majority of peptides were 
sequence unique peptides for the isoform in question.  
In platelets, two predominant phospholipase C isoforms can be found: Beta (β1 – 220 ±30 
copies per cell, β3 – 1,600 ±200, β4 – 1,400 ±100) and gamma (γ1 – 60±20 , γ2 – 11,300 
±1,300). Depending on the upstream receptor a different PLC isoform is activated. In case 
of the gamma isoform, we can confirm that in platelets γ2 is by far the predominant 
isoform [31, 32]. Downstream of PLC, protein kinase C (PKC) is activated by 
diacylglycerol (DAG) and increase Ca2+. We detected five different PKC isoforms: α 
(24,900 ±2,200), β (30 ±10), δ (4,000 ±200), θ (8,000 ±500), ε (1,600 ±300).  By different knock-
out studies (review in [33]) it was shown that the different isoforms play distinct roles in 
the platelet activation process. PKC α for example phosphorylates, among other 
substrates, proteins involved in the secretion of the α-granules and dense granules. Mice 
deficient in Prkca exhibit reduced secretion of ATP [34]. Other examples include the Akt 
kinases of which all three mammalian isoforms have been shown to occur in platelets [35]. 
Using SILAC-PrESTs we quantified all isoforms Akt1 (500 ±200), Akt2 (700 ±300) and Akt3 
(1,600 ±1,700), and confirm that Akt3 is the most abundant isoform as reported recently 
[35].  It is known that they have different roles in platelet activation [36, 37]. Even though 
the Akt isoforms have 75% sequence homology (but not sequence identity), we were able 
to distinguish and quantify the Akt isoforms with multiple unique peptides. These 
examples indicate that shotgun proteomic data with sufficiently high coverage enables the 
determination of expression level differences of distinct isoforms. 
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Global view of protein copy numbers - Altogether using our shotgun proteomics 
workflow, we identified and measured 4,376 platelet protein groups with average 
sequence coverage of 38.5%. Estimated abundances from our data span a very wide full 
dynamic range - six orders of magnitude - from two copies up to 900,000 copies per 
platelet (Fig. 6a). As expected, the most abundant platelet protein is the cytoskeletal 
protein actin with close to one million copies per platelet. Notably, one third of the 
identified platelet proteome (1,500 proteins) has copy numbers below 500. Interestingly, 
for several proteins we even estimated copy numbers less than 10 per platelet, however, 
measurements in this range are likely to be less accurate. The lowest copy number of a 
protein known to have an important function in the proteome, was the alpha-2A 
adrenergic receptor (A2AR) with 140±60 copies per platelet. Conversely, some proteins 
that we would have expected in our platelet proteome, such as nitric oxidase have not 
been identified. 
 
Figure 6: Histogram of all copy numbers. Comparison between the protein abundance distribution of 
fibroblast and platelet copy numbers. Proteins below 500 are depicted in dark brown. 
 
We were intrigued by the high proportion of proteins with low copy numbers and asked 
if they were likely to be functional. To investigate this, we did a bioinformatic enrichment 
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analysis of groups or pathways that were statistically significantly overrepresented. To 
this end we performed a so called 1D enrichment analysis (with abundance being the one 
dimension) on the basis of annotation terms such as Uniprot keywords or Gene Ontology 
(GO) in the Perseus software, which is part of MaxQuant [38] (Supplementary Table 3). It 
employs a two-sample Welch’s t-test for difference of means of the category versus all 
remaining proteins and yields categories with statistically significance and therefore does 
not require arbitrary cutoffs for abundance categories. We then did the same analysis for 
fibroblasts, for which absolute copy numbers have been reported recently (note that 
fibroblasts are much larger and therefore copy numbers are in general much higher [25]). 
First, we could confirm that protein categories that were overrepresented in the high 
abundance region were platelet specific protein groups since these annotation terms 
comprised ‘fibrinogen complex’ (mean copy number value 220,000), ‘platelet alpha 
granule’ (140,000) and ‘platelet activation’ (120,000). In contrast, diverse categories such as 
‘ribosome assembly’ or ‘ribosomal subunits’ (mean copy numbers 6,000,000 to 10,000,000) 
were enriched in the high abundant region of fibroblasts. Another abundant hit in 
fibroblasts was ‘nucleosome’ with a mean copy number of approximately 4,000,000. This 
unbiased analysis directly confirms the different functional processes in platelets vs. 
fibroblasts – one cell type with a specialization on cell adhesion and associated signaling 
but little translation in contrast to a dividing cell line allocating cellular resources to 
protein synthesis.   
In the low abundance region of platelet distribution, chromatin binding (mean copy 
number of 600), tRNA processing (500), RNA-mediated gene silencing (300), Zinc finger 
proteins (400), nucleic acid binding (600) and different categories of proteins involved in 
the ubiquitination pathway were detected. Fibroblasts, in contrast did not show any of 
these enrichments in the low abundance region. Enrichment in the low copy number 
region of the platelet proteome is not surprising as platelets lack a nucleus and are 
therefore not expected to have a functional requirement for proteins involved in 
transcription, DNA repair or replication. Indeed, the fact that low amounts of these 
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proteins are nevertheless clearly quantifiable, suggests that they are vestiges of the 
budding process from the megakaryocytes. The presence of only very low copy numbers 
of proteins in the ubiquitylation process may reflect a relative absence of protein 
degradation – the mirror image of low or absent translation.  
 
CONCLUSIONS AND OUTLOOK 
In this study, we performed a deep and quantitative proteome analysis of murine 
platelets. Platelets are purified from blood therefore it is crucial to discriminate between 
false positive proteins and contaminations from erythrocytes and plasma. To differentiate 
platelet proteins from common contaminations deriving from sample preparation, we 
successfully applied a variant of the protein correlation profiling approach based on the 
fact that true platelet proteins should be enriched, whereas contaminating proteins 
disappear during purification. After subtracting these, 4,400 platelet proteins were 
confidently identified. Notably, this proteome depth was achieved without laborious 
fractionation, enrichment for membrane proteins or post-translationally modified 
peptides.  
Absolute quantification using the recently published SILAC-PrEST method allowed us to 
accurately quantify a number of platelet proteins in an absolute manner, which then 
enabled us to estimate the copy numbers of all identified platelet proteins per cell. These 
copy numbers enabled us to examine complex stoichiometry. For instance we correctly 
determined the composition of the GPib-IX-V complex and of most integrins. We are 
confident that the stoichiometry of many complexes can be deduced from our data.  
We noted that some of our copy numbers are higher than previously published, for 
example in the case of integrin αIIb3 which was reported to have 80,000 copies per 
unstimulated platelet. However, inspection of the literature revealed that only the 
receptors in the outer plasma membrane had been labeled and quantified [39]. It is known 
that a significant proportion (30%) of the receptor is stored in the open canalicular system 
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(OCS) as well as in platelet α granules [40], leading to an agreement with our SILAC-
PrEST measurement of 120,000 copies per platelet. In general, many receptors are stored 
on alpha and dense granules and only incorporated into the plasma membrane upon 
activation. Since we measure the total protein content, some copy numbers might not 
agree with those numbers, which have been generated from surface measurements. 
Furthermore, to the extent that copy numbers are known, they have often been 
determined in human platelets, making them not directly comparable.  
Due to the fact that most murine platelet proteins fulfill identical functions as their human 
counterparts and mice represent valuable model organism to study human pathology, 
which is also demonstrated by numerous genetically modified mice mimicking human 
platelet diseases, our mouse platelet proteome study may further help in understanding 
the role of individual proteins in platelet physiology. At the same time significant 
differences between platelets from mice and men exist, such as platelet size, counts and 
expression of certain critical proteins (e.g. the above-mentioned PAR1 in human vs. PAR3 
in mice). Thus, our data can also serve to further study and follow up differences in 
protein expression and isoforms. 
In conclusion, we here took advantage of recent advances in MS-based proteomics and 
quantification techniques to achieve a very large and high confidence dataset of platelet 
proteins. Estimated absolute quantification to a level down to single copy per cell should 
provide a basis for further characterization of platelets and their functionality.  
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SILAC-PrEST applied to protein complex stoichiometry  
One of the major adhesion receptors on platelets that is crucial for activation and 
aggregation is the integrin αIIB3 complex. Integrins have the ability to change their 
conformation from an inactive state with low affinity to ligands to an active state. The 
activation of integrins (‘inside-out’ signaling) is mediated by two protein families: talins 
and kindlins. In platelets talin-1 and kindlin-3 directly bind to the tail of the integrin 
αIIB3 inducing the conformational change. Previously it was thought that talin alone 
plays a role in integrin activation, but recently it was shown that kindlin-3 is equally 
essential [113, 114]. Here, we investigated the interplay of these two proteins by 
generating mouse strains expressing different amounts of kindlin-3. Furthermore we used 
SILAC-PrEST quantification to reveal the expression levels and stoichiometry of integrin 
3, kindlin-3 and talin-1.  
The study was performed in mice, therefore PrESTs were produced independently of the 
Human Protein Atlas project. We designed the PrEST sequences to be optimal for mass 
spectrometric analysis, specifically unique regions having many tryptic peptides, as well 
as considering uniqueness in case of isoforms. To be as accurate as possible two 
independent PrESTs were designed and produced to target each of the proteins of 
interest. 
 
The manuscript for this study is currently in preparation: 
‘Platelets and neutrophils require different Kindlin-3 copy numbers to control integrin-mediated 
functions in vivo’ 
Sarah Klapproth*, Federico Moretti*, Marlis Zeiler, Raphael Ruppert, Matthias Mann, 
Markus Sperandio, Reinhard Fässler and Markus Moser 
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Many of the diverse functions of blood cells depend on integrins and the cytoplasmic 
proteins kindlin-3 and talin-1. To relate specific functions of platelets and 
polymorphonuclear neutrophils (PMNs) to specific kindlin-3 levels we generated 
mouse strains expressing 50%, 10% and 5% of kindlin-3. We report that in contrast to 
Kindlin-3 null mice, which die of severe bleeding and leucocyte adhesion deficiency, 
mice expressing as little as 5-10% of kindlin-3 were viable, although only a limited 
number of integrins could be activated on platelets and neutrophils. Interestingly, tail 
wounding led to a severely prolonged bleeding tendency due to reduced platelet 
adhesion and aggregation but leukocyte adhesion to endothelial cells in the inflamed 
ear and the cremaster muscle was rather mildly impaired. Absolute quantification of 
protein copy numbers revealed similar kindlin-3 and talin-1 copy numbers in platelets 
and neutrophils. Interestingly, the ratio of the copy number of kindlin-3 and talin-1 
relative to β3 integrin in platelets was 2:1, whereas in neutrophils the ratio relative to 
β2 integrins was 1:2. These data indicate that platelet-mediated hemostasis requires 
high kindlin-3 levels to ensure full-fledged integrin activation, whereas leukocyte 
adhesion and extravasation require lower levels of active integrins. 
Integrins are cell adhesion receptors that consist of α and β subunits. They anchor cells to 
the extracellular matrix and assemble large signaling hubs, with which they regulate 
essential cellular processes including cell adhesion, migration, proliferation, survival and 
differentiation. A hallmark of integrins is their ability to reversibly switch between an 
active and an inactive conformation. In their inactive conformation they have low affinity 
for ligands, while upon activation (inside-out signaling) the affinity increases, which leads 
to ligand binding, integrin clustering and finally signaling (outside-in signaling). Two 
principal protein families are known to regulate integrin affinity, the talins (talin-1 and -2) 
and kindlins (kindlin-1, -2, -3). They both bind directly β integrin tails and thereby induce 
the allosteric change in the integrin ectodomain (Moser et al., 2009b). 
A fast allosteric change and rapid integrin-ligand interaction is particularly important for 
blood cells such as platelets and leukocytes, whose surface integrins continuously 
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encounter ligands in plasma or on the vascular endothelium, respectively. Therefore, it is 
of fundamental importance for these cells to maintain integrins in an inactive state and 
rapidly activate them on demand, for example during bleeding when platelet aggregation 
is needed to seal vascular injuries, or during infection when leukocytes need to 
extravasate and kill microbial invaders. Blood cells express talin-1 and kindlin-3 whose 
binding to β integrin tails is tightly controlled by mechanism(s) that are largely unknown. 
Furthermore, it is also unclear whether a specific stoichiometry is critical for the integrin 
activation process. 
In the present study, we engineered several mouse strains expressing different kindlin-3 
protein levels. This allowed testing how different talin-1/kindlin-3 ratios influence 
integrin-mediated functions. We found that 5% of kindlin-3 in blood cells is sufficient for 
embryonic and postnatal development. However, upon exposure to stress the low levels 
of kindlin-3 impair adhesive functions of platelets and polymorphonuclear neutrophil 
(PMNs). Furthermore, platelets possess more kindlin-3 and talin-1 relative to their 
integrin levels than PMNs suggesting that rapid and full-fledged integrin activation is 
required for platelet functions, while only a limited number of integrins are activated 
during leukocyte extravasation. 
 
RESULTS AND DISCUSSION 
Generation of conditional and hypomorphic kindlin-3 mouse mutants. Kindlin-3 
deficient mice die shortly after birth of anemia caused by bleeding and erythrocyte defects 
(Kruger et al., 2008; Moser et al., 2009b). To enable the disruption of the kindlin-3 gene at 
later stages or in specific blood cells, we generated a conditional kindlin-3 mouse by 
flanking exon 3-6 with loxP sites (suppl. Fig. 1). An intercross of these kindlin-3 floxed 
(K3fl/fl) mice with a deleter Cre strain produced offspring lacking exon 3-6 and the frt-
flanked neomycin cassette, and as expected, with the same defects observed in 
constitutive kindlin-3 null mice (Moser et al., 2009a; Moser et al., 2009b) (suppl. Fig. 1D,E). 
Results 
 
104 
We noticed that the presence of the neomycin cassette in intron 6 of the floxed kindlin-3 
gene (suppl. Fig. 1A; K3+/n mice) significantly reduced kindlin-3 protein levels (Figure 
1A,B). Intercrossing these mice to homozygosity (K3n/n) or with mice carrying a kindlin-3 
null allele (K3n/-) further reduced kindlin-3 protein levels in spleen and thymus to around 
10% and 5%, respectively (Figure 1A,B). Sequence analysis of kindlin-3 mRNA revealed 
aberrant splicing into the neomycin cassette as the major cause for reduced protein levels 
(data not shown). Thus, the introduction of a neomycin cassette into intron 6 of the 
kindlin-3 gene produced a hypomorphic kindlin-3 allele and by intercrossing these mice 
with wild type or kindlin-3 null mice we could differently reduce kindlin-3 protein levels. 
 
Figure 1: Kindlin-3 protein levels in spleen and thymus. (A) Western blot analyses of kindlin-3 in spleen 
and thymus lysates from K3+/+, K3n/n, K3n/- mice. GAPDH served as loading control. (B) Densitometric 
quantification of (A). 
Surprisingly, the different hypomorphic mouse strains including the K3n/- mice 
developed and aged normally, were fertile and showed normal cellularity in spleen and 
thymus (suppl. Fig. 2A-C). Furthermore, their erythroid counts in blood were normal 
indicating that they did not suffer from microbleedings or erythrocyte defects. However, 
the total number of white blood cells (WBC), in particular PMNs and lymphocytes, was 
significantly increased in K3n/n and K3n/- mice suggesting that low kindlin-3 levels 
compromise leukocyte extravasation and tissue patrolling (supplementary table 1).  
Kindlin-3 hypomorphic mice show a bleeding tendency. Kindlin-3 deficiency causes 
fatal bleedings in mice and man (Kuijpers et al., 2009; Malinin et al., 2009; Moser et al., 
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2008; Svensson et al., 2009). Although platelets from K3n/n and K3n/- mice expressed 
around 10% and 5% of kindlin-3 levels, respectively, compared to wild type controls (Fig. 
2A), they did not suffer from spontaneous hemorrhages during development or postnatal 
life (Fig. 2B, and data not shown). However, bleeding assays revealed that wild type and 
K3+/n mice stopped bleeding within 5 min, while K3n/n mice suffered from a similar 
bleeding tendency as kindlin-3 null mice (Fig. 2C). Interestingly, thrombin treatment of 
wild type and K3+/n platelets robustly induced binding of fibrinogen by platelet αIIbβ3, 
while fibrinogen binding was reduced to less than 20% in K3n/n and K3n/- platelets and 
almost entirely lost in K3-/- platelets (Fig. 2D). Consistently, thrombin-induced activation 
of αIIbβ3 integrins measured by flow cytometry using the JON/A-PE antibody decreased 
concomitantly with lowering levels of kindlin-3 in platelets (Fig. 2E). Adhesion and 
spreading of platelets from K3n/n and K3n/- mice on a fibrinogen-coated surface was 
severely impaired (Fig. 2F). Since treatment of platelets with manganese, which can 
bypass integrin activation (Mould et al., 2002) rescued fibrinogen binding (not shown) 
and platelet adhesion but not platelet spreading (Fig. 2F), we conclude that the 
diminished kindlin-3 levels in K3n/n and K3n/- platelets impaired both integrin activation 
and outside-in signaling leading to actin reorganization. These findings were 
corroborated with in vitro aggregation assays, in which platelets from K3n/n and K3n/- 
mice produced much smaller aggregates (Fig. 2G) and displayed a biphasic aggregation 
response (Fig. 2H); the platelet shape change was followed by a rapid initial aggregation, 
while the second phase of aggregation, which depends on secreted auto- and paracrine 
factors, was significantly reduced in K3n/n and K3n/- platelets. Addition of fibrinogen 
normalized the second aggregation phase suggesting that indeed integrin-triggered 
platelet degranulation and release of secondary agonists is impaired and/or delayed in 
kindlin-3 hypomorphic platelets (Fig. 2G). Furthermore, thrombin-induced platelet clot 
retraction was delayed with platelets from K3n/n and K3n/- mice in platelet-rich plasma; 
however, addition of manganese normalized the clot retraction times indicating that acto-
myosin induced pulling forces are induced by active integrins independent of kindlin-3 
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(Fig. 2I), while actin reorganization and platelet spreading require active integrins and 
depend on kindlin-3 (Fig. 2F). 
 
Figure 2: Function of platelet integrins is kindlin-3 dose dependent. (A) Densitometric quantification of 
kindlin-3 levels in K3+/+, K3n/n, K3n/- and K3-/- platelets (N=5;5;4;4). GAPDH served as loading control. 
(B) Kindlin-3 K3+/+, K3n/n, K3n/- E14.5 embryos are free bleedings. (C) Tail bleeding times of K3+/+, 
K3n/n, K3n/- and K3-/- chimeric mice. (D) Binding of fibrinogen to platelets after treatment with 0.1 U/ml 
thrombin. Resting platelets were used as control. N=5;5;5;5;3. (E) Activation of αIIbβ3 integrin on platelets 
upon stimulation with 0.1 U/ml thrombin. N=5;5;5;5;3. (F) Washed platelets were stimulated with 0.01 U/ml 
thrombin and allowed to adhere to coated fibrinogen for 10 min in the presence or absence of 3 mM Mn2+. 
(G) Aggregates of K3+/+, K3n/n and K3n/- platelets in response to 0.1 U/ml thrombin. (H) Platelet 
aggregation assays with K3+/+, K3n/n, K3n/- platelets in response to thrombin in the absence and presence 
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of 100 µg/ml fibrinogen. (I) Clot retraction of platelets from K3+/+, K3n/n, K3n/- and K3-/- mice in the 
absence or presence of 0.5 mM Mn2+. N=7;4;6;6;7. Values are given as mean ± SD. Significant differences 
are indicated by asterisk (*: p<0.05; **: p<0.01; ***p<0.001). 
Altogether, these data indicate that lowering kindlin-3 in platelets to 5-10% of wild type 
levels allows them to activate a limited number of integrins, which is sufficient to fulfill 
basal functions but insufficient to scope with stress conditions. 
K3n/n and K3n/- mice suffer from leukocyte adhesion defects. Absence of Kindlin-3 also 
impairs β2 integrin functions on leukocytes resulting in leukocyte adhesion deficiency in 
mouse and man (Moser et al., 2009a). PMNs from the bone marrow of wild type, K3n/+, 
K3n/n and K3n/- mice displayed reduced kindlin-3 levels ranging from 50% in K3n/+, to 
10% in K3n/n and 5% in K3n/- mice (Fig. 3A). With these different mouse strains we 
investigated in several experiments to which extent leukocyte adhesion, extravasation and 
phagocytosis become compromised when kindlin-3 drops below a certain threshold. First, 
stimulation of K3n/n and K3n/- PMNs with phorbol-12-myristate-13-acetate (PMA) 
showed diminished adhesion to ICAM-1, although adhesion levels were still significantly 
higher than for K3-/- PMNs (Fig. 3B). Next, we treated earflaps with phorbol ester (crotoin 
oil) for 1 h and observed a delay in the extravasation of K3n/n and K3n/- PMNs compared 
to wild type and K3+/n PMNs. Notably, 4 h after treatment K3n/n and K3n/- PMNs have 
crossed the vascular wall and distributed in the interstitium like wild type PMNs, while 
K3-/- PMNs failed to extravasate (Fig. 3C). In order to study leukocyte adhesion and 
extravasation more quantitatively we analysed TNF-stimulated cremaster muscle 
venules in vivo using intravital microscopy. The experiments revealed that leukocyte 
adhesion was normal in wild type and K3n/+ mice, decreased by about 20% in K3n/n mice 
and by about 50% in K3n/- mice (Fig. 3D). Concomitantly with the reduced in vivo 
adhesion of leukocytes, the numbers of rolling leukocytes were increased in K3n/- mice 
(Fig 3E). Similarly, β2 integrin-mediated phagocytosis of serum-opsonized bacteria was 
reduced in K3n/n and K3n/- PMNs and abolished in K3-/- PMNs (Fig. 3F). Altogether, 
these findings indicate that the low kindlin-3 levels in K3n/n and K3n/- PMNs impairs 
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phagocytosis and adhesion. However, the compromised adhesion still allows a rather 
efficient leukocyte extravasation in inflammatory models. 
 
Figure 3: Leukocyte adhesion is Kindlin-3 modulated. (A) Densitometric quantification of kindlin-3 levels 
in K3+/+, K3n/n, K3n/- and K3-/- PMNs (N=3). GAPDH served as loading control. (B) Static adhesion of 
PMNs to ICAM-1 upon PMA stimulation. N=4. (C) Whole mounts of ears treated with phorbol ester for 1 
(left) and 4 h (right) stained with a pan-laminin antibody (LN; green) to visualize endothelial basement 
membranes and a Gr-1 antibody (red) to visualize PMNs. Scale bar: 200 µm. (D-E) Leukocyte adhesion and 
rolling in TNFα-stimulated cremaster muscle venules assessed in 12 venules of 4 K3+/+ mice, in 19 venules 
of 4 K3n/n mice and in 17 venules of 3 K3n/- mice. (D) Leukocyte adhesion efficiency determined as 
number of adherent leukocytes per mm2 vascular surface area divided by the systemic leukocyte count. (E) 
Leukocyte rolling flux fraction determined as rolling leukocytes passing an imaginary perpendicular line 
over the vessel corrected by the total number of passing leukocytes. Values are mean ± SEM. (F) 
Results 
 
109 
Phagocytosis of fluorescently labeled E.coli particles by K3+/+, K3n/n, K3n/- and K3-/- PMNs. N=3;5;4;4;3. 
Significant differences are indicated by asterisk (*: p<0.05; **: p<0.01; ***p<0.001). 
Kindlin-3, talin-1 and integrin copy numbers in platelets and PMNs. The basal 
functions of platelets and PMNs from K3n/n and K3n/- mice are efficiently executed in 
vivo. However, upon stress exposure the functions of platelets and PMNs become 
compromised. Interestingly, stress situations affect K3n/n and K3n/- derived platelets 
more severely than leukocytes. To test whether this difference could be due to different 
copy number ratios of kindlin-3 and talin-1 proteins in platelets versus leukocytes we 
performed Western blot analysis with purified blood cell populations. In comparison with 
various white blood cells platelets contain high levels of kindlin-3 and talin-1 (Fig. 4A). 
Analysis of the platelet proteome by high resolution mass spectrometry (MS) (Cox and 
Mann, 2011) confirmed that kindlin-3, talin-1 and β3 integrins are among the most 
abundant platelet proteins (Fig. 4B).  
To determine the stoichiometry of kindlin-3, talin-1, β2 and β3 integrins in platelets and 
PMNs, we used a recently developed MS method to quantify absolute protein numbers 
by expressing parts of the target protein sequence in a heavy labeled form (Zeiler et al.). 
Specifically, short protein fragments of approximately 150 amino acids from murine 
kindlin-3, talin-1, β3 and β2 integrins were fused to the albumin-binding protein (ABP) 
and expressed in the presence of 13C615N2-lysine (Lys8) and 13C615N4-arginine (Arg10) in an 
auxotrophic Escheria coli strain, which labeled them with heavy isotopes. A precisely 
quantified cocktail of different stable isotope labeled protein standards from kindlin-3, 
talin-1, β2 and β3 integrins was then mixed with platelet and PMN lysates and their 
absolute copy numbers per cell were calculated after determining the heavy to light ratio 
by MS (Fig 4C; for details see material and methods and Zeiler et al., 2012). Kindlin-3 
expression in platelet lysates from wild type, K3+/n, K3n/n and K3n/- mice revealed a 
stepwise decrease, while talin-1 and β3 integrin levels were similar in the different platelet 
populations (Fig. 4D). The measurements also revealed that a wild type platelet contained 
between 260,000 and 290,000 copies of talin-1 and kindlin-3, respectively, and about 
130,000 copies of β3 integrin molecules (Fig. 4D). The PMNs also contained a 
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stoichiometric number of kindlin-3 and talin-1 molecules of about 420,000 molecules per 
cell each. Furthermore, the total numbers of β2 integrins were approximately 800,000 
molecules per cell, and hence was twice the number of talin-1 and kindlin-3 (Fig. 4E). 
These data indicate that platelets have an excess of talin-1 and kindlin-3 over integrins, 
whereas PMNs have an excess of integrins over talin-1 and kindlin-3. 
 
Figure 4: Quantification of kindlin-3, talin-1 and integrin protein levels in platelets and PMNs. (A) 
Western blot of kindlin-3 and talin-1 from different blood cell lysates. GAPDH and actin served as loading 
controls. (B) Copy number counts of platelet proteins were estimated with intensity based absolute 
quantification. (C) Schematic representation of the workflow for quantification of protein copy numbers 
in platelet lysates. Heavy labeled protein standards with known concentration were spiked into platelet 
lysates and peptide ratios were determined by mass spectrometry. (D) Mass spectrometry-based absolute 
quantification of the copy numbers of kindlin-3, talin-1, β3 integrin and β2 integrin in K3+/+, K3n/n and 
K3n/- platelets. (wt N=3; +/n, n/n and n/- N=2) . Values are given as median ± range. (E) Mass spectrometry-
based absolute quantification of the copy numbers of kindlin-3, talin-1 and β2 integrin in wild type PMNs. 
N=3. Values are given as median ± range. 
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Integrin-dependent functions of blood cells are strictly controlled by kindlin-3. In this 
study kindlin-3 hypomorphic mice were generated to address which levels of kindlin-3 
are required for basal and stress induced platelet and PMNs functions. The results allow 
drawing interesting conclusions; first, expression of 5 to 10% of kindlin-3 in blood cells is 
sufficient for survival. Second, the steady state functions of platelets and PMNs with 5-
10% of normal kindlin-3 levels are maintained, although the elevated WBC counts 
indicate reduced tissue patrolling. Third, low kindlin-3 expression allows activation of 
only a reduced number of integrins leading to decreased ligand binding and adhesion. 
This shows that kindlin-3 does not act in a catalytic manner. Fourth, under stress 
conditions such as bleeding or inflammation the low levels of kindlin-3 limit platelet 
functions more than PMN functions indicating that platelets require a higher threshold of 
kindlin-3 to cope with their demands. Fifth, although kindlin-3 is required for integrin-
dependent intracellular signalling controlling platelet spreading and degranulation, it is 
not required for acto-myosin pulling and platelet contraction, which is in contrast to talin-
1 (Haling et al., 2011).  
Why are decreased kindlin-3 levels affecting platelets more than PMNs? The integrin-
mediated adhesion machinery is highly expressed in platelets indicating that it is of 
paramount importance for the organism. The binding of plasma fibrinogen might require 
more functional integrins than the binding of PMNs to insoluble ICAM-1, which is 
upregulated and clustered on inflamed endothelial cells allowing a fast rebinding of 
broken integrin-ligand bonds. We determined the absolute numbers of kindlin-3, talin-1, 
β2 and β3 integrins in platelets and PMNs and found stoichiometric expression of both 
integrin activators, which further corroborates their cooperativeness during integrin 
regulation. In addition, surface density of β3 integrins on platelets (approximately 20,000 
copies per m2 platelet surface area based on a total surface area of 8 m2) and the 
corresponding concentration of talin-1 and kindlin-3 in platelets (40,000 copies each per fL 
platelet volume; total platelet volume appr. 7fL (von Hundelshausen et al., 2007)) are 
much higher than the corresponding values in PMNs (3,000 copies of β2 integrins per m2 
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neutrophil surface area and 1,500 copies of talin-1 and kindlin-3 per fL PMN volume; 
based on 250 m2 surface area and 300fL volume for PMNs (Ting-Beall et al., 1993)). These 
values may very well reflect differences in mechanical stress, platelets and neutrophils are 
exerted to (platelet adhesion in arteries versus neutrophil adhesion in venules). 
Furthermore, the twofold excess of talin-1 and kindlin-3 over β3 integrins in platelets 
ensuring rapid and full-fledged integrin activation critical for primary hemostasis. On the 
contrary, PMNs express only half as much integrin activators than β2 integrins suggesting 
that only a limited number of β2 integrins is activated. Remarkably, even neutrophils 
from kindlin-3 hypomporphic mice can efficiently adhere and leave the inflamed 
vasculature. Probably because a highly dynamic and strongly restricted number of active 
β2 integrins on leukocytes is sufficient to control the dynamic interaction with the 
inflamed endothelium and subendothelial tissue. In this regard, studies on leukocyte 
adhesion deficiency type I patients also showed that the severity of clinical infectious 
complications is directly related to the degree of β2 integrin deficiency. Severely immune 
deficient patients have essentially undetectable β2 integrin expression on leukocytes, 
whereas moderate phenotypes are found in patients expressing 2.5 to 6% of β2 integrins 
on PMNs (Anderson et al., 1985; Anderson and Springer, 1987). The clinical data 
mentioned above, together with our results, indicate that integrin activation and function 
is regulated in a large part by the precise control of the stoichiometry of integrin activators 
relative to integrin levels, thus enabling different blood cells to achieve their diverse 
biological functions. 
MATERIAL AND METHODS 
Animals. Kindlin-3−/− mice have been described previously (Moser et al., 2008). To 
generate conditional kindlin-3 mouse mutants (kindlin-3 fl/fl) a targeting vector was 
cloned, in which exons three to six of the kindlin-3 gene were flanked by loxP sites. This 
vector was electroporated into 129 ES cells. A Neo-cassette flanked by frt sites allowed 
G418 selection. Several homologous recombinant clones were injected into C57BL/6 
blastocysts and resulted in germ line chimeras. The presence of the Neo-cassette within 
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the kindlin-3 genomic locus resulted in strongly reduced kindlin-3 expression giving rise 
to a hypomorphic kindlin-3 allele. Mating with mice carrying a wild type, hypomorphic 
or kindlin-3 null (K3-/-) allele resulted in offspring with different levels of kindlin-3. In 
parallel, the Neo-cassette was removed from the kindlin-3 genomic locus by mating 
kindlin-3 hypomorphic mice with a strain expressing a deleter flipase resulting in 
conditional kindlin-3 mice. Finally, conditional kindlin-3 mice were crossed with a deleter 
Cre mouse strain (Betz et al., 1996) to obtain K3-/- mice. 
All mouse experiments were performed with the approval of the District Government of 
Bavaria. 
Generation of fetal liver cell chimeras. Fetal liver cells were obtained from embryonic 
day 15 K3+/+ or K3-/- embryos by pushing liver tissue through a cell strainer (Falcon). 4 x 
106 cells were then injected into the tail vein of lethally irradiated (twice 6.5 Gy) recipient 
C57BL/6 mice. Mice were used not before 6 weeks after transfer.  
Antibodies. The following antibodies were used for immunostaining of cells: mouse anti-
vinculin antibody, (from Sigma-Aldrich); Cy3-labeled secondary antibody (Jackson 
ImmunoResearch Laboratories, Inc.). Phalloidin-488 dye was obtained from Invitrogen.  
The following antibodies were used for flow cytometry: hamster IgG anti-integrin β1, 
isotype control hamster IgG, and isotype control mouse IgG1 (all from Biolegend); rat 
IgG2a anti-integrin β2, rat IgG2a anti-integrin β7, rat IgG2a anti-integrin α4, rat IgG2a 
anti-integrin α5, rat IgG2a anti-integrin αL, rat IgG1 anti-integrin αv, isotype control rat 
IgG1, and isotype control rat IgG2a (all from BD); hamster IgG anti-integrin β3, mouse 
IgG1 anti-integrin β5, rat IgG2b anti-integrin αM and isotype control rat IgG2b (all from 
eBioscience).  
The following antibodies were used for Western blotting: mouse anti-glyceraldehyde 3-
phosphate dehydrogenase (anti-GAPDH; Merck); rabbit anti-actin and mouse anti-talin 
(both from Sigma-Aldrich); rabbit anti-P42/44 MAPK, rabbit anti-pP42/44 MAPK 
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Thr202/Tyr204, rabbit anti-Akt, and rabbit anti-pAkt Ser473 (all from Cell Signaling 
Technology); rabbit anti-kindlin-3 antibody is homemade (Ussar et al., 2006).  
Peripheral blood cell counts.Mice were bled from the retro-orbital sinus into EDTA-
coated tubes. Blood cell counts were determined using a Hemavet 950 analyzer (Drew 
Scientific Inc., Oxford, CT). 
Cell preparation. CD4-positive T-cells were isolated from spleen using the CD4+ T cell 
Isolation Kit II from Miltenyi Biotech (Bergisch Gladbach, Germany). PMNs 
(polymorphonuclear neutrophils) were FACS sorted from whole bone marrow for high 
expression of Gr1 using a FITC-labeled antibody (eBioscience). B220-positive B-cells were 
FACS-sorted from whole spleen. Macrophages and dendritic cells (DCs) were derived 
from whole bone marrow by culturing in medium containing M-CSF and GM-CSF. 
Platelet analyses. Integrin activation studies were performed with blood samples washed 
twice with modified Tyrode´s HEPES buffer (134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM 
KCl, 12 mM NaHCO3, 20 mM HEPES, pH 7.0) containing 5 mM glucose, 0.35% bovine 
serum albumin (BSA) and 1 mM CaCl2, which then were activated with 0.1 U/ml 
thrombin (Sigma Aldrich) and either stained with fluorophore-labeled anti-activated 
αIIbβ3 (JON/A, Emfret Analytics) or fibrinogen (Molecular Probes).  
Platelet adhesion and spreading was analysed on fibrinogen-coated (1mg/ml; Sigma 
Aldrich) glass bottom dishes blocked with 3% BSA. Washed platelets were re-suspended 
at a concentration of 0.5x 106 platelets/ml and then further diluted 1:10 in Tyrode’s-HEPES 
buffer. Shortly before plating, platelets were activated with 0.01 U/ml thrombin. Platelets 
were allowed to spread for 10 min and imaged by differential interference contrast (DIC) 
microscopy. Additionally, washed platelets were allowed to adhere to fibrinogen in the 
presence of 3 mM Mn2+ without thrombin stimulation. 
Platelet aggregation was measured with 2 x 108/ml washed platelets stimulated with 0.1 
U/ml Thrombin in the absence or presence of 100 ug/ml human fibrinogen. Light 
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transmission was recorded on a ChronoLog aggregometer over 15 min and was expressed 
as arbitrary units with the transmission through buffer defined as 100% transmission. 
Platelet clot retraction was measured in platelet-rich plasma (PRP) obtained from blood 
drawn into 1/10 volume of 3.8% sodium citrate. Platelets were diluted to 1x 108/ml with 
platelet-poor plasma obtained from wild type mice. PRP was added to siliconized glass 
cuvettes containing a paperclip, and clot retraction was initiated after addition of 2 mM 
CaCl2 and 1 U/ml thrombin (Sigma Aldrich). In parallel, samples were also treated with 
0.5 mM MnCl2. Samples were incubated at 25°C for 2 hrs and clot retraction was analysed 
by weighing the residual serum to calculate the percentage of serum extruded from the 
clot at the indicated time points. 
Skin inflammation model. Croton oil (Sigma-Aldrich) was diluted to 1% in acetone and 
topically applied to the ventral and the dorsal sides (20μl each) of ears from K3+/+, K3n/n, 
K3n/- and K3-/- chimeric mice. After 1 and 4 h, mice were sacrificed and the earflaps were 
split into two halves by carefully separating the dorsal and ventral skin. For histological 
analysis, dorsal and ventral ear halves were subjected to whole-mount immunostaining. 
After fixation in paraformaldehyde (PFA), ear halves were blocked with 1% BSA (PAA 
Laboratories) in PBS for 1h at room temperature, probed with biotin-labeled anti-Gr-1 
(RB6-8C5; BD Biosciences-Pharmingen) to identify PMNs and anti-pan-laminin (L9393; 
Sigma-Aldrich) to visualize vessels, diluted in 1% BSA in PBS overnight at 4°C (wile 
shaking), and finally washed with 1% BSA in PBS. Antibodies were detected with a 
repeated cycle of staining with anti-rabbit Alexa Fluor 488 (Invitrogen) and anti-rat Cy3 
(Dianova) before tissue was embedded in elvanol and representative images taken with a 
Zeiss Axio Imager equipped with an ApoTome (Zeiss). 
Intravital microscopy. rmTNF-α (R&D Systems) was injected intrascrotally at a dose of 
500 ng per mouse in a volume of 0.15 ml sterile physiological NaCl solution. Two hours 
later, the mice were anesthesized (Frommhold et al., 2008) and placed onto a heating pad 
to maintain body temperature at 37 °C. After intubation and carotid artery cannulation for 
blood sampling and application of antibodies and chemokines, the cremaster muscle was 
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surgically prepared for intravital microscopy as previously described (Sperandio et al., 
2006). Intravital microscopy was performed on an upright microscope (Olympus BX51) 
with a saline immersion objective (40x and 0.8 numerical aperture). Experiments were 
recorded via CCD camera (model CF8/1, Kappa) on a Panasonic S-VHS recorder and with 
a digital camera (LaVision Biotech), and stored on a computer with Imspector software 
package (LaVision Biotech). The digital recordings were used offline to generate movie 
clips with ImageJ software (US National Institutes of Health). During the experiment, 
systemic blood samples were obtained (10 µl into 90 µl Türck's solution, Merck) to assess 
systemic white blood cell counts. Rolling flux was defined as the number of rolling cells 
per min and rolling PMN flux fraction as the percentage of rolling PMNs in all PMNs 
passing the same vessel in 1 min (Sperandio et al., 2006). PMNs that did not move for 
more than 30 s were considered to be adherent. The number of adherent leukocytes was 
assessed as the number of adherent cells per mm2 vessel surface area (Frommhold et al., 
2008). 
Adhesion assays. For PMN adhesion to ICAM-1, 96-well plates were coated with 4 µg/ml 
recombinant human ICAM-1 (R&D Systems) in coating buffer (150 mM NaCl, 20 mM 
Tris-HCl, and 2 mM MgCl2, pH 9) ON at 4°C and blocked with 3% BSA in PBS for 1 h at 
RT. PMNs sorted from bone marrow were either left untreated, or treated either with 33 
ng/ml PMA (Phorbol-12-Myristate-13-Acetate; Calbiochem) or 1 mM MnCl2. The adhesion 
assay was performed with 50.000 cells per well for 30 min. Adherent cells were fixed with 
4% PFA after washing. The number of adherent cells was determined by acquisition of 3 
phase contrast pictures from each well. 
Phagocytosis assay. Phagocytosis was measured using the pHrodoTM Red E.coli 
BioParticle Phagocytosis Kit for Flow cytometry (invitrogen) according to the 
manufacturer´s instructions. Blood was collected from the retro-orbital sinus and each 
blood sample was measured in triplicates. Granulocytes were identified by their position 
in a forward vs. side scatter plot. 
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Absolut quantification of proteins in platelets and neutrophils. We produced two 
protein standards spanning over different regions of talin-1, b3 and b2 integrins, and 3 
standards for kindlin-3. The protein standards were designed with an approximate length 
of 150 amino acids and with as many unique tryptic cleavage sites as possible. They 
covered in kindlin-3 the aminoacids 114-276, 304-477 and 522-605; in talin-1 1752-1948 and 
2021-2188; in β3 integrin 34-162 and 589-714; and in β2 integrin 176-325 and 334-480. 
Subsequently they were fused to the albumin binding protein (ABP), whose cDNA was 
was inserted into the expression vector pET28a(+) then fused with the gene sequences of 
interest using HindIII and XhoI. In a next step the proteins fused to ABP were expressed 
in an auxotrophic E. coli strain and labeled with 'heavy' isotopes (13C615N2-lysine and 
13C615N4-arginine). The labeled proteins were purified via His6-Tag using spin columns 
from Qiagen (Hilden, Germany). 
The proteins of interest were quantified as previously described (Zeiler et al.). In brief, 
unlabeled ABP was quantified beforehand with amino acid analysis. These measurements 
were used to quantify the 'heavy' protein standards via SILAC ratios. The different 
protein standards with known concentration were then mixed. The platelets or 
neutrophils were lysed and the 'protein standard mix' was spiked in at approximately 
endogenous level. The mixture was further processed using the filter-aided sample 
preparation (FASP) method (Wisniewski et al., 2009), in which proteins were captured on 
a 30 kDa filter and SDS was removed with an urea-containing buffer. Proteins were 
alkylated with iodoacetamide and typsinized. The peptides were measured by MS, and 
peptide ratios between endogenous and labeled peptides were extracted.  
For the platelet proteome FASP peptides were further fractionated with strong anion 
exchange chromatography. Six fractions of pH 11, 8, 6, 5, 4 and 3 were obtained. 
All samples were measured using the LTQ-Orbitrap Elite or Q Exactive proteomic 
pipeline (Michalski et al., 2012). Raw mass spectrometric data were analyzed using the 
MaxQuant software (Cox and Mann, 2008). Detailed description of the MS analysis as 
well as the data analysis can be found in the supplementary material. 
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For calculation of the absolute copy number per cell we used the peptide ratios and 
converted the ratios to pmol. We took the median of all peptides amounts (derived from 
different protein standards) to calculate the copy number. We required at least 3 peptides 
for the quantification of each protein. 
Statistical analysis. All data are shown as mean ± SD or mean ± SEM as indicated in the 
figure legends. To test significance level an unpaired student t-Test was performed.  
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SUPPLEMENTARY METHODS 
Liquid chromatography and mass spectrometry analysis. The peptides were separated 
on a 20 cm column packed with Reprosil-Pur 1.9 µm resin (Dr. Maisch GmbH, 
Ammerbuch-Entringen, Germany) using an UPLC system (Thermo Fisher Scientific). A 
linear gradient 180 min 5–25% buffer B (80% acetonitrile, 0,5 % acetic acid) at a constant 
flow rate of 300nl/min was applied. The UPLC was coupled via nanoelectrospray ion 
source (Proxeon Biosystems) to an LTQ-Orbitrap Elite mass spectrometer (Michalski et al., 
2012). The data was acquired with a data-dependent top10 method, automatically 
selecting the most abundant precursor ions for fragmentation. Full scans, 300-1750m/z, 
were measured with a target value 1e6 at a resolution of 60,000 followed by 
10 fragmentation spectra using higher energy collisional dissociation also measured in the 
Orbitrap using 5e4 ions at a resolution of 15,000. The injection time for MS spectra was 
restricted to 100 ms and for MS/MS spectra to 150 ms. The platelet proteome was 
measured on a QExactive instrument (Michalski et al., 2011)Thermo Scientific) using the 
same liquid chromatography setup as described above. A linear gradient 180 min 5–35% 
buffer B at a constant flow rate of 300 nl/min was applied. Full scans, 300-1650m/z, were 
measured with a target value 3e6 at a resolution of 70,000 followed by 20 fragmentation 
spectra using higher energy collisional dissociation and measured in the Orbitrap using 
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1e6 ions at a resolution of 17,500. The injection time for MS spectra was restricted to 20 ms 
and for MS/MS spectra to 60 ms. 
Data analysis. The raw files were analyzed using MaxQuant (version 1.3.7.4; (Cox and 
Mann, 2008). For peptide identification Andromeda search engine incorporated into 
MaxQuant (Cox et al., 2011) was used to search fragmentation spectra against the 
UniProtKB mouse database (downloaded on 16 June 2012), which contains 54,232 entries. 
247 common contaminants were added to this database. A time-dependent mass 
recalibration algorithm was used for recalibration to improve the mass accuracy of 
precursor ions. Peptide identification was based on a search with an initial mass deviation 
of the precursor ion of up to 6 ppm and the allowed fragment mass deviation was set to 
20 ppm. The search included cysteine carbamidomethylation as a fixed modification and 
N-terminal acetylation and methionine oxidation as variable modifications. Enzyme 
specificity was set to trypsin allowing N-terminal cleavage to proline. Two mis-cleavages 
were allowed and a minimum of seven amino acids per identified peptide was required. 
The second peptide identification option in Andromeda was enabled. For statistical 
evaluation of the data obtained, the posterior error probability and false discovery rate 
(FDR) were used. The false discovery rate was determined by searching a reverse 
database and was set to 0.01 for peptide and protein identification. Additional peptides 
were identified by the “match between run” option in MaxQuant, which matches 
precursor masses in a 2 min retention time window (after realignment of the runs) based 
on the accurate mass 
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SUPPLEMANTARY TABLE 
Blood counts of K3+/+, K3+/n, K3n/n, K3n/- and K3-/- chimeras. Values are shown as mean 
± SD. WBC, white blood cell; NE, neutrophil; LY, lymphocyte; RBC, red blood cell; Hb, 
hemoglobin; PLT, platelet. 
  +/+ [n=9]    +/n  
[n=8] 
  n/n 
[n=9] 
  -/n  
[n=9] 
  -/-chimera 
[n=4] 
  
  mean SD mean SD mean SD mean SD mean SD 
[103/µl] WBC 5,70 (± 2,45) 6,38 2,05 13,30 2,58 9,76 4,01 18,23 2,97 
[103/µl] NE 1,01 (± 0,49) 1,21 0,46 4,15 1,48 2,53 2,38 13,97 2,99 
[103/µl] LY 4,32 (± 2,09) 4,72 1,49 8,37 2,27 6,62 3,68 3,33 0,55 
[106/µl] RBC 9,44 (± 1,27) 9,19 0,82 8,35 1,21 8,35 0,95 2,44 0,47 
[g/dL] Hb 13,93 (± 2,29) 13,56 1,19 12,56 2,12 12,71 1,53 5,78 0,77 
[106/µl] PLT 603,44 (± 138,5) 452,0 61,8 593,2 112,5 695,3 216,4 648,0 167,1 
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SUPPLEMENTARY FIGURES 
 
Supplementary Figure 1: Generation of mutant Kindlin-3 mice. (A) Targeting strategy of kindlin-3. Partial 
map of the kindlin-3 gene and the targeting vector carrying a loxP sites flanking exons 3 to 6 of the 
kindlin-3 gene. A frt flanked neomycin resistance cassette was inserted into intron 6. Exons are indicated 
as rectangles and restriction enzymes by name. Probe used for Southern blotting is shown as red rectangle. 
(B) Southern blot on DNA samples from R1 ES cells electroporated with the targeting construct. The 
genomic DNA was digested with HindIII and hybridized with the probe indicated in A. (C) Genomic PCR 
performed with primers indicated as red arrows in A to identify mice carrying the K3+/+, K3n/n, K3n/- and 
K3-/- alleles. (D) Deletion of the kindlin-3 gene by crossing conditional kindlin-3 mice with deletor Cre 
mice. (E) Western blots of thymus lysates from K3+/+ and K3-/- mice. 
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Supplementary Figure 1: Normal development of K3+/n, K3n/n, K3n/- mice. (A) Weight gains. (B) 
Cellularity of the thymus and spleen. (C) Differentiation of precursor cells into CD4- and CD8-positive T-
cells. 
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Conclusion and future outlook 
In this thesis, I have established a method for accurate absolute protein quantification 
termed ‘SILAC-PrEST’. To date, quantitative western blotting is widely applied to detect 
and quantify proteins in research settings. However, only a limited number of proteins 
and samples can be quantified using this labor-intensive technique. Thus, absolute protein 
quantification methods based on MS represent an attractive alternative thanks to 
multiplexing capabilities and high selectivity [115]. Numerous strategies have been 
developed over the last years to absolutely quantify proteins using MS-based proteomics, 
and it could be argued that absolute quantification instead of relative quantification 
methods should dominate the field of quantitative proteomics. However, there are a 
number of limitations in the currently available absolute quantification methods that 
would first have to be tackled. This was the main aim of this thesis. 
In the SILAC-PrEST quantification developed here, the standard is spiked in at an early 
stage in sample preparation, therefore both the standard and the sample are subjected to 
identical treatments e.g. proteolytic digestion. Indeed, we observed that the cleavage 
efficiency of PrEST and endogenous protein is virtually the same as peptides with missed 
cleavage sites have the same SILAC ratio. Furthermore, since the PrESTs typically cover 
150 aa, multiple peptides can generally be used for quantification which significantly 
improves accuracy and robustness. Lastly, each PrEST includes a 120 aa ABP domain in 
addition to the protein specific sequence, making all protein classes (including membrane 
proteins) amenable to recombinant expression and purification and enabling a high-
throughput production pipeline. Although the method developed here is clearly powerful 
and superior to existing ones, it can still be further advanced by for instance combining it 
with a targeted acquisition mode such as multiple reaction monitoring or multiplexed 
single ion monitoring on the latest high resolution instruments such as the Q Exactive 
[116]. Given this, application in a clinical setting appears feasible.  
To further increase sensitivity of the approach the immuno-SILAC workflow was 
established. It combines antibody-based enrichment with absolute protein quantification, 
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exploiting the high enrichment factor of antibodies with the quantification accuracy of the 
SILAC-PrEST method. We utilize the polyclonal antibodies from the Human Protein Atlas 
project, which are raised against the PrESTs, to enrich multiple peptides. Several proteins 
can be quantified by multiplexing the MS-readout. Additionally, measuring time is 
significantly reduced due to the lowered sample complexity. Therefore, one could 
envision the immuno-SILAC method to be part of biomarker development pipeline and 
applied to clinical samples. In particular, body fluids such as plasma are highly complex 
and have a very large dynamic range between abundant and clinically relevant marker 
proteins. An additional enrichment step would enable quantification of low-abundant 
proteins such as cytokines. Currently, enzyme-linked immunosorbent assay (ELISA) are 
considered the gold standard assay to routinely quantify biomarkers in clinical settings. 
However in ELISA, assay development is time-consuming and various factors can 
influence the quality of the assay, including specificity, avidity, concentration of 
antibodies as well as incubation time, temperature, sample volume, dilution, and pH. At 
present numerous candidate biomarkers are discovered by the proteomics field and 
therefore verification and validation is much needed [117]. This could be achieved with an 
accurate, sensitive method such as immuno-SILAC. 
The SILAC-PrEST technology can easily be combined with label-free quantification 
methods, where the PrESTs are used as reference points for scaling the intensities. This 
enables absolute quantification of all proteins detected in the measurement. However, it 
should be kept in mind that these absolute quantification values are estimates, expected to 
be accurate generally within a factor of two but also less accurate on a case by case basis. 
Nevertheless, knowing the identity of all proteins in a cell and having an estimate of their 
quantities provides an important basis for studying complex biological processes. In case 
of the platelet study described here it opens up more possibilities for investigation of 
platelet activation and aggregation in health and disease.  
Another powerful application of the SILAC-PrEST method is the determination of protein 
stoichiometry in mixtures. Proteins rarely operate in isolation but work together or 
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assemble into a complex to fulfill their functional roles. Although MS-based methods 
allow identification of protein-protein interactions in high-throughput (see for example 
reference [118]) so far protein stoichiometries have usually relied on methods such as size-
exclusion chromatography, analytical ultracentrifugation and gel electrophoresis. 
However, since MS-based methods for absolute protein quantification have been 
established, protein stoichiometries can also be deduced [119, 120]. In the case of platelets, 
integrin activation is achieved by mutual binding of two proteins talin-1 and kindlin-3. 
We set out to estimate their abundance and stoichiometry, and showed that they are 
expressed at the same levels, suggesting that they directly cooperate. 
Next to the developments in absolute protein quantification using spike in standards 
label-free methods have matured independently. Although these label-free methods have 
existed for many years, they have become mainstream only in the last few years owing to 
progress in the resolution and robustness of LC-MS systems and advances in algorithms. 
It is a valid question to ask if label-free quantification methods will eventually supersede 
absolute protein quantification based on labeled spike-in standards. Indeed, from an 
economic and convenience perspective, label-free experiments are attractive. However, 
the accuracy of label-free methods currently cannot match that of quantification 
approaches based on spike in standards, largely because individual peptides can display 
unpredictable behavior in mass spectrometry, which currently cannot be accounted for in 
the label-free algorithm. Nevertheless, to obtain a global, quantitative view of a proteome, 
label-free methods are very feasible especially if combined with spike-in references that 
allow for correct absolute scaling, they may be able to answer most of the systems biology 
questions. 
In conclusion, the novel SILAC-PrEST method described in my thesis allows for accurate 
and robust quantification and shows great promise for further applications in biological 
research and clinical medicine. 
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Abbreviations 
aa Amino acid(s) 
ABP Albumin binding protein 
ADP Adenosine diphosphate 
APEX Absolute protein expression 
AQUA Absolute quantification 
CID Collision induced dissociation 
Da Dalton 
E. coli Escherichia coli 
ECM Extracellular matrix 
ELISA Enzyme-linked immunosorbent assay 
emPAI Exponentially modified protein abundance index 
ESI Electrospray ionization 
ETD Electron-transfer dissociation 
FDR False discovery rate 
FT Fourier transformation 
GP Glycoprotein 
GPCR G-protein couples receptor 
HCD Higher energy collisional dissociation 
HPA Human Protein Atlas 
HPLC High-performance liquid chromatography 
iBAQ Intensity-based absolute quantification 
ICAT Isotope coded affinity tags 
ICR Ion cyclotron resonance 
IT Ion trap 
iTRAQ Isobaric tags for relative and absolute quantification 
LMCO Low mass cut off 
LTQ Linear trap quadrupole 
m/z Mass-to-charge ratio 
MALDI Matrix-assisted laser desorption ionization 
MRM Multiple reaction monitoring 
MS Mass spectrometry 
MS/MS Tandem mass spectrum 
NHS N-hydroxy succinimide 
NSAF Normalized spectral abundance factor 
OCS Open canalicular system 
PAI Protein abundance index 
PBMC Peripheral blood mononucleated cell 
PSAQ Protein standard absolute quantification 
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PTM Post translational modification 
QconCAT Quantification concatemer 
QQQ Triple quadrupole 
RP Reverse phase 
SAF Spectral abundance factor 
SILAC Stable isotope labeling of amino acids in cell culture 
SIM Single ion monitoring 
SISCAPA Stable isotope standards and capture by anti-peptide antibodies 
TOF Time-of-flight 
TrEMBL Translated EMBL Nucleotide Sequence Data Library 
TXA2 Thromboxane A2 
UPS Universal protein standard 
VWF Von Willebrand factor 
XIC Extracted ion chromatogram 
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